MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF - Patent application
Compounds of formula I, with specific heterocyclic groups, address the need for improved MC4R antagonists, effectively treating MC4R-related conditions by modulating MC4R activity, enhancing stability and bioavailability for conditions like cachexia, anorexia, and osteoporosis.
Patent Information
- Application Number
- JP2024533208
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-15
- Filing Date
- 2022-12-05
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for new and improved pharmaceutical compounds that act as melanocortin receptor 4 (MC4R) antagonists with enhanced biopharmaceutical properties, such as physical stability, solubility, oral bioavailability, metabolic stability, and clearance, to effectively treat MC4R-related conditions and disorders.
Development of compounds of formula I, including specific heterocyclic groups, which can be administered as pharmaceutical compositions to antagonize MC4R, thereby treating conditions like cachexia, anorexia, nausea, weight loss, sarcopenia, osteoporosis, and other disorders by modulating MC4R activity.
The compounds provide effective treatment for MC4R-related conditions by selectively antagonizing the MC4R receptor, improving therapeutic outcomes for cachexia, anorexia, sarcopenia, osteoporosis, and other disorders with enhanced stability and bioavailability.
Smart Images

Figure 2024544021000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to new pharmaceutical compounds, pharmaceutical compositions containing the compounds, and the use of the compounds as melanocortin receptor 4 (MC4R) antagonists. [Background technology]
[0002] Melanocortins are peptides derived from proopiomelanocortin (POMC) that bind to and activate G protein-coupled receptors (GPCRs) of the melanocortin receptor family. Melanocortins regulate a diverse number of physiological processes, including sexual function and behavior, food intake, and metabolism. Five melanocortin receptors (MCRs), MC1R, MC2R, MC3R, MC4R, and MC5R, have been identified in mammals and are expressed in various tissues. MC1R is specifically expressed in melanocytes and melanoma cells; MC2R is an ACTH receptor and is expressed in adrenal tissue; MC3R is primarily expressed in the brain and limbic system; MC4R is widely expressed in the brain and spinal cord; and MC5R is expressed in the brain and many peripheral tissues, including skin, adipose tissue, skeletal muscle, and lymphatic tissue. See, for example, U.S. Patent No. 8,138,188 and Saleh et al., Front. Pharmacol., 2018, 9:560.
[0003] MC4R is a G protein-coupled seven-transmembrane receptor primarily expressed in the hypothalamus, hippocampus, and thalamus (Gantz et al., 1993 J. Biol. Chem. 268:15174-15179). This receptor is involved in the central regulation of body weight, and MC4R is activated by α-melanocyte-stimulating hormone (MSH), which is derived from proopiomelanocortin and inactivated by agouti gene-related protein (AGRP). α-MSH induces weight loss, whereas ectopic expression of agouti protein leads to obesity in agouti mice (Fan et al., 1993 Nature 385:165-168; Lu et al., 1994 Nature 371:799-802). Additional evidence for the role of MC4R in body weight regulation comes from both knockout models in mice (Huszar et al., 1997 Cell 88:131-141) and haploinsufficient mutations in humans (Vaisse et al., 1998 Nat. Genet. 20:113-114; Yeo et al., 1998 Nat. Genet. 20:111-112; Hinney et al., 1999 J. Clin. Endocrinol. Metab. 84:1483-1486). In MC4R knockout mice, increased body weight was discernible by 5 weeks of age. By 15 weeks of age, homozygous mutant females weighed, on average, twice as much as their wild-type littermates, whereas homozygous mutant males were approximately 50% heavier than wild-type controls. Mice heterozygous for the MC4R knockout exhibited weight gain intermediate to that seen in wild-type and homozygous mutant littermates, thus demonstrating a gene dosage effect of MC4R ablation on weight regulation. Food intake in homozygous mutants was increased by approximately 50% compared with that in wild-type siblings (Huszar et al., 1997 Cell 88:131-141) [from Am. J. Hum. Genet., 65:1501-1507, 1999].MC4R activation has been shown to induce penile erection in rodents, and MC4R inactivation has been shown to cause obesity (reviewed in Hadley, 1999, Ann. NY Acad. Sci., 885:1-21; Wikberg et al., 2000, Pharmacol. Res., 42(5), 393-420; and Saleh et al., Front. Pharmacol., 2018, 9:560).
[0004] In recent years, several small molecule MC4R antagonists have been reported in the literature and patent applications [e.g., WO2010052256; WO2010081666; U.S. Patent No. 8,044,068; Chaki et al., Current Topics in Medicinal Chemistry, 2007, 7, 1145-1151; Foster et al., Current Topics in Medicinal Chemistry, 2007, 7, 1131-1136; Pontillo et al., Bioorganic & Medicinal Chemistry Letters, 2005, 15, 2541-2546; Vos et al., Bioorganic & Medicinal Chemistry Letters, 2006, 16, 2302-2305; Tao, Endocrine Reviews, 2010, 31(4):506-543; and Saleh et al., Front.Pharmacol., 2018, 9:560. These MC4R antagonists have been reported to be effective in treating MC4R-associated conditions, diseases, or disorders, such as cachexia (e.g., cachexia associated with chronic illness, including, for example, cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, including, for example, cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with treatment for chronic illness, including, for example, cachexia associated with treatment for cancer or cachexia associated with treatment for heart failure (e.g., CHF)); loss of appetite or anorexia nervosa (e.g., loss of appetite in the elderly); , anorexia associated with chemotherapy and / or radiation therapy); nausea; vomiting; weight loss (e.g., involuntary weight loss); growth retardation; sarcopenia; muscle wasting; muscle weakness; frailty; osteoporosis; bone disorders (e.g., bone loss); pain; neuropathic pain; anxiety (e.g., post-traumatic stress disorder or PTSD); depression; hypertension; malnutrition; obesity (e.g., sarcopenia resulting from chronic obesity); sexual dysfunction; and inflammatory diseases (e.g., anorexia or cachexia or inflammatory diseases associated with sarcopenia or muscle wasting). Summary of the Invention [Problem to be solved by the invention]
[0005] There is a continuing need for alternative MC4R antagonists, for example, for the development of new and / or improved pharmaceuticals (e.g., more effective, more selective, less toxic, and / or having improved biopharmaceutical properties, e.g., physical stability; solubility; oral bioavailability; adequate metabolic stability; clearance; half-life) for treating or preventing MC4R-associated conditions, diseases, or disorders, such as those described herein. The present invention is directed to these and other important ends. [Means for solving the problem]
[0006] In one embodiment, the present invention provides a compound of formula I:
[0007] [ka] or a pharmaceutically acceptable salt thereof, R 1 is 1,2,4-triazolyl, tetrazolyl, 1,2,4-oxadiazolyl, imidazolyl, 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl, [1,2,4]triazolo[1,5-a]pyridinyl-, parazolyl or pyrimidinyl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 cycloalkyl; R 2 and R 3 each independently represents H, a halogen, or C 1~4 Alkyl or C 1~4 Is it a haloalkyl? Or, R 2 and R 3 are optionally substituted, together with the carbon atom to which they are attached, with 1, 2, 3, 4 or 5 substituents each independently selected from halogen, C3~4 forming a cycloalkyl, Y 1 and Y 2 Each of these is independently 4 or N, Each R 4 are independently H, halogen, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy or C 1~4 haloalkoxy, Each R F are independently halogen, -OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy, C 1~4 Haloalkoxy, C 3~4 Cycloalkyl or (C 3~4 Cycloalkyl)-C 1~4 alkyl- or Or, two R F When groups are substituted on the same carbon atom of the pyrrolidine ring of formula I, they, together with the carbon atom to which they are attached, are halogen, —OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 3~6 may form a cycloalkyl, R 7 is methyl or ethyl, t1 is 0, 1, 2, 3, or 4] to provide.
[0008] In one embodiment, the present invention provides a compound of formula I:
[0009] [ka] or a pharmaceutically acceptable salt thereof, R 1is 1,2,4-triazolyl, tetrazolyl, 1,2,4-oxadiazolyl, imidazolyl, 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl, [1,2,4]triazolo[1,5-a]pyridinyl- or pyrimidinyl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 cycloalkyl; R 2 and R 3 each independently represents H, a halogen, or C 1~4 Alkyl or C 1~4 Is it a haloalkyl? Or, R 2 and R 3 are optionally substituted, together with the carbon atom to which they are attached, with 1, 2, 3, 4 or 5 substituents each independently selected from halogen, C 3~4 forming a cycloalkyl, Y 1 and Y 2 Each of these is independently 4 or N, Each R 4 are independently H, halogen, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy or C 1~4 haloalkoxy, Each R F are independently halogen, -OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy, C 1~4 Haloalkoxy, C 3~4 Cycloalkyl or (C 3~4 Cycloalkyl)-C 1~4 alkyl- or Or, two R F When groups are substituted on the same carbon atom of the pyrrolidine ring of formula I, they, together with the carbon atom to which they are attached, are halogen, —OH, C 1~4Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 3~6 forming a cycloalkyl, R 7 is methyl or ethyl, t1 is 0, 1, 2, 3, or 4] to provide.
[0010] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt of said compound, and a pharmaceutically acceptable carrier.
[0011] The present invention also provides a method for treating an MC4R-associated condition, disease or disorder in a mammal (e.g., a human) in need of such treatment, comprising administering to the mammal (e.g., a human) a compound of formula I or a pharmaceutically acceptable salt of the compound.
[0012] The present invention also provides a compound of Formula I, or a pharmaceutically acceptable salt of said compound, for use in treating an MC4R-associated condition, disease or disorder.
[0013] MC4R-associated conditions, diseases, or disorders include cachexia (e.g., cachexia associated with chronic illness, including, for example, cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, such as cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with treatment for chronic illness, including, for example, cachexia associated with treatment for cancer or cachexia associated with treatment for heart failure (e.g., CHF)); anorexia or anorexia nervosa (e.g., anorexia in the elderly, or cachexia associated with chemotherapy and / or radiation therapy); anorexia associated with chronic obesity; nausea; vomiting; weight loss (e.g., involuntary weight loss); growth retardation; sarcopenia; muscle wasting; muscle weakness [e.g., muscle wasting associated with chronic obstructive pulmonary disease (COPD)]; frailty; osteoporosis; bone disorders (e.g., bone loss); pain; neuropathic pain; anxiety (e.g., post-traumatic stress disorder or PTSD); depression; hypertension; malnutrition; obesity (e.g., sarcopenia resulting from chronic obesity); sexual dysfunction; and inflammatory diseases (e.g., anorexia or cachexia or inflammatory diseases associated with sarcopenia or muscle wasting).
[0014] The present invention provides a method for treating a condition, disease, or disorder in a mammal (e.g., a human) in need of such treatment, comprising the step of administering to the mammal (e.g., a human) a compound of Formula I or a pharmaceutically acceptable salt of said compound, wherein the condition, disease, or disorder is cachexia (e.g., cachexia associated with a chronic disease, for example, cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, for example, cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with the treatment of a chronic disease, for example, cachexia associated with cancer treatment or heart failure (e.g., and inflammatory diseases (e.g., anorexia or anorexia nervosa (e.g., anorexia in the elderly, anorexia associated with chemotherapy and / or radiation therapy); nausea; vomiting; weight loss (e.g., involuntary weight loss); growth retardation; sarcopenia; muscle wasting; muscle weakness; frailty; osteoporosis; bone disorders (e.g., bone loss); pain; neuropathic pain; anxiety (e.g., post-traumatic stress disorder or PTSD); depression; hypertension; malnutrition; obesity (e.g., sarcopenia resulting from chronic obesity); sexual dysfunction; and inflammatory diseases (e.g., anorexia or cachexia or inflammatory diseases associated with sarcopenia or muscle wasting).
[0015] The present invention also provides a method for antagonizing the melanocortin-4 receptor (MC4R), comprising contacting the MC4R with a compound of formula I or a pharmaceutically acceptable salt of said compound.
[0016] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. [Brief explanation of the drawings]
[0017] [Figure 1] FIG. 1 shows an illustrative single crystal structure of compound Example 3A. [Figure 2] FIG. 1 shows an illustrative single crystal structure of compound Example 6. [Figure 3] FIG. 1 shows an illustrative single crystal structure of compound Example 7. DETAILED DESCRIPTION OF THE INVENTION
[0018] The present invention may be understood more readily by reference to the following detailed description of exemplary embodiments of the invention and the examples included therein.
[0019] It is understood that the present invention is not limited to specific synthetic methods for preparation, which may, of course, vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings:
[0020] As used herein, "a" or "an" can mean one or more. When used in the claims, when used in conjunction with the word "comprising," the word "a" or "an" can mean one or more than one. As used herein, "another" can mean at least a second or more.
[0021] The term "about" refers to a relative term indicating an approximation of plus or minus 10% of the nominal value to which it refers, in one embodiment, plus or minus 5%, and in another embodiment, plus or minus 2%. Within the scope of this disclosure, this level of approximation is appropriate unless the value is specifically stated to require a narrower range.
[0022] The term "and / or" refers to one or more of the stated expressions / possibilities listed in connection with this term. For example, "X and / or Y" shall be understood to mean either "X and Y" or "X or Y," and shall be interpreted as providing explicit support for both meanings or for either meaning. Similarly, when more than two expressions / possibilities are listed, such as in "X, Y and / or Z," it shall be understood to mean either i) "X and Y," "X, Y and Z," "X and Z," or "Y and Z," or ii) "X or Y," "X or Z," "Y or Z," or "X or Y or Z," and shall be interpreted as providing explicit support for all meanings.
[0023] "Compound," as used herein, includes conformational isomers (e.g., cis and trans isomers) and all optical isomers (e.g., enantiomers and diastereomers), racemic, diastereomeric and other mixtures of such isomers, as well as any pharmaceutically acceptable derivatives or variations, including solvates, hydrates, isomorphs, polymorphs, tautomers, esters, salt forms and prodrugs. The expression "prodrug" refers to a compound that is a drug precursor that releases the drug in vivo after administration through some chemical or physiological process (e.g., the prodrug is converted to the desired drug form when brought to physiological pH or via enzymatic action).
[0024] The term "alkyl" refers to an acyclic saturated aliphatic hydrocarbon group, which may be straight / linear or branched. Examples of such groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, sec-butyl, isobutyl, and tert-butyl. The carbon atoms comprising alkyl and various other hydrocarbon-containing moieties are designated by prefixes that specify the lower and upper number of carbon atoms in the moiety, i.e., the prefix C i~j refers to the portion of carbon atoms from integer "i" to integer "j", including the boundary. Thus, for example, C 1~4Alkyl refers to alkyl of 1 to 4 carbon atoms, inclusive. 1~4 Representative examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl. 1~4 Alkyl refers to an alkyl of 1 to 2 carbon atoms, inclusive (i.e., methyl or ethyl). When so specified, an alkyl group may be optionally substituted by one or more (e.g., 1 to 5) suitable substituents.
[0025] At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include all individual subcombinations of the members of each such group and range. For example, the term "C 1~4 The term "alkyl" is specifically intended to include C alkyl (methyl), C alkyl (ethyl), C alkyl, and C alkyl. As another example, the term "4- to 7-membered heterocycloalkyl" is specifically intended to include any 4-, 5-, 6-, or 7-membered heterocycloalkyl group.
[0026] As used herein, the term "n-membered," where n is an integer, typically describes the number of ring-forming atoms in a moiety where n is the number of ring-forming atoms. For example, pyridinyl is an example of a 6-membered heteroaryl ring, and pyrazolyl is an example of a 5-membered heteroaryl group.
[0027] As used herein, the term "alkoxy" or "alkyloxy" refers to an -O-alkyl group. For example, the term "C 1~4 Alkoxy" or "C 1~4 "Alkyloxy" is -O-(C 1~4 As another example, the term "C 1~2 Alkoxy" or "C 1~2 "Alkyloxy" is -O-(C 1~2Examples of alkoxy include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), tert-butoxy, and the like. When so specified, an alkoxy or alkyloxy group may be optionally substituted by one or more (e.g., 1 to 5) suitable substituents.
[0028] The term "halo" or "halogen," as used herein, means -F, -Cl, -Br, or -I.
[0029] As used herein, the term "haloalkyl" refers to an alkyl group having one or more halogen substituents (up to perhaloalkyl, i.e., all hydrogen atoms of the alkyl group are replaced by halogen atoms). For example, the term "C 1~4 "Haloalkyl" refers to a C alkyl group having one or more halogen substituents (up to perhaloalkyl, i.e., all hydrogen atoms of the alkyl group are replaced by halogen atoms). 1~4 The term "C" refers to an alkyl group. 1~2 "Haloalkyl" refers to a C alkyl group having one or more halogen substituents (up to perhaloalkyl, i.e., all hydrogen atoms of the alkyl group are replaced by halogen atoms). 1~2 refers to an alkyl group (i.e., methyl or ethyl). Examples of haloalkyl groups include -CF3, -CHF2, -CH2F, -CH2CF3, -C2F5, -CH2Cl, and the like.
[0030] "Fluoroalkyl" means alkyl, as defined herein, substituted with one or more fluoro (-F) substituents (up to perfluoroalkyl, i.e., all hydrogen atoms of the alkyl group are replaced by fluorine atoms). 1~2 "Fluoroalkyl" refers to a C alkyl group having one or more fluorine substituents (up to perfluoroalkyl, i.e., all hydrogen atoms of the alkyl group are replaced by fluorine atoms). 1~2The term "C1 fluoroalkyl" refers to an alkyl group (i.e., methyl or ethyl); the term "C1 fluoroalkyl" refers to a methyl group having one, two, or three fluorine substituents. Examples of C1 fluoroalkyl include fluoromethyl, difluoromethyl, and trifluoromethyl; some examples of C2 fluoroalkyl include 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 1,2-difluoroethyl, 2,2,2-trifluoroethyl, 1,1,2-trifluoroethyl, etc.
[0031] As used herein, the term "haloalkoxy" refers to an -O-haloalkyl group. For example, the term "C 1~4 "Haloalkoxy" refers to -O-(C 1~4 haloalkyl) groups; the term "C 1~2 "Haloalkoxy" refers to -O-(C 1~2 As yet another example, the term "C1 haloalkoxy" refers to a methoxy group having one, two, or three halogen substituents. Examples of haloalkoxy are -OCF3 or -OCHF2.
[0032] As used herein, the term "fluoroalkoxy" refers to an -O-fluoroalkyl group. For example, the term "C 1~2 "Fluoroalkoxy" is -O-(C 1~2 The term "C1 fluoroalkoxy" refers to an -O-(C1 fluoroalkyl) group; the term "C1 fluoroalkoxy" refers to an -O-(C1 fluoroalkyl) group. Examples of C1 fluoroalkoxy include -O-CH2F, -O-CHF2, and -O-CF3. Some examples of C2 fluoroalkoxy include -O-CH2CHF2, -O-CH2-CHF2, -O-CH2CF3, -O-CF2CH3, and -O-CF2CF3.
[0033] As used herein, the term "hydroxylalkyl" or "hydroxyalkyl" refers to an alkyl group having one or more (e.g., 1, 2, or 3) OH substituents. 1~4 hydroxyl alkyl" or "C 1~4"Hydroxyalkyl" refers to a C alkyl group having one or more (e.g., 1, 2, or 3) OH substituents. 1~4 The term "C" refers to an alkyl group. 1~2 hydroxyl alkyl" or "C 1~2 "Hydroxyalkyl" refers to a C alkyl group having one or more (e.g., 1, 2, or 3) OH substituents. 1~2 It refers to an alkyl group. Examples of hydroxylalkyl are -CHOH or -CHCHOH.
[0034] As used herein, the term "cycloalkyl" refers to a saturated or unsaturated, non-aromatic, monocyclic or polycyclic (e.g., bicyclic) hydrocarbon ring (e.g., a monocyclic ring, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or a bicyclic ring containing a spiro, fused, or bridged system (e.g., bicyclo[1.1.1]pentanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.2.1]octanyl, or bicyclo[5.2.0]nonanyl, decahydronaphthalenyl, etc.)). A cycloalkyl group has 3 to 15 (e.g., 3 to 14, 3 to 10, 3 to 6, 3 to 4, or 4 to 6) carbon atoms. In some embodiments, a cycloalkyl may contain one, two, or more non-cumulative non-aromatic double or triple bonds and / or one to three oxo groups. In some embodiments, the bicycloalkyl group has 6 to 14 carbon atoms. 3~4 "Cycloalkyl," as used herein, means a saturated cyclic hydrocarbon group containing from 3 to 4 carbons. 3~4Examples of cycloalkyl include cyclopropyl and cyclobutyl. Also included within the definition of cycloalkyl are moieties having one or more aromatic rings (including aryl and heteroaryl) fused to a cycloalkyl ring, such as benzo or pyridinyl derivatives of cyclopentane (5-membered cycloalkyl), cyclopentene, cyclohexane (6-membered cycloalkyl), etc., such as 6,7-dihydro-5H-cyclopenta[b]pyridinyl, 5,6,7,8-tetrahydroquinolinyl, or 15,6,7,8-tetrahydroisoquinolinyl, each of which contains a 5- or 6-membered cycloalkyl moiety (i.e., a pyridinyl ring) fused to a heteroaryl ring. Cycloalkyl or C 3~4 Where so specified, a cycloalkyl group may be optionally substituted by one or more (eg, 1 to 5) suitable substituents.
[0035] The term “C 3~4 Cycloalkyl-C 1~4 "Alkyl-", as used herein, refers to a C alkyl group, as defined herein. 1~4 A C, as defined herein, appended to the parent molecular moiety through an alkyl group. 3~4 means cycloalkyl. C 3~4 Cycloalkyl-C 1~4 Some examples of alkyl- include cyclopropylmethyl, 2-cyclopropylethyl, 2-cyclopropylpropyl, 3-cyclopropylpropyl, cyclobutylmethyl, 2-cyclobutylethyl, 2-cyclobutylpropyl, and 3-cyclobutylpropyl.
[0036] As used herein, the term "heterocycloalkyl" refers to a monocyclic or polycyclic [including two or more rings fused together, including spiro, fused, or bridged systems, e.g., bicyclic ring systems], saturated or unsaturated, non-aromatic 4- to 15-membered ring system (such as a 4- to 14-membered ring system, a 4- to 12-membered ring system, a 5- to 10-membered ring system, a 4- to 7-membered ring system, a 4- to 6-membered ring system, or a 5- to 6-membered ring system) containing 1 to 14 ring-forming carbon atoms and 1 to 10 ring-forming heteroatoms independently selected from O, S, and N (and, if present, optionally including P or B). Heterocycloalkyl groups can also contain one or more oxo (i.e., ═O) or thiono (i.e., ═S) groups. For example, the term "4- to 7-membered heterocycloalkyl" refers to a monocyclic or polycyclic, saturated or unsaturated, non-aromatic 4- to 7-membered ring system that includes one or more ring-forming heteroatoms each independently selected from O, S, and N. As another example, the term "5- or 6-membered heterocycloalkyl" refers to a monocyclic or polycyclic, saturated or unsaturated, non-aromatic 5- or 6-membered ring system that includes one or more ring-forming heteroatoms each independently selected from O, S, and N. A heterocycloalkyl group, when so specified, can be optionally substituted by one or more (e.g., 1 to 5) suitable substituents.
[0037] Some examples of 4 to 7 membered heterocycloalkyl include azetidinyl, oxetanyl, tetrahydrofuranyl, imidazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, thiomorpholinyl, tetrahydrothiazinyl, tetrahydrothiadiazinyl, morpholinyl, 1,3-oxazinanyl, tetrahydrodiazinyl, and tetrahydropyranyl (also known as oxanyl). Some further examples of 4 to 7-heterocycloalkyl are tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyranyl (e.g., tetrahydro-2H-pyran-4-yl), imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, piperazin-2-yl, 1,3-oxazolidin-3-yl, 1,4-oxazolidin-4-yl, 1,4-oxazolidin-1-yl, 1,4-oxazolidin-2-yl, 1,5-oxazolidin-3-yl, 1,6-oxazolidin-4-yl, 1,7-oxazolidin-4-yl, 1,8-oxazolidin-4-yl, 1,9-oxazolidin-4-yl, 1,9-oxazolidin-4-yl, 1,3-oxazolidin-4-yl, 1,4-oxazolidin-4-yl, 1,5-oxazolidin-4-yl, 1,6-oxazolidin-4-yl, 1,7-oxazolidin-4-yl, 1,8-oxazolidin-4-yl, 1,9-oxazolidin-4-yl, 1,9-oxazolidin-4-yl, 1,3-oxazolidin-4-yl, 1,4-oxazolidin-4-yl, 1,4-oxazolidin-4-yl, 1,4-oxazolidin-4-yl, 1,5-oxazolidin-4-yl, 1,4-oxazolidin-4-yl, 1,5-ox These include sazepan-2-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,2-tetrahydrothiazin-2-yl, 1,3-thiazinan-3-yl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, 1,3-oxazinan-2-yl (also known as tetrahydro-1,3-oxazin-2-yl), 1,4-oxazin-4-yl, oxazolidinonyl, 2-oxo-piperidinyl (e.g., 2-oxo-piperidin-1-yl), 2-oxoazepan-3-yl, and the like.
[0038] As used herein, the term "heteroaryl" refers to a monocyclic or fused-ring polycyclic aromatic heterocyclic group having one or more heteroatom ring members (ring-forming atoms) independently selected from O, S, and N in at least one ring. Heteroaryl groups have 1 to 13 carbon atoms and 5 to 14 ring-forming atoms, including 1 to 8 heteroatoms selected from O, S, and N. In some embodiments, heteroaryl groups have 5 to 10 ring-forming atoms, including 1 to 4 heteroatoms. Heteroaryl groups can also contain 1 to 3 oxo or thiono (i.e., ═S) groups. In some embodiments, heteroaryl groups have 5 to 8 ring-forming atoms, including 1, 2, or 3 heteroatoms. For example, the term "5-membered heteroaryl" refers to a monocyclic heteroaryl group as defined above having 5 ring-forming atoms in the monocyclic heteroaryl ring; the term "6-membered heteroaryl" refers to a monocyclic heteroaryl group as defined above having 6 ring-forming atoms in the monocyclic heteroaryl ring; and the term "5- or 6-membered heteroaryl" refers to a monocyclic heteroaryl group as defined above having 5 or 6 ring-forming atoms in the monocyclic heteroaryl ring. When specified as such, the heteroaryl group may be substituted with one or more (e.g., 1 to 5) suitable substituents. Examples of monocyclic heteroaryls include those having 5 ring-forming atoms, including 1 to 3 heteroatoms, or those having 6 ring-forming atoms, including 1, 2, or 3 nitrogen heteroatoms. Examples of fused bicyclic heteroaryls include two fused 5- and / or 6-membered monocyclic rings, each containing 1 to 4 heteroatoms.
[0039] Some examples of heteroaryl groups are pyridinyl (e.g., pyridin-2-yl, pyridin-3-yl, pyridin-4-yl), pyrazinyl, pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, or pyrimidin-5-yl), pyridazinyl (e.g., pyridazin-3-yl or pyridazin-4-yl), thienyl, furyl, imidazolyl (e.g., 1H-imidazol-4-yl), pyrrolyl, oxazolyl (e.g., 1,3-oxazolyl, 1,2-oxazolyl), thiazolyl (e.g., 1,2-thiazolyl, 1, 3-thiazolyl), pyrazolyl (e.g., pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl), tetrazolyl (e.g., 2H-tetrazol-5-yl), triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl), oxadiazolyl (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, or 1,3,4-oxadiazolyl), thiadiazolyl (e.g., 1,3,4-thiadiazolyl or 1,2,4-thiadiazolyl), quinolyl, isoquinolyl, benzothienyl, benzophenone, Zofuryl, indolyl, benzothiazolyl, 1,2-benzoxazolyl, 1H-imidazo[4,5-c]pyridinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-c]pyridinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-c][1,2,4]triazinyl, imidazo[1,5-a]pyrazinyl, imidazo[1,2-a]pyrimidinyl, 1H-indazolyl, 9H-purinyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5 -a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, isoxazolo[5,4-c]pyridazinyl, isoxazolo[3,4-c]pyridazinyl, pyrazolo[1,5-a]pyrimidinyl, 6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolyl, pyridone, pyrimidone, pyrazinone, pyrimidinone, 1H-imidazol-2(3H)-one, 1H-pyrrole-2,5-dione, 3-oxo-2H-pyridazinyl, 1H-2-oxo-pyrimidinyl, 1H-2-oxo-pyridinyl, 2,4(1H,3H)-dioxo-pyrimidinyl, 1H-2-oxo-pyrazinyl, etc.
[0040] As used herein, the compounds of formula I as described herein include optional substitutions and variables.It is understood that the normal valence of each designated (optionally substituted) atom or moiety is not exceeded, and any optional substitution will result in a stable compound.It is also understood that the combination of optional substituents and / or variables is acceptable only if such combination results in a stable compound.
[0041] As used herein, unless otherwise specified, the bonding point of a substituent can be from any suitable position of the substituent.For example, piperidinyl can be piperidin-1-yl (bonded through the N atom of piperidinyl), piperidin-2-yl (bonded through the C atom at the 2-position of piperidinyl), piperidin-3-yl (bonded through the C atom at the 3-position of piperidinyl) or piperidin-4-yl (bonded through the C atom at the 4-position of piperidinyl).As another example, pyridinyl (or pyridyl) can be 2-pyridinyl (or pyridin-2-yl), 3-pyridinyl (or pyridin-3-yl) or 4-pyridinyl (or pyridin-4-yl).
[0042] As used herein, the point of attachment of a substituent may be designated to indicate the position at which the substituent is attached to another moiety. For example, "(C 3~4 Cycloalkyl)-C 1~4 Alkyl-" is "(C 3~4 Cycloalkyl)-C 1~4 Alkyl-"C 1~4 means the point of attachment occurs at the "alkyl" portion.
[0043] When a substituted or optionally substituted moiety is described without indicating the atom through which such moiety is attached to the substituent, the substituent may be attached through any suitable atom in such moiety. For example, a substituted "(C 3~4 Cycloalkyl)-C 1~4 In "alkyl-", the substituents on the cycloalkylalkyl [i.e., (C 3~4 Cycloalkyl)-C 1~4 The alkyl-] is attached to any carbon atom on the alkyl or cycloalkyl portion of the cycloalkylalkyl. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0044] As used herein, the term "adjacent" when describing the relative positions of two substituent groups in a ring structure refers to two substituent groups that are respectively attached to two ring-forming atoms of the same ring, where the two ring-forming atoms are directly connected via a chemical bond. For example, in the structure below:
[0045] [ka] In each of the 2 R's 70 Any of the groups is R 60 is a neighboring group of
[0046] As used herein, two R F are substituted on the same carbon atom in the pyrrolidine moiety M-200 as shown below, and the two R F together with the same carbon atom to which they are attached to form C 3~6 When forming a cycloalkyl (eg, cyclobutyl), some examples of such moieties M-200 include moieties M-201, M-202 or M-203.
[0047] [ka]
[0048] "Mammal" refers to warm-blooded vertebrate animals characterized by the production of milk by females for the nourishment of their young, such as guinea pigs, mice, rats, gerbils, cats, rabbits, dogs, cows, goats, sheep, horses, monkeys, chimpanzees, and humans.
[0049] The term "pharmaceutically acceptable" means a substance (e.g., a compound of the invention) and any salts thereof, or a composition containing a substance or salt of the invention, that is suitable for administration to a patient.
[0050] As used herein, the expressions "reaction-inert solvent" and "inert solvent" refer to a solvent or mixture thereof that does not interact with the starting materials, reagents, intermediates, or products in a manner that adversely affects the yield of the desired product.
[0051] As used herein, the term "selectivity" or "selective" refers to the effect of a compound in a first assay being greater than the effect of the same compound in a second assay. For example, for an "intestine-selective" compound, the first assay measures the half-life of the compound in the small intestine, and the second assay measures the half-life of the compound in the liver.
[0052] "Therapeutically effective amount" means an amount of a compound of the present invention that (i) treats or prevents a particular disease, condition, or disorder; (ii) attenuates, ameliorate, or eliminates one or more symptoms of a particular disease, condition, or disorder; or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein.
[0053] The terms "treating," "treat," or "treatment" as used herein encompass both preventative, i.e., protective, and palliative treatment, including reversing, alleviating, relieving, or slowing the progression of any tissue damage associated with a disease (or disorder or condition) or one or more symptoms of a disease (or disorder or condition).
[0054] As used herein, the term "contacting" refers to bringing the indicated moieties into contact with each other in an in vitro system or in vivo system. For example, "contacting" an MC4R with a compound of the invention includes administering a compound of the invention to a mammal, such as a human, that has an MC4R, and, for example, introducing a compound of the invention into a sample containing a cell or purified preparation that contains an MC4R.
[0055] In a first aspect, the present invention provides a compound of formula I:
[0056] [ka] or a pharmaceutically acceptable salt thereof, R 1 is 1,2,4-triazolyl, tetrazolyl, 1,2,4-oxadiazolyl, imidazolyl, 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl, [1,2,4]triazolo[1,5-a]pyridinyl-, pyrazolyl or pyrimidinyl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 cycloalkyl, or R 1 is 1,2,4-triazolyl, tetrazolyl, 1,2,4-oxadiazolyl, imidazolyl, 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl, [1,2,4]triazolo[1,5-a]pyridinyl- or pyrimidinyl, each of which is selected from the group consisting of halogen, C 1~4Alkyl, C 1~4 Haloalkyl and C 3~4 cycloalkyl; R 2 and R 3 each independently represents H, a halogen, or C 1~4 Alkyl or C 1~4 Is it a haloalkyl? Or, R 2 and R 3 are optionally substituted, together with the carbon atom to which they are attached, with 1, 2, 3, 4 or 5 substituents each independently selected from halogen, C 3~4 forming a cycloalkyl, Y 1 and Y 2 Each of these is independently 4 or N, Each R 4 are independently H, halogen, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy or C 1~4 haloalkoxy, Each R F are independently halogen, -OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy, C 1~4 Haloalkoxy, C 3~4 Cycloalkyl or (C 3~4 Cycloalkyl)-C 1~4 alkyl- or Or, two R F When groups are substituted on the same carbon atom of the pyrrolidine ring of formula I, they, together with the carbon atom to which they are attached, are halogen, —OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 3~6 may form a cycloalkyl, or two RF When groups are substituted on the same carbon atom of the pyrrolidine ring of formula I, they, together with the carbon atom to which they are attached, are halogen, —OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 3~6 forming a cycloalkyl, R 7 is methyl or ethyl, t1 is 0, 1, 2, 3, or 4] to provide.
[0057] In some embodiments, the compound of Formula I or salt thereof comprises a deuterated alkyl. For example, each C 1~4 The alkyl may independently be a deuterated C 1~4 It can be alkyl.
[0058] In some embodiments, the compound of Formula I or a salt thereof is a compound of Formula Ia:
[0059] [ka] or a pharmaceutically acceptable salt thereof, wherein the variable group R 1 , R 2 , R 3 , R 4 , R 7 , R F , t1, Y 1 and Y 2 are defined the same as in compounds of formula I.
[0060] In some embodiments, the compound of formula I or a salt thereof is a compound of formula Ib:
[0061] [ka] or a pharmaceutically acceptable salt thereof, wherein the variable group R 1 , R2 , R 3 , R 4 , R 7 , R F , t1, Y 1 and Y 2 are defined the same as in compounds of formula I.
[0062] In some embodiments, the compound of formula I or salt thereof is a compound of formula II:
[0063] [ka] or a pharmaceutically acceptable salt thereof, R 5 and R 6 each is independently H, methyl or ethyl; Or, R 5 and R 6 together with the carbon atoms to which they are attached, form halogens, -OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 3~6 forming a cycloalkyl, Variable group R 1 , R 2 , R 3 , R 4 , R 7 , Y 1 and Y 2 are defined the same as in the compounds of formula I. is.
[0064] In some further embodiments of the compound of Formula II or a salt thereof: R 5 and R 6 each is independently H, methyl or ethyl; Or, R 5 and R 6together with the carbon atoms to which they are attached, form halogens, -OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 3~5 Forms a cycloalkyl (eg, cyclobutyl).
[0065] In some further embodiments of the compound of Formula II or a salt thereof: R 5 and R 6 each is independently H, methyl or ethyl; Or, R 5 and R 6 together with the carbon atoms to which they are attached, form halogens, -OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 4~6 Forms a cycloalkyl (eg, cyclobutyl or cyclopentyl).
[0066] In some embodiments, the compound of formula II or a salt thereof is a compound of formula II-a:
[0067] [ka] or a pharmaceutically acceptable salt thereof, wherein the variable group R 1 , R 2 , R 3 , R 4 , R 7 , Y 1 and Y 2 are defined the same as in the compounds of formula I or II or a pharmaceutically acceptable salt thereof, and the variable group R 5 and R 6are defined the same in the compound of formula II or a pharmaceutically acceptable salt thereof.
[0068] In some embodiments, the compound of formula II-a or salt thereof is a compound of formula II-b:
[0069] [ka] or a pharmaceutically acceptable salt thereof, wherein the variable group R 1 , R 2 , R 3 , R 4 , R 7 , Y 1 and Y 2 are defined the same as in a compound of Formula I, II, or IIa, or a pharmaceutically acceptable salt thereof, and the variable R 5 and R 6 are defined the same in a compound of formula II or IIa or a pharmaceutically acceptable salt thereof.
[0070] In some embodiments, the compound of Formula I or II or a salt thereof is a compound of Formula III:
[0071] [ka] or a pharmaceutically acceptable salt thereof, wherein the variable group R 1 , R 2 , R 3 , R 4 , R 7 , Y 1 and Y 2 Each of the following is defined the same in a compound of Formula I or II or a pharmaceutically acceptable salt thereof.
[0072] In some embodiments, the compound of formula III or a salt thereof is a compound of formula III-a:
[0073] [ka] or a pharmaceutically acceptable salt thereof, wherein the variable group R 1 , R 2 , R 3 , R 4 , R 7 , Y 1 and Y 2 Each of the following is defined the same in a compound of Formula I, II, or III, or a pharmaceutically acceptable salt thereof.
[0074] In some embodiments, the compound of formula III-a or salt thereof is a compound of formula III-b:
[0075] [ka] or a pharmaceutically acceptable salt thereof, wherein the variable group R 1 , R 2 , R 3 , R 4 , R 7 , Y 1 and Y 2 are defined the same in a compound of formula III or III-a or a pharmaceutically acceptable salt thereof.
[0076] In some embodiments of the compounds of Formula I or a pharmaceutically acceptable salt thereof (e.g., including compounds of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof), R 1 is 1,2,4-triazolyl, tetrazolyl, 1,2,4-oxadiazolyl or imidazolyl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 In some further embodiments, R 1 is 1,2,4-triazolyl, tetrazolyl, 1,2,4-oxadiazolyl or imidazolyl, each of which is selected from the group consisting of halogen, C 1~2 Alkyl, C 1~2Haloalkyl and C 3~4 It may be optionally substituted with 1, 2, or 3 substituents each independently selected from cycloalkyl.
[0077] In some embodiments of the compounds of Formula I or a pharmaceutically acceptable salt thereof (e.g., including compounds of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof), R 1 is 1H-1,2,4-triazol-3-yl, 2H-tetrazol-5-yl, 1,2,4-thiadiazol-5-yl or 1H-imidazol-4-yl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 In some further embodiments, R 1 is 1H-1,2,4-triazol-3-yl, 2H-tetrazol-5-yl, 1,2,4-thiadiazol-5-yl or 1H-imidazol-4-yl, each of which is selected from the group consisting of halogen, C 1~2 Alkyl, C 1~2 Haloalkyl and C 3~4 It may be optionally substituted with 1, 2, or 3 substituents each independently selected from cycloalkyl.
[0078] In some embodiments of the compounds of Formula I or a pharmaceutically acceptable salt thereof (e.g., including compounds of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof), R 1 is 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl or [1,2,4]triazolo[1,5-a]pyridinyl-, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 In some further embodiments, R 1is 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl or [1,2,4]triazolo[1,5-a]pyridinyl-, each of which is selected from the group consisting of halogen, C 1~2 Alkyl, C 1~2 Haloalkyl and C 3~4 It may be optionally substituted with 1, 2, or 3 substituents each independently selected from cycloalkyl.
[0079] In some embodiments of the compounds of Formula I or a pharmaceutically acceptable salt thereof (e.g., including compounds of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof), R 1 is a halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 In some further embodiments, R is 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl, optionally substituted with 1, 2, or 3 substituents each independently selected from cycloalkyl. 1 is a halogen, C 1~2 Alkyl, C 1~2 Haloalkyl and C 3~4 In some further embodiments, R is 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl, optionally substituted with 1, 2, or 3 substituents each independently selected from cycloalkyl. 1 is 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl optionally substituted with 1, 2 or 3 substituents each independently selected from halogen (e.g., F).
[0080] In some embodiments of the compounds of Formula I or a pharmaceutically acceptable salt thereof (e.g., including compounds of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof), R 1 is a halogen, C 1~2 Alkyl, C 1~2 Haloalkyl and C3~4 and [1,2,4]triazolo[1,5-a]pyridinyl- optionally substituted with 1, 2 or 3 substituents each independently selected from cycloalkyl.
[0081] In some embodiments of the compounds of Formula I or a pharmaceutically acceptable salt thereof (e.g., including compounds of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof), R 1 is a halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 In some further embodiments, R is pyrimidinyl optionally substituted with 1, 2, or 3 substituents each independently selected from cycloalkyl. 1 is a halogen, C 1~2 Alkyl, C 1~2 Haloalkyl and C 3~4 and pyrimidinyl optionally substituted with 1, 2 or 3 substituents each independently selected from cycloalkyl.
[0082] In some embodiments of the compounds of Formula I or a pharmaceutically acceptable salt thereof (e.g., including compounds of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof), R 1 is a halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 In some further embodiments, R is pyrimidin-2-yl, optionally substituted with 1, 2, or 3 substituents each independently selected from cycloalkyl. 1 is a halogen, C 1~2 Alkyl, C 1~2 Haloalkyl and C 3~4 In some embodiments, R is pyrimidin-2-yl, optionally substituted with 1, 2, or 3 substituents each independently selected from cycloalkyl. 1 is pyrimidin-2-yl.
[0083] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), R 2 and R 3 each independently represents H, F, or C 1~4 It is alkyl.
[0084] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), R 2 and R 3 each independently represents H, F, or C 1~2 It is alkyl.
[0085] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), R 2 and R 3 Each of is independently H or methyl.
[0086] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), R 2 is C 1~2 alkyl, and R 3 is H.
[0087] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), R 2 is methyl and R 3 is H.
[0088] In some embodiments of a compound of Formula II or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula II-a or II-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), R 5 and R 6 Each of is independently H or methyl.
[0089] In some embodiments of a compound of Formula II or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula II-a or II-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above, if applicable), R 5 and R 6 together with the carbon atoms to which they are attached, form C 3~5 Forms a cycloalkyl (eg, cyclobutyl).
[0090] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), R 7 is methyl.
[0091] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), Y 1 and Y 2 Each of these is independently4 is.
[0092] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), Y 1 and Y 2 One of them is N and the other is Y 1 and Y 2 The other is CR 4 is.
[0093] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), Y 2 is N and Y 1 is CR 4 is.
[0094] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above, if applicable), Y 1 is N and Y 2 is N.
[0095] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), each R 4 are independently H, halogen, C 1~2 Alkyl, C 1~2 Haloalkyl, C 1~2 Alkoxy or C 1~2In some further embodiments, each R 4 are independently H, F, Cl, C 1~2 Alkyl, C 1~2 Fluoroalkyl, C 1~2 Alkoxy or C 1~2 It is a fluoroalkoxy.
[0096] In some embodiments of a compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Ia, Ib, II, II-a, II-b, III, III-a, or III-b, or a pharmaceutically acceptable salt thereof, including, for example, any one of the embodiments described herein above), each R 4 are independently H, halogen (e.g., F or Cl), or C 1~2 It is an alkoxy.
[0097] In some embodiments, the present invention provides (2R)-2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-(2-methyl-2H-tetrazol-5-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one; (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(3S)-3-({6-methyl-5-[1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyridin-2-yl}amino)pyrrolidin-1-yl]propan-1-one; (2R)-1-[(3S)-3-({5-[5-(1,1-difluoroethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidin-1-yl]-2-(5-fluoro-2-methoxypyridin-4-yl)propan-1-one; (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-(2-methyl-2H-tetrazol-5-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one; (2R)-2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-(pyrimidin-2-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one; (2R)-1-[(3S)-3-({5-[5-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidin-1-yl]-2-(5-fluoro-2-methoxypyridin-4-yl)propan-1-one; (2R)-1-[(3S)-3-({5-[5-(difluoromethyl)-1-( 2 H3) methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidin-1-yl]-2-(5-fluoro-2-methoxypyridin-4-yl)propan-1-one; 2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-({5-[5-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidin-1-yl]propan-1-one, DIAST-2; 2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-({6-methyl-5-[1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyridin-2-yl}amino)pyrrolidin-1-yl]propan-1-one, DIAST-2; and (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-([1,2,4]triazolo[1,5-a]pyridin-2-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one, or a pharmaceutically acceptable salt thereof.
[0098] Each embodiment, example, or pharmaceutically acceptable salt thereof may be claimed individually or grouped together in any combination with any number of any and all embodiments described herein.
[0099] The compounds of formula I of the present invention (including, for example, compounds of formula Ia, Ib, II, II-a, IIb, III, IIIa, or III-b) or a pharmaceutically acceptable salt thereof may be used in any of the pharmaceutical compositions, uses, and methods of the invention described herein.
[0100] The compounds of formula I of the present invention (including, for example, compounds of formula Ia, Ib, II, II-a, IIb, III, IIIa, or III-b) or pharmaceutically acceptable salts thereof are MC4R antagonists.
[0101] In some embodiments, the amount of the compound of formula I, or a pharmaceutically acceptable salt thereof, used in any one of the methods (or uses) of the invention is effective to antagonize MC4R.
[0102] In a second aspect, the present invention provides a method for antagonizing MC4R (either in vitro or in vivo), comprising contacting (including incubating) MC4R with a compound of formula I described herein or a pharmaceutically acceptable salt thereof (such as any one of the embodiments or Examples 1 to 44B described herein).
[0103] In a third aspect, the present invention provides methods for treating a condition, disease, or disorder in a mammal (e.g., a human), comprising administering to the mammal (e.g., a human) a therapeutically effective amount of a compound of Formula I as described herein or a pharmaceutically acceptable salt thereof (such as any one of the embodiments described herein or Examples 1 to 44B), wherein the condition, disease, or disorder is an MC4R-associated condition, disease, or disorder. In some embodiments, the mammal (e.g., a human) is in need of such treatment.
[0104] In a fourth aspect, the present invention provides a method for treating a condition, disease, or disorder in a mammal (e.g., a human), comprising the step of administering to the mammal (e.g., a human) a therapeutically effective amount of a compound of Formula I as described herein or a pharmaceutically acceptable salt thereof (such as any one of the embodiments described herein or Examples 1 to 44B), wherein the condition, disease, or disorder is cachexia (e.g., cachexia associated with a chronic disease, for example, cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, for example, cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with the treatment of a chronic disease, for example, cachexia associated with steroids, steroids, or steroid drugs;
[0013] The method is provided in which the therapeutic effect is selected from the group consisting of: anorexia or anorexia nervosa (e.g., anorexia in the elderly, anorexia associated with chemotherapy and / or radiation therapy); nausea; vomiting; weight loss (e.g., involuntary weight loss); growth retardation; sarcopenia; muscle wasting; muscle weakness; frailty; osteoporosis; bone disorders (e.g., bone loss); pain; neuropathic pain; anxiety (e.g., post-traumatic stress disorder or PTSD); depression; hypertension; malnutrition; obesity (e.g., sarcopenia resulting from chronic obesity); sexual dysfunction; and inflammatory diseases (e.g., anorexia or cachexia or inflammatory diseases associated with sarcopenia or muscle wasting). In some embodiments, a mammal (e.g., a human) is in need of such treatment.
[0105] In a fifth aspect, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt of the compound (such as any one of the embodiments described herein or Examples 1 to 44B) for use as a medicament. In some further embodiments, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt of the compound ...medicament for use as a medicament. In some further embodiments, the present invention provides a compound of Formula I or a medicament for use as a medicament. In some further embodiments, the present invention provides a compound of Formula I or a medicament for use as a medicament. In some further embodiments, the present invention provides a compound of Formula I or a medicament for use as a medicament. In some further embodiments, the present invention provides a compound of Formula I or a medicament for use as a medicament. In some further embodiments, the present invention provides a compound of Formula I or a medicament for use as a medicament. In some further embodiments, the present invention provides a compound of Formula I or a medicament for use as a medicament. and inflammatory diseases (e.g., anorexia or cachexia or inflammatory diseases associated with sarcopenia or muscle wasting).
[0106] In a sixth aspect, the present invention provides the use of a compound of formula I as described herein or a pharmaceutically acceptable salt thereof (such as any one of the embodiments or Examples 1 to 44B described herein) as a medicament, in particular, the medicament is for use in the treatment of an MC4R-associated condition, disease or disorder, comprising administering a therapeutically effective amount to a mammal, such as a human, in need of such treatment.
[0107] In a seventh aspect, the present invention provides a method for the treatment of a disease, particularly a condition in which the medicament is for the treatment of cachexia (e.g., cachexia associated with a chronic disease, for example, cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, for example, cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with the treatment of a chronic disease, for example, cachexia associated with the treatment of cancer or cachexia associated with the treatment of heart failure (e.g., CHF)); anorexia or anorexia nervosa (e.g., anorexia in the elderly, or cachexia associated with chemotherapy and / or radiation therapy)), comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to a mammal, such as a human, in need of such treatment. and inflammatory diseases (e.g., anorexia or cachexia associated with sarcopenia or muscle wasting).
[0108] In an eighth aspect, the invention includes the use of a compound of Formula I or a pharmaceutically acceptable salt of the compound (such as any one of the embodiments or Examples 1-44B described herein) in the manufacture of a medicament. In some further embodiments, the invention includes the use of a compound of Formula I or a pharmaceutically acceptable salt of the compound (such as any one of the embodiments or Examples 1-44B described herein) in the manufacture of a medicament for treating an MC4R-associated condition, disease, or disorder, comprising administering a therapeutically effective amount to a mammal, such as a human, in need of such treatment.
[0109] In a ninth aspect, the present invention provides a method for treating cachexia (e.g., cachexia associated with a chronic disease, for example, cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, for example, cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with the treatment of a chronic disease, for example, including cachexia associated with the treatment of cancer or cachexia associated with the treatment of heart failure (e.g. CHF)); anorexia or anorexia nervosa (e.g., anorexia in the elderly, anorexia associated with chemotherapy and / or radiotherapy); nausea; vomiting; weight loss (e.g., involuntary weight loss); The present invention includes the use of a compound of Formula I or a pharmaceutically acceptable salt of the compound (such as any one of the embodiments or Examples 1 to 44B described herein) in the manufacture of a medicament for treating a condition, disease or disorder selected from growth retardation; sarcopenia; muscle wasting; muscle weakness; frailty; osteoporosis; bone disorders (e.g., bone loss); pain; neuropathic pain; anxiety (e.g., post-traumatic stress disorder or PTSD); depression; hypertension; malnutrition; obesity (e.g., sarcopenia resulting from chronic obesity); sexual dysfunction; and inflammatory diseases (e.g., anorexia or cachexia or inflammatory diseases associated with sarcopenia or muscle wasting).
[0110] The compounds of the present invention may contain asymmetric or chiral centers, and therefore may exist in various stereoisomeric forms.Unless otherwise specified, all stereoisomeric forms of the compounds of the present invention, as well as mixtures thereof, including racemic mixtures, are intended to form part of the present invention.In addition, the present invention encompasses all geometric and positional isomers.For example, if the compounds of the present invention incorporate double bonds or fused rings, both cis and trans forms, as well as mixtures, are encompassed within the scope of the present invention.
[0111] The chiral compounds of the present invention (and their chiral precursors) can be obtained in enantiomerically enriched form on a resin using chromatography, typically high-pressure liquid chromatography (HPLC) or supercritical fluid chromatography (SFC), with a chiral stationary phase and a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing 0 to 50% isopropanol, typically 2 to 20%, and 0 to 5% alkylamine, typically diethylamine (DEA) or 0.1% isopropylamine. The eluent is concentrated to yield the enriched mixture. When using SFC, the mobile phase may consist of a supercritical fluid, typically carbon dioxide, containing 2 to 50% alcohol, such as methanol, ethanol, or isopropanol.
[0112] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with a suitable optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers, and converting the individual diastereomers into their corresponding pure enantiomers (e.g., by hydrolysis). Enantiomers can also be separated using chiral HPLC columns. Alternatively, specific stereoisomers can be synthesized by asymmetric synthesis using optically active starting materials, optically active reagents, substrates, catalysts, or solvents, or by asymmetric transformation, converting one stereoisomer into another.
[0113] In some embodiments, compounds of the present invention may have asymmetric carbon atoms. Carbon-carbon bonds in compounds of Formula I are represented herein by solid lines (
[0114] [ka] ), wavy line (
[0115] [ka] ), solid wedge (
[0116] [ka] ), or dotted wedge (
[0117] [ka] ). The use of a solid line to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers at that carbon atom (e.g., specific enantiomers, racemic mixtures, etc.) are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is intended to indicate that only the stereoisomer shown is included. The use of a wavy line to depict bonds to asymmetric carbon atoms is intended to indicate that the stereochemistry is unknown (unless otherwise specified). It is possible that compounds of the present invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers are included. For example, unless otherwise stated, it is intended that compounds of the present invention may exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
[0118] Where a compound of the invention possesses two or more asymmetric centers and the absolute or relative stereochemistry is indicated in the name, the symbols R and S each refer to each asymmetric center in ascending numerical order (1, 2, 3, etc.) according to the conventional IUPAC numbering scheme for each molecule. Where a compound of the invention possesses one or more asymmetric centers and the stereochemistry is not indicated in the name or structural formula, it is understood that the name or structure is intended to encompass all forms of the compound, including the racemate.
[0119] The compounds of the present invention may contain olefin-like double bonds. When such bonds are present, the compounds of the present invention exist as cis and trans configurations, as well as mixtures thereof. The term "cis" refers to the orientation of two substituents relative to each other and to the plane of the ring (either both "up" or both "down"). Similarly, the term "trans" refers to the orientation of two substituents relative to each other and to the plane of the ring (these substituents are on opposite sides of the ring).
[0120] The intermediates and compounds of the present invention may also exist in different tautomeric forms, and all such forms are encompassed within the scope of the present invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations.
[0121] Valence tautomers include interconversions by reorganization of some of the bonding electrons.
[0122] All stereoisomers, geometric isomers, and tautomeric forms of the compounds of Formula I, including compounds exhibiting more than one type of isomerism and mixtures thereof, are included within the scope of the claimed compounds of the present invention. Also included are acid addition or base salts in which the counterion is optically active, e.g., D-lactate or L-lysine, or racemic, e.g., DL-tartrate or DL-arginine.
[0123] The present invention includes all pharmaceutically acceptable isotopically labeled compounds of Formula I in which one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
[0124] Examples of isotopes suitable for inclusion in the compounds of the present invention are: 2 H and 3 Hydrogen such as H 11 C. 13 C and 14 Carbon such as C, 36 chlorine such as Cl, 18 fluorine such as F, 123 I, 124 I and 125 Iodine, such as I 13 N and 15 Nitrogen such as N 15 O. 17 O and 18 Oxygen such as O 32 Phosphorus such as P, and 35 Contains sulfur isotopes such as S.
[0125] Certain isotopically labeled compounds of Formula I, for example, those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium, i.e., 3 H, and carbon-14, i.e., 14 C are particularly useful for this purpose given their ease of incorporation and ready means of detection.
[0126] Deuterium, i.e., 2 Substitution with heavier isotopes, such as H, may afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and therefore may be preferable in some circumstances.
[0127] 11 C. 18 F, 15 O and 13Substitution with positron emitting isotopes, such as N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
[0128] Isotopically labeled compounds of formula I can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples and preparations, substituting the appropriate isotopically labeled reagent for the previously used unlabeled reagent.
[0129] The compound of the present invention can be isolated and used as it is, or, if possible, in the form of its pharmaceutically acceptable salt.The term "salt" refers to the inorganic and organic salts of the compound of the present invention.These salts can be prepared in situ during the final isolation and purification of the compound, or by separately treating the compound with a suitable organic or inorganic acid or base and isolating the salt thus formed.
[0130] Salts encompassed by the term "pharmaceutically acceptable salts" generally refer to compounds of the present invention prepared by reacting the free base with a suitable organic or inorganic acid to provide a salt of the compound of the present invention that is suitable for administration to a patient. Suitable acid addition salts are formed from acids that form non-toxic salts. Examples include acetate, adipate, aspartate, benzoate, besylate, bicarbonate / carbonate, hydrogensulfate / sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hybenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, and lactate. , malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate, and xinofoate. See, e.g., Berge et al., J. Pharm. Sci. 66, 1-19 (1977); Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use (Wiley-VCH, 2002).
[0131] The compound of formula I and its pharmaceutically acceptable salts can exist in unsolvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising a compound of formula I or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable solvent molecules, such as ethanol. The term "hydrate" is used when the solvent is water.
[0132] The currently accepted classification system for organic hydrates defines isolated site, channel, or metal ion coordinated hydrates. See Polymorphism in Pharmaceutical Solids, by KR Morris (ed. HG Brittain, Marcel Dekker, 1995). Isolated site hydrates are those in which the water molecules are isolated from direct contact with each other by intervening organic molecules. In channel hydrates, the water molecules lie in lattice channels where they are adjacent to other water molecules. In metal ion coordinated hydrates, the water molecules are bound to the metal ion.
[0133] When the solvent or water is tightly bound, the complex may have a well-defined stoichiometry that is independent of humidity. However, when the solvent or water is weakly bound, such as in channel solvates and hygroscopic compounds, the water / solvent content may depend on humidity and drying conditions. In such cases, non-stoichiometry becomes the norm.
[0134] Also included within the scope of the present invention are multicomponent complexes (other than salts and solvates) in which the drug and at least one other component are present in stoichiometric or non-stoichiometric amounts. This type of complex includes clathrates (drug-host inclusion complexes) and cocrystals. The latter are typically defined as crystalline complexes of neutral molecular components bound together through non-covalent interactions, but may also be complexes of neutral molecules and salts. Cocrystals can be prepared by melt crystallization, recrystallization from solvents, or by physically grinding the components together. See O. Almarsson and MJ Zaworotko, Chem. Commun., 17, 1889-1896 (2004). For a general review of multicomponent complexes, see Haleblian, J. Pharm. Sci., 64(8), 1269-1288 (1975).
[0135] Compounds of the present invention include compounds of formula I, as defined herein above, or pharmaceutically acceptable salts thereof, polymorphs thereof, and isomers (including optical, geometric and tautomeric forms) as defined herein below, as well as isotopically labeled compounds of formula I, or pharmaceutically acceptable salts thereof.
[0136] The compounds of the present invention can be administered as prodrugs. Thus, certain derivatives of compounds of Formula I or their pharmaceutically acceptable salts, which may themselves have little or no pharmacological activity, can be converted, for example by hydrolytic cleavage, upon administration into or onto the body to compounds of Formula I or their pharmaceutically acceptable salts having the desired activity. Such derivatives are referred to as "prodrugs." [Further information on the use of prodrugs can be found in "Prodrugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and "Bioreversible Carriers in Drug Design," Pergamon Press, 1987 (E.B. Broche, ed., American Pharmaceutical Association)]
[0137] For example, prodrugs can be prepared by replacing suitable functional groups present in the compounds of formula I or their pharmaceutically acceptable salts with certain moieties known to those skilled in the art as "promoieties," for example, as described in "Design of Prodrugs" by H. Bundgaard (Elsevier, 1985).
[0138] Some examples of such prodrugs are: (i) When a compound of formula I or a pharmaceutically acceptable salt thereof contains an alcohol functional group (—OH), replacement of the hydrogen with an ether thereof, e.g., (C1-C6) alkanoyloxymethyl; or a phosphate ester (—O—PO3H2) or sulfate ester (—O—SO3H) or a pharmaceutically acceptable salt thereof; and (ii) The hydrogen atoms of the amino NH group are each (C1 to C 10 ) alkanoyl or (C1-C 10 ) amides or carbamates of the amino functions present in formula (I) or (II) replaced by alkoxycarbonyl Includes.
[0139] Also included within the scope of the present invention are active metabolites of the compounds of Formula I (including prodrugs) or their pharmaceutically acceptable salts, i.e., compounds formed in vivo upon administration of the drug, often by oxidation or dealkylation. Some examples of metabolites in accordance with the present invention are: (i) When a compound of formula I or a pharmaceutically acceptable salt thereof contains a methyl group, its hydroxymethyl derivative (-CH3 → -CH2OH) and (ii) When a compound of formula I or a pharmaceutically acceptable salt thereof contains an alkoxy group, its hydroxy derivative (—OR→—OH) Includes.
[0140] Certain compounds of the present invention may exist in multiple crystalline forms (generally referred to as "polymorphs"). Polymorphs can be prepared under various conditions, such as by crystallizing using different solvents or different solvent mixtures for recrystallization; by crystallizing at different temperatures; and / or by various cooling modes ranging from very fast to very slow cooling during crystallization. Polymorphs may also be obtained by heating or melting the compounds of the present invention, followed by slow or rapid cooling. The presence of polymorphs can be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffraction, or other such techniques.
[0141] Generally, the compounds of the present invention can be prepared by processes that include processes similar to those known in the chemical arts, particularly in light of the description contained herein. Certain processes for the preparation of the compounds of the present invention are provided as further features of the present invention and are illustrated by the following reaction schemes. Other processes can be described in the experimental section. Specific synthetic schemes for the preparation of compounds of Formula I and / or their pharmaceutically acceptable salts are outlined below. It should be noted that tetrazoles are generally high-energy functional groups, and care should be taken when synthesizing and handling tetrazole-containing molecules.
[0142] Starting materials are generally available from commercial sources such as MilliporeSigma (Milwaukee, WI), or can be easily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, vol. 1-19, Wiley, New York (ed. 1967-1999), or Beilstein's Handbuch der Organischen Chemie, 4th edition, Springer-Verlag, Berlin, including supplements (also available through the Beilstein online database)). Many of the compounds used herein are related to or derived from compounds of great scientific interest and commercial demand, and therefore many of these compounds are commercially available, or have been reported in the literature, or can be easily prepared from other commercially available materials by methods reported in the literature.
[0143] It should be noted that in preparing compounds of Formula I or their salts, some of the preparation methods described herein may require protection of remote functional groups (e.g., primary amines, secondary amines, carboxyls in the precursors of Formula I). The need for such protection will vary depending on the nature of the remote functional group and the conditions of the preparation method. The need for such protection is readily determined by those skilled in the art. The use of such protection / deprotection methods is also within the skill of those skilled in the art. For a general overview of protecting groups and their use, see T.W. Greene, Protective Groups in Organic Synthesis, 5th Edition, John Wiley & Sons, New York, 2014. For example, certain compounds contain primary amine or carboxylic acid functional groups that, if left unprotected, may interfere with reactions at other sites in the molecule. Therefore, such functional groups may be protected by appropriate protecting groups that can be removed in a subsequent step. Suitable protecting groups for amine and carboxylic acid protection include protecting groups commonly used in peptide synthesis (such as N-tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc) for amines, and lower alkyl or benzyl esters for carboxylic acids), which are generally not chemically reactive under the reaction conditions described and can typically be removed without chemically altering other functional groups in the compound of Formula I or its salts.
[0144] The reaction can be monitored according to any suitable method known in the art. For example, product formation can be monitored by nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometric methods (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
[0145] Compounds of Formula I, their salts, and intermediates can be prepared according to the following reaction schemes and accompanying discussion. The reaction schemes described below are intended to provide an overview of the methodology used in preparing the compounds of the present invention. Some compounds of the present invention will contain a single chiral center with a stereochemical assignment (R or S), while others will contain two separate chiral centers with a stereochemical assignment (R or S). It will be apparent to those skilled in the art that most of the synthetic transformations can be carried out in a similar manner whether the materials are enantiomerically enriched or racemic. Furthermore, resolution to the desired optically active materials can occur at any desired point in the sequence using well-known methods, such as those described herein and in the chemical literature.
[0146] Unless otherwise indicated, R in the reaction schemes and discussion that follow 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , (R F ) t1 , Y 1 , Y 2 and structural formula I (including, for example, Ia, Ib, and II) are as defined herein or correspond to those described herein. Certain processes for the preparation of compounds of the present invention and intermediates thereof are provided as further features of the present invention and are illustrated by the following reaction schemes. Other processes are described in the experimental section. The schemes and examples provided herein (including corresponding descriptions) are for illustrative purposes only and are not intended to limit the scope of the present invention.
[0147] In the reaction scheme that follows, the variable group X c , X F , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , Y 6 , M1 , R 2c , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , L.G. 1 , L.G. 2 , L.G. 3 , P.G. 1 , P.G. 2 , P.G. 3 , P.G. 4 and P.G. 5 are as described herein or in the claims unless otherwise noted, consistent with that of Formula I. For each variable, its meaning remains the same as originally stated unless otherwise indicated later.
[0148] Scheme 1 illustrates the synthesis of compounds of formula I, Ia, and Ib. An acid of formula 1-1 can be reacted with an amine of formula 1-2 (or a salt thereof) using standard amidation conditions employing coupling reagents such as 1,1'-carbonyldiimidazole, 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (T3P), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), etc., to provide a compound of formula I. Alternatively, an acid of formula 1-1 can be reacted with an amine of formula 1-3 in a similar manner to form a compound of formula Ia. Alternatively, an acid of type 1-4 can be reacted with an amine of formula 1-3 in a similar manner to form a compound of formula Ib. Acids of formula 1-1 and 1-4 can be purchased, synthesized as described in Org. Process Res. Dev. 1997, 1, 72, or synthesized as described herein. Acids of formula 1-1 containing a mixture of enantiomers can be separated into individual diastereomers or enantiomers as desired to produce compounds of formula 1-4 using supercritical fluid chromatography or reverse-phase chromatography with a chiral column.
[0149] Amines of Formula 1-2 can be synthesized as described herein. Compounds of Formula I containing a mixture of enantiomers or diastereomers can be separated into individual diastereomers or enantiomers as desired to produce compounds of Formula Ia or Ib using supercritical fluid chromatography or reverse-phase chromatography with a chiral column. When a single enantiomer of the acid of Formula 1-4 is used, racemization or epimerization can occur under some common amidation conditions. Alternatively, a high enantiomeric excess can be maintained throughout the reaction by using lower temperatures, using a solvent to aid in dissolving the reactants, using additives such as imidazolium or pyridinium salts, or other methods as described in Org. Process Res. Dev. 2016, 20, 140; Org. Lett. 2012, 14, 1970; or Org. Process Res. Dev. 2009, 13, 106, or by using the free base of the amine of Formula 1-3. Alternatively, when typical conditions are used, or when epimerization or racemization occurs, the mixture of diastereomers formed can be separated using supercritical fluid or reverse phase chromatography with a chiral column, or as diastereomeric salts with an appropriate chiral acid under typical resolution conditions to form compounds of formula Ib.
[0150] [ka]
[0151] Scheme 2 describes an alternative synthesis of compounds of formula I and Ib. An amine of formula 2-1 is reacted with a heterocycle of formula 2-2 (where X 1 are F, Cl, Br, I, OTf, SO2Me, etc.) and S NCompounds of formula Ib can be formed under Ar-type conditions (using organic or inorganic bases such as N,N-diisopropylethylamine, triethylamine; sodium, potassium, or cesium carbonate or bicarbonate; DBU, cesium fluoride, tetrabutylammonium fluoride, etc., with a variety of solvents such as dimethyl sulfoxide, ethanol, 1,4-dioxane, N,N-dimethylacetamide, etc., under conventional heating or microwave conditions) or under standard C-N cross-coupling conditions with palladium or copper catalysts bearing appropriate ligands. Alternatively, compounds of formula 2-3 (wherein X 2 is Cl, Br, I, OTf, etc.) with a diboron source [such as tetrahydroxydiboron, bis(neopentylglycolato)diboron (5,5,5',5'-tetramethyl-2,2'-bi-1,3,2-dioxaborinane) or bis(pinacolato)diboron (4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane)], a ditin source such as bis(tributyltin), etc., a strong metal-containing base such as isopropylmagnesium chloride, followed by a zinc source such as zinc dichloride, etc., to produce a compound of formula 2-4, where M 1 X can be a boronic acid, boronate, organotin, organozinc, or other metal capable of reacting under CC cross-coupling conditions) and can be isolated if stable or inserted into another reaction if desired. 3 are Cl, Br, I, OTf, etc.) and Suzuki (M 1 = boron), Still (M 1 =Suzu), Negishi (M 1 = zinc halide), Kumada (M 1= magnesium halide)-type reaction, etc. to form compounds of formula Ib. Alternatively, compounds of formula 2-3 and 2-6 can be reacted with an inverted nucleophile and electrophile in a cross-coupling reaction in a manner similar to 2-4 and 2-5 to form compounds of formula Ib. Alternatively, compounds of formula 2-7, 2-8, 2-9 can be reacted under the same conditions as their stereodefined analogous intermediates from this scheme, without modification of the conditions, to result in the formation of compounds of formula I.
[0152] Additionally, compounds of formula 2-7, 2-8, 2-9 can be separated into their analogous single enantiomers at any point along the pathway by using similar separation techniques as described above for the separation into compounds of formula Ib.
[0153] [ka]
[0154] Scheme 3 describes a method for the selective synthesis of acids of formula 1-4 as single enantiomers. Acids of formula 3-1 can be purchased or synthesized using methods described in the literature or herein, and can be catalyzed by the addition of well-known chiral auxiliaries (X) such as Evans-type (optically pure oxazolidinones), Myers-type (derived from pseudoephedrine), or others described in the literature. c ) to form an intermediate of formula 3-2. The compound of formula 3-2 can be reacted with a strong base such as lithium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, and an alkyl halide (R 2 and / or R 3 is an alkyl group) or other electrophiles such as N-fluorobenzenesulfonimide (R 2 and / or R 3is fluorine), compounds of formula 3-3 can be formed in high diastereomeric excess. c The conditions for hydrolysis of groups will depend on the particular properties, but often neat or aqueous reagents such as potassium hydroxide, sodium hydroxide, lithium hydroxide (inorganic bases), among others, with or without hydrogen peroxide and protic solvents such as methanol, ethanol, etc. or aprotic solvents such as tetrahydrofuran can be used to form compounds of formula 1-4.
[0155] [ka]
[0156] Scheme 4 describes a method that can be used to synthesize acids of formula 4-9 (a subtype of compounds of formula 1-1), 4-7 (a subtype of compounds of formula 1-4), or 4-8 (a subtype of compounds of formula 1-4). Aryl or heteroaryl compounds of formula 4-1 (wherein X 1 is as defined above) to a diprotected malonate of formula 4-2 (wherein PG 1 can be methyl, ethyl, tert-butyl, benzyl, p-methoxybenzyl, etc., and PG 2 can be orthogonally removed protecting groups selected from the same group or can be the same protecting group), and S NCross-coupling reactions as described in Org. Lett. 2007, 9, 3469 using Ar conditions or palladium catalysts such as palladium(II) acetate or tris(dibenzylideneacetone)dipalladium(0) [Pd(dba)], etc., with a range of available phosphine ligands, or copper catalysts such as copper(I) iodide, or acidic ligands such as 2-picolinic acid, can provide intermediates of formula 4-3. Compounds of formula 4-3 can be treated with a suitable base such as sodium hydride, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, potassium carbonate, cesium carbonate, etc., followed by alkylation with alkylating agents such as methyl iodide, ethyl iodide, etc., fluorinating agents such as N-fluorobenzenesulfonimide, or other electrophiles to provide compounds of formula 4-4. Alternatively, compounds of formula 4-1 can be reacted with compounds of formula 4-6 to form compounds of formula 4-4 directly (under conditions similar to those used for the conversion of compounds of formula 4-1 to compounds of formula 4-3). Removal of the protecting group in compounds of formula 4-4 can be accomplished using standard methods (basic or acidic hydrolysis); or by PG 1 Or PG 2When is benzyl, this can be accomplished by using a palladium catalyst with a hydrogen or reducing source such as a formate, trialkylsilane, etc. to form an intermediate of formula 4-5. Alternatively, a compound of formula 4-4 can directly form an acid of formula 4-9 under similar conditions (as used in making a compound of formula 4-5) or conditions that may require elevated temperatures. The diacid of formula 4-5 can be monodecarboxylated using a base, acid, copper(I) oxide, heating, or other suitable conditions to provide the racemic acid of formula 4-9. Acids of formula 4-9, containing a mixture of enantiomers, can be separated using supercritical fluid or reverse-phase chromatography using a chiral column, or separated and isolated as diastereomeric salts with appropriate chiral acids under classical resolution conditions, such as those described in Org. Process Res. Dev. 2011, 15, 53, or one enantiomer can be selectively converted to an ester using a biocatalyst as described in Adv. Synth. Catal., 2009, 351, 2333 (see also J. Org. Chem. 2003, 68, 7234), and separated to form acids of formula 4-7 or 4-8 in high enantiomeric excess. Diacids of formula 4-5 can also be monodecarboxylated using a biocatalyst, such as an arylmalonate decarboxylase (AMDase) enzyme, to provide single enantiomers of compounds of formula 4-7 or 4-8 in high enantiomeric excess. See, for example, (a) J. Am. Chem. Soc. 1990, 112, 4077; (b) Eur. J. Biochem. 1992, 210, 475; (c) Appl. Environ. Microbiol. 2007, 73, 5676; (d) Appl. Microbiol. Biotechnol. 2016, 100, 8621.
[0157] [ka]
[0158] Scheme 5 illustrates the synthesis of acids of formula 5-6 (a subtype of compounds of formula 1-1), 5-7 (a subtype of compounds of formula 1-4), and 5-8 (a subtype of compounds of formula 1-4), where R 2c can be, for example, H, alkyl, halogen, etc. (R 2 or R 3 aryl or heteroaryl halides of formula 5-1 (wherein X 4(I, Br, or in some cases Cl) can be purchased or synthesized using methods well known to those skilled in the synthetic arts. Aryl or heteroaryl halides of formula 5-1 can be reacted with a suitable reagent, such as n-butyllithium, isopropylmagnesium chloride, or a similar metal-containing base or magnesium metal, to perform a metal-halogen exchange and quench with a dicarbonyl compound of formula 5-3 to provide compounds of formula 5-4. Alternatively, arenes or heteroarene of formula 5-2 can be directly deprotonated with a similar strong base or reagent, such as lithium diisopropylamide, lithium 2,2,6,6-tetramethylpiperidide, bis(2,2,6,6-tetramethylpiperidinyl)zinc, or other variations thereof, and reacted with a dicarbonyl compound of formula 5-3 to form compounds of formula 5-4. Compounds of formula 5-4 can be treated with a strong acid, such as hydrochloric acid, sulfuric acid, boron trifluoride diethyl etherate, or other Bronsted or Lewis acids, to form compounds of formula 5-5. Compounds of formula 5-5 can be treated with a reducing agent such as silane in the presence of an acid, or with hydrogen and a metal catalyst such as palladium, to form compounds of formula 5-6. Alternatively, compounds of formula 5-4 can be treated with a similar acid or with hydrogen and a metal catalyst such as palladium in the presence of a reducing agent such as silane to form acids of formula 5-6. Alternatively, compounds of formula 5-5 can be treated with hydrogen and a metal such as ruthenium or rhodium, and a chiral ligand, or many other methods, such as those described in Org. Chem. Front. 2014, 1, 155, to selectively form acids of formula 5-7 or 5-8 in high enantiomeric excess. Alternatively, compounds of formula 5-5 can be converted with a biocatalyst such as ENE reductase (such as those described in ACS Catal. 2018, 8, 3532) or other methods to selectively form compounds of formula 5-7 or 5-8 in high enantiomeric excess.Alternatively, compounds of formula 5-6 containing a mixture of enantiomers can be separated using supercritical fluid or reverse phase chromatography using a chiral column, or can be separated and isolated under typical resolution conditions as diastereomeric salts with a suitable chiral acid to form compounds of general formula 5-7 or 5-8.
[0159] [ka]
[0160] Scheme 6 describes certain other methods for synthesizing acids of formula 1-1 and 1-4. Compounds of formula 6-1 are deprotonated with a strong base to afford carbon dioxide or carbonyl compounds of formula 6-2 (wherein LG 1 is a leaving group such as chloride or alkoxide, and PG 1 is a protecting group such as those described above) to form compounds of formula 6-3. Compounds of formula 6-3 can be deprotonated with a strong base and treated with an alkylating agent to form compounds of formula 6-4 in a manner similar to that described above for the conversion of compounds of formula 3-2 to compounds of formula 3-3. Compounds of formula 6-4 can be acylated with PG under hydrolysis conditions or with PG in a manner similar to that described above for the conversion of compounds of formula 3-3 to compounds of formula 1-4. 1 is a benzyl group, then with a metal catalyst such as palladium on carbon and hydrogen, or with PG to form compounds of formula 1-1 1If 6-3 can be eliminated or eliminated as a stable cation, it can be treated with acid to form a compound of formula 1-1. Alternatively, the steps can be rearranged so that a compound of formula 6-3 is hydrolyzed to a compound of formula 6-5, which is then alkylated using similarly described conditions to form a compound of formula 1-1. Alternatively, a compound of formula 6-4 can be treated with biocatalytic conditions, such as an esterase enzyme, to form an acid of formula 1-4 in high enantiomeric excess. Alternatively, a compound of formula 6-6 can be treated with a strong acid, such as hydrochloric acid or sulfuric acid, in the presence of an alcohol, such as methanol or ethanol, to form a compound of formula 6-3. A compound of formula 6-6 can be alkylated to form a compound of formula 6-7 using similar methods described for the conversion of a compound of formula 6-3 to a compound of formula 6-4. Alternatively, compounds of formula 6-7 can be directly hydrolyzed to acids of formula 1-1 using either strong acids such as hydrochloric acid or sulfuric acid or strong bases such as sodium hydroxide, potassium hydroxide, or lithium hydroxide in the presence of water. Alternatively, compounds of formula 6-8 (wherein LG 2 (wherein 1 is a leaving group such as Cl, Br, I, OMs, OTs, etc.) can be treated with a cyanide source such as sodium cyanide, trimethylsilyl cyanide, etc. to form compounds of formula 6-6. Compounds of formula 6-8 can be purchased or prepared by various methods as described in the literature or by LG. 2 When R is, for example, Br or Cl, compounds of formula 6-1 can be synthesized by reacting them with a halogenated electrophile such as N-bromosuccinimide, bromine, etc., with a radical initiating activator such as 2,2'-azobisisobutyronitrile, light, or other reagents. Compounds of formula 6-12 (R 2The subtype of compounds of formula 6-8, where is H, can be converted to all of the analogous intermediates and compounds derived from 6-8 using similar methods. Compounds of formula 6-14 can be treated with a base and alkylating agent as described for the conversion of 6-3 to 6-4 to form compounds of formula 1-1. Compounds of formula 6-11 can be purchased or synthesized using methods described in the literature. Compounds of formula 6-9 can also be oxidized using an oxidizing reagent such as potassium permanganate to form compounds of formula 6-11. Compounds of formula 6-11 can be homologated to form compounds of formula 6-10 using any number of methods reported in the literature, such as the Arndt-Eistert reaction (using an activating reagent such as thionyl chloride, ethyl chloroformate, etc.; followed by a diazomethane reagent; a silver salt such as silver benzoate, silver oxide, etc.; and a nucleophile such as water or an alcohol) or other methods described in the literature, such as that described in J. Org. Chem. 2001, 66, 5606. Acids of formula 1-1 containing a mixture of enantiomers can be separated using supercritical fluid or reverse-phase chromatography using chiral columns, or as diastereomeric salts with appropriate chiral acids under classical resolution conditions such as those described in Org. Process Res. Dev. 2011, 15, 53, or the undesired enantiomer can be converted to an ester and separated using a biocatalyst as described in Adv. Synth. Catal., 2009, 351, 2333 (see also J. Org. Chem. 2003, 68, 7234) to form acids of formula 1-4 in high enantiomeric excess.
[0161] [ka]
[0162] Scheme 7 shows the synthesis of compounds of formula 7-3, 7-4, 7-7, 7-8 and 7-9, where Q 1This describes the synthesis of compounds of formula 7-1 (where PG may be any fragment of a compound described in formula I, Ia, Ib, or in Schemes 3-6), which can be used as any of the intermediates already described above, where appropriate, and these substituents can be placed at many points during the synthesis described in Schemes 3-6. 1 (as previously described) can be deprotected using dealkylation conditions such as trimethylsilyl iodide, sodium methanethiolate, etc., strong acids such as hydrobromic acid, boron tribromide, etc., or PG 1 When LG is a benzyl group, compounds of formula 7-2 can be formed using palladium or related metals and hydrogen gas. Compounds of formula 7-2 can be reacted with a difluoromethyl source such as a difluorohaloacetate or (bromodifluoromethyl)trimethylsilane to form compounds of formula 7-3. Compounds of formula 7-2 can also be reacted with a trifluoromethyl source such as a difluorohaloacetate with the addition of an electrophilic fluorine source such as Selectfluor™, a trifluoromethyl halide, or via an intermediate xanthate that can be treated with XtalFluor® and an electrophilic fluorine source such as N-fluorobenzenesulfonimide or 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione (TCCA) (as described in J. Org. Chem. 2019, 84, 15776), etc. to form compounds of formula 7-4. Compounds of formula 7-5 (wherein LG 3(wherein Λ can be Cl, Br, I, OTf, etc.) can be treated with a nucleophilic vinyl source such as vinyl boronate, vinyl stannane, etc., using palladium-catalyzed cross-coupling conditions described in the literature to form compounds of formula 7-6. Compounds of formula 7-6 can be oxidatively cleaved to aldehydes to form compounds of formula 7-7 using reagents such as ozone with triphenylphosphine or dimethyl sulfide, osmium tetroxide (or ruthenium trichloride), and sodium periodate, etc. Alternatively, compounds of formula 7-5 can be directly converted to compounds of formula 7-7 by reacting them under metal-halogen exchange conditions such as isopropylmagnesium chloride, n-butyllithium, magnesium, etc., and quenching with a carbonyl source such as N,N-dimethylformamide, morpholine-4-carbaldehyde, etc. Compounds of formula 7-7 can be reacted with nucleophilic difluoromethylation sources such as Deoxo-Fluor® or XtalFluor® and related reagents to form compounds of formula 7-8. N Treatment with alcohols using Ar or palladium under cross-coupling conditions and various ligands affords compounds of formula 7-9, where R 10 For example, C 1~4 Alkyl (e.g., methyl) or C 1~4 Alternatively, compounds of formula 7-2 can be converted to methyl- (where R 10 is methyl), ethyl- (wherein R 10 is ethyl), isopropyl- (wherein R 10 is isopropyl) or cyclopropyl iodide (wherein R 10 is cyclopropyl) to form compounds of formula 7-9.
[0163] [ka]
[0164] Scheme 8 describes the synthesis of compounds of formula 1-2 and 1-3. Compounds of formula 8-1 (wherein PG 3 can be benzyl, p-methoxybenzyl, tert-butoxycarbonyl, benzyloxycarbonyl, acetyl, benzoyl or other common nitrogen protecting groups, and PG 4 PG 3 or a similar protecting group that can be orthogonally removed, or can be hydrogen if no protecting group is needed) with an electrophilic halogenating reagent such as dibromohydantoin, N-bromosuccinimide, N-chlorosuccinimide, bromine, iodine, etc. to give compounds of formula 8-3, where X 2 is defined above), can be formed. Compounds of formula 8-3 can be reacted with a diboron source [such as tetrahydroxydiboron, bis(neopentylglycolato)diboron (5,5,5',5'-tetramethyl-2,2'-bi-1,3,2-dioxaborinane) or bis(pinacolato)diboron (4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane)], a ditin source such as bis(tributyltin) or the like, a strong metal-containing base such as isopropylmagnesium chloride, followed by a zinc source such as zinc dichloride or the like, to form compounds of formula 8-2, where M 1 X can be a boronic acid, boronate, organotin, organozinc, or other metal capable of reacting under CC cross-coupling conditions) and can be isolated if stable or inserted into another reaction if desired. 3 (as described above) and Suzuki (M 1 = boron), Still (M 1 =Suzu), Negishi (M 1 = zinc halide), Kumada (M 1= magnesium halide) type reaction or the like to form compounds of formula 8-4. Alternatively, compounds of formula 8-3 and 2-6 can be reacted with a nucleophile and electrophile inverted in a cross-coupling reaction in a manner similar to 8-2 and 2-5 to form compounds of formula 8-4. Alternatively, in some cases, compounds of formula 8-1 can be reacted with compounds of formula 2-5 under CH activation / direct arylation conditions to form compounds of formula 8-4 directly. PG of compounds of formula 8-4 3 and P.G. 4 The group can be removed using appropriate deprotection conditions, such as acid or hydrogenolysis, to form compounds of formula 1-2. Note: When compounds of formula 8-1, 8-2, 8-3, 8-4, or 1-2 contain a mixture of stereochemistry or are racemic, they can be separated into single enantiomers using supercritical fluid or reverse-phase chromatography with a chiral column, or separated as diastereomeric salts with an appropriate chiral acid under classical resolution conditions to form compounds of formula 8-5, 8-7, 8-6, 8-8, or 1-3, respectively, in high enantiomeric excess. Alternatively, compounds of formula 8-5, 8-7, 8-6, and 8-8 can be reacted under the same conditions as their analogous intermediates from this scheme, without modification of the conditions, to result in the formation of compounds of formula 1-3.
[0165] [ka]
[0166] Scheme 9 describes the synthesis of compounds of formula 2-3 and 2-8. Compounds of formula 9-1 can be prepared by Scheme 2 synthesis using a similar Scheme 2 reaction to that described for the synthesis of Ib from 2-1 (Scheme 2). N Halo-pyridines of formula 9-2 (wherein X 1 and X 2 is as described above) to form compounds of formula 8-3. 3 and P.G. 4The group can be removed using appropriate deprotection conditions, such as acid or hydrogenolysis, to form compounds of formula 9-3. Compounds of formula 9-3 can be amidated with compounds of formula 1-1 or 1-4 in a manner similar to the conversion of amines of formula 1-2 to compounds of formula I (Scheme 1). Note—When compounds of formula 9-1, 8-3, 9-3, or 2-8 contain a mixture of stereochemistry or are racemic, they can be separated into single enantiomers using supercritical fluid or reverse-phase chromatography with a chiral column, or separated as diastereomeric salts with an appropriate chiral acid under classical resolution conditions to form compounds of formula 9-4, 8-6, 9-5, or 2-3, respectively, in high enantiomeric excess. Alternatively, compounds of formula 9-4, 8-6, and 9-5 can be reacted under the same conditions as their analogous intermediates from this scheme, without modification of the conditions, to result in the formation of compounds of formula 2-3.
[0167] [ka]
[0168] Scheme 10 describes the synthesis of compounds of formula 2-2 and the alternative syntheses of 8-4 and 8-8. Compounds of formula 10-1 (wherein R 11 is H, Me, Et, or can cyclize with each other to form a 5- or 6-membered alkyl ring, such as in boron pinacolate or neopentyl glycolate, can be reacted with a compound of formula 2-5 under Suzuki cross-coupling conditions [similar to those previously described for the conversion of 2-4 to Ib (Scheme 2)] to form a compound of formula 2-2. Alternatively, a compound of formula 9-2 (where X 1 and X 2 As mentioned above, X 2 is X 1 are more reactive than e.g., X 2 If is I, then X 1 is Br, Cl or F, or X 2 If Br, then X 1is Cl or F) can be reacted with a compound of formula 2-6 in a manner similar to the conversion of 2-3 to Ib (Scheme 2). A compound of formula 9-1 can be reacted with a compound of formula 2-2 and S N Compounds of formula 8-4 can be formed under Ar or metal-catalyzed cross-coupling conditions similar to those described for the synthesis of Ib from 2-1 (Scheme 2). Compounds of formula 9-4 can also be reacted in an analogous manner with compounds of formula 2-2 to form compounds of formula 8-8.
[0169] [ka]
[0170] Scheme 11 illustrates the synthesis of compounds of formula 2-5, as well as 11-3, a subtype of 2-5 that may not be commercially available (wherein Y 6 is N or CH) and describes the synthesis of compounds of formula 11-9. Compounds of formula 11-1 can be reacted with an electrophilic halogen source in a manner similar to the conversion of compounds of formula 8-1 to 8-3 to form compounds of formula 11-2. Compounds of formula 11-2 (where X 3 are defined above) with compounds of formula 7-2 to 7-3 (R 12 is H) or compounds of formula 7-2 to 7-4 (where R 12 is F) to give compounds of formula 11-3. 5 is X 3 or X 3 If is Cl, then X 5 is Br or X 3 If is Br or Cl, then X 5 (where R is more reactive than I) can be prepared under Chang-Lam-type conditions to afford boronic acid 11-5 (where R 13where R is cyclopropyl, methyl, ethyl, other alkyl groups with or without fluorine atoms, or other variations thereof containing deuterium instead of hydrogen) and a copper source such as copper(II) acetate or the like and a suitable ligand such as 2,2'-bipyridine, as well as any number of bases such as carbonates or amines and a co-oxidant such as oxygen, which may be added or derived from the air, can be reacted to produce compounds of formula 11-7. Alternatively, compounds of formula 11-4 can be reacted with compounds of formula 11-6 (where R 13 and L.G. 3 (described above) can be reacted in a nucleophilic substitution reaction using an organic base such as N,N-diisopropylethylamine, triethylamine, or an inorganic base such as cesium, potassium, or sodium carbonate; sodium or potassium hydride; lithium diisopropylamide; lithium, sodium, or potassium hexamethyldisilazide; or sodium or potassium hydroxide, etc. to form a compound of formula 11-7. 13 is methyl) under metal-halogen exchange conditions such as isopropylmagnesium chloride, n-butyllithium, magnesium, etc., and quenched with a carbonyl source such as N,N-dimethylformamide, morpholine-4-carbaldehyde, etc., to produce compounds of formula 11-8. Compounds of formula 11-8 can be reacted under conditions similar to the conversion of compounds of formula 7-7 to 7-8 to give compounds of formula 11-9. 14 is hydrogen, compounds of formula 11-9 can be prepared. Alternatively, compounds of formula 11-10 can be treated with hydrobromic acid, potassium bromide, potassium iodide, sodium nitrite or isoamyl nitrite, or other standard Sandmeyer-type conditions to form compounds of formula 2-5.
[0171] [ka]
[0172] Scheme 12 shows the R 1is an optionally substituted alkyl or aryl group, 15 This paper describes a method for the synthesis of compounds of formula 12-5, a subtype of compounds of formula 8-8, which are tetrazoles substituted with . Compounds of formula 8-6 can be reacted via transformations similar to those described for the synthesis of compounds of formula 7-6 and 7-7 from formula 7-5 (Scheme 7) to form compounds of formula 12-1 and 12-2, respectively. Alternatively, compounds of formula 8-6 (X 2 Compounds of formula 12-2 can be directly converted to compounds of formula 12-2 by reacting them with substituted hydrazines 12-3 (or salts thereof, where R 15 is methyl, ethyl, other alkyl, fluorinated alkyl, or deuterated alkyl) under standard condensation conditions using an acid or base additive (e.g., triethylamine or N,N-diisopropylethylamine) with a variety of solvents such as methanol, tetrahydrofuran, toluene, dimethyl sulfoxide, etc. to form compounds of formula 12-4. Compounds of formula 12-4 can be reacted with an azo compound such as diethyl or di-tert-butyl azodicarboxylate in the presence of a hypervalent iodine source such as [bis(trifluoroacetoxy)iodo]benzene, etc. to produce compounds of formula 12-5.
[0173] [ka]
[0174] Scheme 13 shows the R 1 This paper describes the synthesis of compounds of formula 13-4, which are a subtype of compounds of formula 8-8, in which the oxadiazole group is present. Compounds of formula 9-4 can be synthesized by reacting compounds of formula 13-1 with S NCompounds of formula 13-2 can be formed by reaction under Ar or metal-catalyzed cross-coupling conditions (similar to those described for the conversion of 2-1 to Ib in Scheme 2). Compounds of formula 13-2 can be reacted with hydroxylamine (as a salt or in the free form) to form compounds of formula 13-3. Compounds of formula 13-3 can be cyclized to oxadiazoles of formula 13-4 by reaction with electrophilic trifluoroacetate-containing reagents such as trifluoroacetic anhydride, trifluoroacetyl halides, etc. under acidic or basic conditions (such as cesium, potassium, or sodium carbonate), or with organic bases such as triethylamine or N,N-diisopropylethylamine, or with heating.
[0175] [ka]
[0176] Scheme 14 illustrates the synthesis of compounds of formula 14-6 (R 1 is a substituted imidazole as described herein. Carboxylic acids of formula 14-1 can be converted to methyl ketones of formula 14-2 using a variety of homologating conditions, such as treatment with methyllithium, initial conversion of the acid to a Weinreb amide or other amide followed by treatment with a nucleophilic methyl source such as methyllithium, methylmagnesium halide, or other similar reagent, or other single or multi-step conditions known in the literature or to those skilled in the art. Compounds of formula 14-2 are treated with a halogenated electrophile (such as N-bromosuccinimide, bromine, chlorine, iodine, dibromoethane, dibromotetrachloroethane, etc.) with a radical initiating activator (such as 2,2'-azobisisobutyronitrile, light, or other reagents) with or without a base or with or without an acid (such as p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid, etc.) to give compounds of formula 14-3, where X 6is Cl, Br, or I. Compounds of formula 14-3 can be reacted with amidines of formula 14-4 in the presence or absence of a base such as triethylamine to form imidazoles of formula 14-5. Compounds of formula 14-5 can then be reacted with compounds of formula 11-6, where R 13 (as described above) can be reacted with compounds of formula 11-4 and 11-6 to form compounds of formula 11-7 (Scheme 11) to form compounds of formula 14-6.
[0177] [ka]
[0178] Scheme 15 shows the R 1 This paper describes the synthesis of compounds of formula 15-6, which are a subtype of compounds of formula 2-5, a bicyclic system as described below. Compounds of formula 11-4 can be converted to epoxides of formula 15-1 (wherein PG 5 (can be any stable oxygen protecting group compatible with the reaction conditions, such as t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, benzyl, p-methoxybenzyl, or many other common groups) can be reacted with compounds of formula 11-4 to form compounds of formula 11-6 (Scheme 11) to form compounds of formula 11-7, forming compounds of formula 15-2. Compounds of formula 15-2 can be oxidized to compounds of formula 15-3 using an oxidizing reagent such as Dess-Martin periodinane, under Swern-type conditions using a metal catalyst and stoichiometric oxidant such as tetrapropylammonium perruthenate with N-methylmorpholine N-oxide, or any of a number of other oxidation conditions known to those skilled in the art or found in the literature. Compounds of formula 15-3 can be converted to difluoro compounds of formula 15-4 using conditions similar to the conversion of compounds of formula 7-7 to compounds of formula 7-8 (Scheme 7). The compound of formula 15-4 is reacted with PG 5 Deprotection of the PG group 5is a silyl protecting group, tetrabutylammonium fluoride; PG 5 is a p-methoxybenzyl group, acidic conditions; or PG 5 is a benzyl protecting group, selective hydrogenolysis conditions; or given PG 5 The compound of formula 15-5 may be converted to a compound of formula 15-5 by deprotection of the S group, such as that described for the conversion of compounds of formula 2-1 and 2-2 to compounds of formula Ib (Scheme 2). N Compounds of formula 15-4 can be cyclized to compounds of formula 15-6 using Ar or metal catalyzed coupling conditions. Under certain conditions, the deprotection conditions used to convert compounds of formula 15-4 to compounds of formula 15-5 can be used to convert t-butyldimethylsilyl PG 5 Intramolecular S, such as when tetrabutylammonium fluoride is used to remove N If the Ar reaction is also facile, compounds of formula 15-4 can be directly converted to compounds of formula 15-6.
[0179] [ka]
[0180] Detailed descriptions of the individual reaction steps are provided in the Examples section below. Those skilled in the art will recognize that other synthetic routes can be used to synthesize the compounds. While specific starting materials and reagents are discussed below, other starting materials and reagents can be readily substituted to provide a variety of derivatives and / or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.
[0181] Combination drugs The compound of the present invention can be administered alone or in combination with one or more additional therapeutic agents. "Administered in combination" or "combination therapy" means that the compound of the present invention and one or more additional therapeutic agents are administered simultaneously to the mammal being treated. When administered in combination, each component can be administered simultaneously or sequentially in any order at different times. Thus, each component can be administered separately but sufficiently close in time to provide the desired therapeutic effect. The terms "concurrent administration," "co-administration," "simultaneous administration," and "administered simultaneously" mean that the compounds are administered in combination. Thus, the methods of prevention and treatment described herein include the use of combinations.
[0182] The combination is administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" is meant an amount of a compound of the present invention that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to treat the desired disease / disorder / condition (e.g., cachexia, anorexia, anorexia nervosa, nausea; vomiting, growth retardation, sarcopenia, muscle wasting, weakness, osteoporosis, bone loss, pain, anxiety, depression, or hypertension).
[0183] In some embodiments, the compounds of the present invention may be administered in combination with one or more other agents, such as orlistat, TZDs and other insulin sensitizers, FGF21 analogs, metformin, omega-3 acid ethyl esters (e.g., Lovaza), fibrates, HMG, to name a few. CoA-reductase inhibitors, ezetimibe, probucol, ursodeoxycholic acid, TGR5 agonists, FXR agonists, vitamin E, betaine, pentoxifylline, CB1 antagonists, carnitine, N-acetylcysteine, reduced glutathione, lorcaserin, a combination of naltrexone and bupropion, SGLT2 inhibitors (including dapagliflozin, canagliflozin, empagliflozin, tofogliflozin, ertugliflozin, ASP-1941, THR1474, TS-071, ISIS388626 and LX4211 and those in WO2010023594), phentermine, topiramate, GLP-1 receptor agonists, GIP receptor agonists, dual GLP-1 receptor / glucagon receptor agonists (e.g., OPK88003, MEDI0382, JNJ-64565111, NN9277, BI456906), dual GLP-1 receptor / GIP receptor agonists [e.g., tirzepatide (LY3298176), NN9423], angiotensin receptor blockers, acetyl-CoA carboxylase (ACC) inhibitors, BCKDK inhibitors, ketohexokinase (KHK) inhibitors, ASK1 inhibitors, branched-chain alpha ketoacid dehydrogenase kinase inhibitors (BCKDK inhibitors), inhibitors of CCR2 and / or CCR5, PNPLA3 inhibitors, DGAT1 inhibitors, DGAT2 inhibitors, FGF21 analogs, FGF19 analogs, PPAR agonists, FXR agonists, AMPK activators [e.g., ETC-1002 (bempedoic acid)], SCD1 inhibitors, or MPO inhibitors.
[0184] Exemplary GLP-1 receptor agonists include liraglutide, albiglutide, exenatide, albiglutide, lixisenatide, dulaglutide, semaglutide, HM15211, LY3298176, Medi-0382, NN-9924, TTP-054, TTP-273, epheglenatide, those described in WO2018109607, those described in PCT / IB2019 / 054867 filed June 11, 2019, and those described in PCT / IB2019 / 054961 filed June 13, 2019, including: 2-({4-[2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-cyano-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-3-(1,3-oxazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(1-ethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(1,3-oxazol-4-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(pyridin-3-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(1,3-oxazol-5-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(1-ethyl-1H-1,2,3-triazol-5-yl)methyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-chloro-2-fluorophenyl)-7-fluoro-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(4-cyano-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-cyano-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(1-ethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2R)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(1-ethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[(2R)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-({4-[2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, DIAST-X2; 2-[(4-{2-[(4-chloro-2-fluorobenzyl)oxy]pyridin-3-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-[(4-{2-[(4-chloro-2-fluorobenzyl)oxy]pyridin-3-yl}piperidin-1-yl)methyl]-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-[(4-{2-[(4-cyano-2-fluorobenzyl)oxy]pyridin-3-yl}piperidin-1-yl)methyl]-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-[(4-{2-[(4-cyano-2-fluorobenzyl)oxy]pyridin-3-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-[(4-{3-[(4-chloro-2-fluorobenzyl)oxy]pyrazin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-(6-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}-6-azaspiro[2.5]oct-1-yl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-(6-{2-[(4-chloro-2-fluorobenzyl)oxy]-5-fluoropyrimidin-4-yl}-6-azaspiro[2.5]oct-1-yl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-(6-{2-[(4-chloro-2-fluorobenzyl)oxy]-5-fluoropyrimidin-4-yl}-6-azaspiro[2.5]oct-1-yl)-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid; 2-(6-{6-[(4-cyano-2-fluorobenzyl)oxy]-5-fluoropyridin-2-yl}-6-azaspiro[2.5]oct-1-yl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-(6-{6-[(4-cyano-2-fluorobenzyl)oxy]-3-fluoropyridin-2-yl}-6-azaspiro[2.5]oct-1-yl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-[(4-{2-[(4-chloro-2-fluorobenzyl)oxy]pyrimidin-4-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-{[(2S)-4-{2-[(4-chloro-2-fluorobenzyl)oxy]-5-fluoropyrimidin-4-yl}-2-methylpiperazin-1-yl]methyl}-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; 2-{[(2S)-4-{2-[(4-chloro-2-fluorobenzyl)oxy]pyrimidin-4-yl}-2-methylpiperazin-1-yl]methyl}-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; and 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, and pharmaceutically acceptable salts thereof.
[0185] Exemplary ACC inhibitors include 4-(4-[(1-isopropyl-7-oxo-1,4,6,7-tetrahydro-1′H-spiro[indazol-5,4′-piperidine]-1′-yl)carbonyl]-6-methoxypyridin-2-yl)benzoic acid, gemcabene, and filsocostat (GS-0976), and pharmaceutically acceptable salts thereof.
[0186] Exemplary FXR agonists include tropifexor (2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid), cilofexor (GS-9674), obeticholic acid, LY2562175, Met409, TERN-101, and EDP-305, and pharmaceutically acceptable salts thereof.
[0187] Exemplary KHK inhibitors include [(1R,5S,6R)-3-{2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid and pharmaceutically acceptable salts thereof.
[0188] An exemplary DGAT2 inhibitor includes (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide, including its crystalline solid forms (Form 1 and Form 2). See U.S. Pat. No. 10,071,992.
[0189] Exemplary BCKDK inhibitors are those described in U.S. Patent Application No. 62 / 868,057, filed June 28, 2019, and U.S. Patent Application No. 62 / 868,542, filed June 28, 2019, including: 5-(5-chloro-4-fluoro-3-methylthiophen-2-yl)-1H-tetrazole; 5-(5-chloro-3-difluoromethylthiophen-2-yl)-1H-tetrazole; 5-(5-fluoro-3-methylthiophen-2-yl)-1H-tetrazole; 5-(5-chloro-3-methylthiophen-2-yl)-1H-tetrazole; 5-(3,5-dichlorothiophen-2-yl)-1H-tetrazole; 5-(4-bromo-3-methylthiophen-2-yl)-1H-tetrazole; 5-(4-bromo-3-ethylthiophen-2-yl)-1H-tetrazole; 5-(4-chloro-3-ethylthiophen-2-yl)-1H-tetrazole; 3-chloro-5-fluorothieno[3,2-b]thiophene-2-carboxylic acid; 3-Bromo-5-fluorothieno[3,2-b]thiophene-2-carboxylic acid; 3-(Difluoromethyl)-5-fluorothieno[3,2-b]thiophene-2-carboxylic acid; 5,6-difluorothieno[3,2-b]thiophene-2-carboxylic acid; and 3,5-Difluorothieno[3,2-b]thiophene-2-carboxylic acid; or a pharmaceutically acceptable salt thereof.
[0190] In some embodiments, a compound of the invention may be co-administered with one or more antidiabetic agents. Suitable antidiabetic agents include insulin, metformin, GLP-1 receptor agonists (as described herein above), acetyl-CoA carboxylase (ACC) inhibitors (as described herein above), SGLT2 inhibitors (as described herein above), monoacylglycerol O-acyltransferase inhibitors, phosphodiesterase (PDE)-10 inhibitors, AMPK activators (e.g., ETC-1002 (bempedoic acid)), sulfonylureas (e.g., acetohexamide, chlorpropamide, diabinese, glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, gliquidone, glisolamide, tolazamide, and tolbutamide), meglitinides, α-amylase inhibitors (e.g., tendamistat, trestatin, and AL-3688). , α-glucoside hydrolase inhibitors (e.g., acarbose), α-glucosidase inhibitors (e.g., adiposine, camiglibose, emiglitate, miglitol, voglibose, pradimicin-Q, and salbostatin), PPARγ agonists (e.g., balaglitazone, ciglitazone, darglitazone, englitazone, isaglitazone, pioglitazone, tazone and rosiglitazone), PPARα / γ agonists (e.g., CLX-0940, GW-1536, GW-1929, GW-2433, KRP-297, L-796449, LR-90, MK-0767, and SB-219994), protein tyrosine phosphatase-1B (PTP-1B) inhibitors [e.g., trodusquemine, hiruthiosal extract, and Zhang, S.et al., Drug Discovery Today, 12(9 / 10), 373-381(2007)], SIRT-1 activators (e.g., resveratrol, GSK2245840 or GSK184072), dipeptidyl peptidase IV (DPP-IV) inhibitors (e.g., those in WO2005116014, sitagliptin, vildagliptin, alogliptin, dutogliptin, linagliptin and saxagliptin), insulin secretagogues, fatty acid oxidation inhibitors, A2 antagonists, c-jun amino-terminal kinase (JNK) inhibitors, glucokinase activity inhibitors Glycoproteins (GKa), for example, those described in WO2010103437, WO2010103438, WO2010013161, WO2007122482, TTP-399, TTP-355, TTP-547, AZD1656, ARRY403, MK-0599, TAK-329, AZD5658 or GKM-001, insulin, insulin mimetics, glycogen phosphorylase inhibitors (e.g., GSK1362885), VPAC2 receptor agonists, glucagon receptor modulators, for example, Demong, DE et al., Annual Reports in Medicinal Chemistry 2008, 43, 119-137; GPR119 modulators, particularly agonists, for example, WO2010140092, WO2010128425, WO2010128414, WO2010106457, Jones, RM et al., Annual Reports in Medicinal Chemistry 2009, 44, 149-170 (e.g., MBX-2982, GSK1292263, APD597 and PSN821); FGF21 derivatives or analogs, for example, Kharitonenkov, A. et al., Current Opinion in Investigational Drugs 2009, 10(4)359-364, TGR5 (also called GPBAR1) receptor modulators, particularly agonists, e.g., those described in Zhong, M., Current Topics in Medicinal Chemistry, 2010, 10(4), 386-396, and INT777; GPR40 agonists, including but not limited to TAK-875, as described in Medina, JC, Annual Reports in Medicinal Chemistry, 2008, 43, 75-85; GPR120 modulators, particularly agonists; high-affinity nicotinic acid receptor (HM74A) activators; and SGLT1 inhibitors, including GSK1614235. A further representative list of antidiabetic agents that can be combined with the compounds of the invention can be found, for example, in WO2011005611, page 28, line 35 to page 30, line 19.
[0191] Other antidiabetic agents may include inhibitors or modulators of the enzyme carnitine palmitoyltransferase, inhibitors of fructose 1,6-diphosphatase, inhibitors of aldose reductase, mineralocorticoid receptor inhibitors, inhibitors of TORC2, inhibitors of CCR2 and / or CCR5, inhibitors of PKC isoforms (e.g., PKCα, PKCβ, PKCγ), inhibitors of fatty acid synthase, inhibitors of serine palmitoyltransferase, modulators of GPR81, GPR39, GPR43, GPR41, GPR105, Kv1.3, retinol binding protein 4, glucocorticoid receptors, somatostatin receptors (e.g., SSTR1, SSTR2, SSTR3 and SSTR5), inhibitors or modulators of PDHK2 or PDHK4, inhibitors of MAP4K4, modulators of the IL1 family including IL1 beta, modulators of RXR alpha. Additionally, suitable antidiabetic agents include those mechanisms listed by Carpino, PA, Goodwin, B. Expert Opin. Ther. Pat., 2010, 20(12), 1627-51.
[0192] The compounds of the present invention are useful as ACE inhibitors (e.g., captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril), angiotensin II receptor blockers (e.g., candesartan, losartan, valsartan), angiotensin receptor neprilysin inhibitors (sacubitril / valsartan), I f It may be co-administered with anti-heart failure agents such as the channel blocker ivabradine, beta-adrenergic blockers (e.g., bisoprolol, metoprolol succinate, carvedilol), aldosterone antagonists (e.g., spironolactone, eplerenone), hydralazine and isosorbide dinitrate, diuretics (e.g., furosemide, bumetanide, torsemide, chlorothiazide, amiloride, hydrochlorothiazide, indapamide, metolazone, triamterene), or digoxin.
[0193] The compounds of the present invention may be used in combination with the following exemplary agents: HMG CoA reductase inhibitors (e.g., pravastatin, pitavastatin, lovastatin, atorvastatin, simvastatin, fluvastatin, NK-104 (also known as itavastatin, or nisvastatin or nisbastatin) and ZD-4522 (also known as rosuvastatin, or atavastatin or visastatin); squalene synthetase inhibitors; fibrates (e.g., gemfibrozil, pemafibrate, fenofibrate, clofibrate); bile acid sequestrants (questran, colestipol, colesevelam, etc.). may be co-administered with cholesterol or lipid-lowering agents, including: ACAT inhibitors; MTP inhibitors; lipoxygenase inhibitors; cholesterol absorption inhibitors (e.g., ezetimibe); nicotinic acid agonists (e.g., niacin, niacol, slo-niacin); omega-3 fatty acids (e.g., epanova, fish oil, eicosapentaenoic acid); cholesteryl ester transfer protein inhibitors (e.g., obiscetrapib) and PCSK9 modulators [e.g., alirocumab, evolocumab, bococizumab, ALN-PCS (incrisiran)].
[0194] The compounds of the present invention may be used in combination with antihypertensive agents, and such antihypertensive activity is readily determined by those skilled in the art according to standard assays (e.g., blood pressure measurements). Examples of suitable antihypertensive agents include alpha-adrenergic blocking agents; beta-adrenergic blocking agents; calcium channel blockers (e.g., diltiazem, verapamil, nifedipine, and amlodipine); vasodilators (e.g., hydralazine); diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid, tricrynafen, chlorthalidone, torsemide, furosemide, musolimine, bumetanide, triamterene, amiloride, and spironolactone); renin inhibitors; ACE inhibitors (e.g., captopril, zofranil, and the like). Examples of antianginal agents include: enopril, fosinopril, enalapril, serranopril, cilazopril, delapril, pentopril, quinapril, ramipril, and lisinopril; AT-1 receptor antagonists (e.g., losartan, irbesartan, and valsartan); ET receptor antagonists (e.g., sitaxsentan, atrasentan, and compounds disclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265); dual ET / AII antagonists (e.g., compounds disclosed in WO00 / 01389); neutral endopeptidase (NEP) inhibitors; and vasopeptidase inhibitors (dual NEP-ACE inhibitors) (e.g., gemopatrilat and nitrates). An exemplary antianginal agent is ivabradine.
[0195] Examples of suitable calcium channel blockers (L-type or T-type) include diltiazem, verapamil, nifedipine and amlodipine, and mybefradil.
[0196] Examples of suitable cardiac glycosides include digitalis and ouabain.
[0197] In one embodiment, a compound of the invention may be co-administered with one or more diuretics. Examples of suitable diuretics include (a) loop diuretics, such as furosemide (such as LASIX™), torsemide (such as DEMADEX™), bumetanide (such as BUMEX™), and ethacrynic acid (such as EDECRIN™); (b) thiazide diuretics, such as chlorothiazide (such as DIURIL™, ESIDRIX™, or HYDRODIURIL™), hydrochlorothiazide (such as MICROZIDE™ or ORETIC™), benzthiazide, hydroflumethiazide (such as SALURON™), benzisothiazide, and thiazide. (c) phthalimidine diuretics, such as chlorthalidone (HYGROTON™) and metolazone (ZAROXOLYN™); (d) quinazoline diuretics, such as quinethazone; and (e) potassium-sparing diuretics, such as triamterene (DYRENIUM™) and amiloride (MIDAMOR™ or MODURETIC™).
[0198] In another embodiment, the compounds of the present invention may be co-administered with a loop diuretic. In yet another embodiment, the loop diuretic is selected from furosemide and torsemide. In yet another embodiment, one or more compounds of Formula I or pharmaceutically acceptable salts thereof may be co-administered with furosemide. In yet another embodiment, one or more compounds of Formula I or pharmaceutically acceptable salts thereof may be co-administered with torsemide, which may be a controlled or modified release form of torsemide.
[0199] In another embodiment, the compounds of the present invention may be co-administered with a thiazide diuretic. In yet another embodiment, the thiazide diuretic is selected from the group consisting of chlorothiazide and hydrochlorothiazide. In yet another embodiment, one or more compounds of Formula I or pharmaceutically acceptable salts thereof may be co-administered with chlorothiazide. In yet another embodiment, one or more compounds of Formula I or pharmaceutically acceptable salts thereof may be co-administered with hydrochlorothiazide.
[0200] In another embodiment, one or more compounds of Formula I or pharmaceutically acceptable salts thereof may be co-administered with a phthalimidine diuretic, hi yet another embodiment, the phthalimidine diuretic is chlorthalidone.
[0201] Examples of suitable mineralocorticoid receptor antagonists include spironolactone and eplerenone.
[0202] Examples of suitable phosphodiesterase inhibitors include PDE III inhibitors (such as cilostazol) and PDE V inhibitors (such as sildenafil).
[0203] Those skilled in the art will recognize that the compounds of the present invention may also be used in conjunction with other cardiovascular or cerebrovascular procedures, including PCI, stenting, drug-eluting stents, stem cell therapy and medical devices such as implantable pacemakers, defibrillators, or cardiac resynchronization therapy.
[0204] Particularly when provided as a single dosage unit, there is a potential for chemical interaction between the combined active ingredients.For this reason, when the compound of the present invention and a second therapeutic agent are combined in a single dosage unit, they are formulated so that the physical contact between the active ingredients is minimized (i.e., reduced) even when the active ingredients are combined in a single dosage unit.For example, one active ingredient may be enteric-coated.By enteric-coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also to control the release of one of these ingredients in the gastrointestinal tract, so that these ingredients are not released in the stomach but in the intestine.One of the active ingredients may be coated with a material that achieves sustained release throughout the gastrointestinal tract and also serves to minimize the physical contact between the combined active ingredients.In addition, a sustained-release component may be additionally enteric-coated so that the release of this component occurs only in the intestine. Another approach would involve formulating a combination product in which one component is coated with a sustained and / or enteric release polymer to further separate the active ingredients, and the other component is coated with a polymer such as low viscosity grades of hydroxypropylmethylcellulose (HPMC) or other suitable materials as known in the art. The polymer coating serves to form an additional barrier to interaction with the other component.
[0205] These and other techniques for minimizing contact between the components of the combination products of the present invention, whether administered in a single dosage form or in separate forms but administered simultaneously by the same mode, will be readily apparent to those of skill in the art upon reading the present disclosure.
[0206] In combination therapy treatment, both the compounds of this invention and the other medications are administered to a mammal (e.g., a human, male or female) by conventional methods. The compounds of Formula I or salts thereof are adapted for therapeutic use as agents that antagonize (including inhibit) MC4R in mammals, particularly humans, and are therefore useful in treating a variety of conditions (e.g., those described herein) in which such action is implicated.
[0207] Diseases / disorders / conditions that may be treated in accordance with the present invention include, but are not limited to, cachexia (e.g., cachexia associated with cancer, AIDS, CHF and / or CKD); anorexia / anorexia nervosa (e.g., anorexia in the elderly, anorexia associated with chemotherapy and / or radiation therapy); nausea; vomiting; weight loss (e.g., involuntary weight loss); growth retardation; sarcopenia; muscle wasting; frailty; osteoporosis; bone disorders (e.g., bone loss); pain; neuropathic pain; anxiety; depression; hypertension; malnutrition; obesity; sexual dysfunction; and inflammatory diseases.
[0208] The administration of the compounds of the present invention can be via any method that delivers the compounds of the present invention systemically and / or locally. These methods include oral route, parenteral, intraduodenal route, buccal, intranasal, etc. Generally, the compounds of the present invention are administered orally, but parenteral administration (e.g., intravenous, intramuscular, subcutaneous, or intramedullary) can be utilized, for example, when oral administration is inappropriate for the target or when the patient is unable to ingest the drug.
[0209] In the case of administration to human patients, the oral daily dose of the compounds herein can be, for example, within the range of 0.01 mg to 5000 mg, depending on the mode and frequency of administration, the disease state, and the age and condition of the patient, etc. The oral daily dose can be within the range of 1 mg to 2000 mg (for example, 3 mg to 2000 mg). Another oral daily dose is within the range of 5 mg to 1000 mg. For convenience, the compounds of the present invention can be administered in unit dosage form. If desired, the total daily dose can be increased by using a unit dosage form with multiple doses per day. The unit dosage form may be, for example, a tablet or capsule containing about 0.1, 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 500, or 1000 mg of a compound of the invention. The total daily dose may be administered in single or divided doses and, at the physician's discretion, may fall outside of the typical ranges given herein.
[0210] For administration to human patients, the daily infusion dose of the compounds herein may range from 1 mg to 2000 mg, depending, of course, on the mode and frequency of administration, the disease state, and the age and condition of the patient, etc. Further daily infusion doses are in the range of 5 mg to 1000 mg. The total daily dose may be administered in single or divided doses and, at the physician's discretion, may fall outside the typical ranges set forth herein.
[0211] According to the methods of treatment of the present invention, a compound of the present invention or a combination of a compound of the present invention and at least one additional pharmaceutical agent (herein referred to as a "combination") is administered to a subject in need of such treatment, preferably in the form of a pharmaceutical composition. In the combination aspect of the present invention, the compound of the present invention and at least one other pharmaceutical agent (e.g., another anti-cachexia or anti-anorexia agent) can be administered separately or in a pharmaceutical composition containing both. Such administration is generally preferred to be oral.
[0212] When the compound of the present invention and at least one other medicinal agent are administered together, such administration can be sequential or simultaneous.In some embodiments, simultaneous administration of drug combinations is used.In separate or sequential administration, the compound of the present invention and the additional medicinal agent can be administered in any order, and each of them can be administered with an independent frequency or dosage regimen.In some embodiments, such administration is oral.In some embodiments, such administration can be oral and simultaneous.When the compound of the present invention and the additional medicinal agent are administered sequentially, each administration can be by the same method or by different methods.
[0213] According to the method of the present invention, the compound or combination of the present invention can be administered in the form of pharmaceutical compositions.Therefore, the compound or combination of the present invention can be administered to patients separately or together in any conventional oral, rectal, transdermal, parenteral (for example, intravenous, intramuscular or subcutaneous), intracisternal, intravaginal, intraperitoneal, topical (for example, powder, ointment, cream, spray or lotion), buccal or nasal dosage form (for example, spray, drop or inhalant).
[0214] The compounds or combinations of the present invention can be administered alone or in admixture with one or more suitable pharmaceutical excipients, adjuvants, vehicles or carriers known in the art and selected with regard to the intended route of administration and standard pharmaceutical practice. The compounds or combinations of the present invention can be formulated to provide immediate, delayed, modified, sustained, pulsed or controlled release dosage forms depending on the specifics of the desired route of administration and release profile to meet the therapeutic needs.
[0215] Pharmaceutical compositions generally contain a compound or combination of the invention in an amount ranging from about 1% to about 75%, 80%, 85%, 90% or even 95% (by weight) of the composition, usually from about 1%, 2% or 3% to about 50%, 60% or 70%, more often from about 1%, 2% or 3% to less than 50%, for example, about 25%, 30% or 35%.
[0216] Methods for preparing various pharmaceutical compositions with specific amounts of active compounds are known to those skilled in the art. See, for example, Remington, JP, The Science and Practice of Pharmacy, Lippincott Williams and Wilkins, Baltimore, Md., 20th Edition, 2000.
[0217] Compositions suitable for parenteral injection generally include pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers or excipients (including solvents and vehicles) include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, etc.), suitable mixtures thereof, triglycerides, including vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. A preferred carrier is Miglyol® brand caprylic / capric acid esters (e.g., Miglyol® 812, Miglyol® 829, Miglyol® 840) with glycerin or propylene glycol, available from Condea Vista Co., Cranford, NJ. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0218] These compositions for parenteral injection may also contain additives such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of microbial contamination of the compositions can be accomplished by using various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, etc. Prolonged absorption of injectable pharmaceutical compositions can be brought about by the use of agents capable of delaying absorption, for example, aluminum monostearate and gelatin.
[0219] Solid dosage forms for oral administration include capsules, tablets, chewable tablets, lozenges, pills, powders, and multiparticulate preparations (granules). In such solid dosage forms, the compounds or combinations of the present invention are admixed with at least one inert additive, excipient, or carrier. Suitable additives, excipients, or carriers include materials such as sodium citrate or dicalcium phosphate, and / or (a) one or more fillers or bulking agents (e.g., microcrystalline cellulose (FMC)). (b) one or more binders (e.g., carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, gelatin, gum arabic, ethylcellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, alginates, gelatin, polyvinylpyrrolidone, sucrose, acacia, etc.); (c) one or more humectants (e.g., glycerol, etc.); (d) one or more disintegrants (e.g., agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, sodium carbonate, sodium lauryl sulfate, sodium starch glycolate (Edward Mendell Co.(available as Explotab™ from Co., Ltd.), cross-linked polyvinylpyrrolidone, croscarmellose sodium type A (available as Ac-di-sol™), polyacrilin potassium (ion exchange resin), etc.; (e) one or more solution retardants (e.g., paraffin, etc.); (f) one or more absorption accelerators (e.g., quaternary ammonium compounds, etc.); (g) one or more wetting agents (e.g., cetyl alcohol, glycerol monostearate, etc.); (h) one or more adsorbents (e.g., kaolin, bentonite, etc.); and / or (i) one or more lubricants (e.g., talc, calcium stearate, magnesium stearate, stearic acid, polyoxyl stearate, cetyl alcohol, hydrogenated castor oil, sucrose fatty acid esters, dimethylpolysiloxane, microcrystalline wax, yellow wax, white wax, solid polyethylene glycol, sodium lauryl sulfate, etc.). In the case of capsules and tablets, the dosage form may also include buffering agents.
[0220] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0221] Solid dosage forms such as tablets, sugar-coated tablets, capsules and granules can be prepared with coatings and shells, such as enteric coatings and other coatings known in the art.They can contain opacifiers and be of a composition that releases the compound of the present invention and / or additional pharmaceutical active substances in a delayed manner.The examples of embedding compositions that can be used are polymeric substances and waxes.Drugs can also be in the form of microcapsules, if appropriate, with one or more of the additives mentioned above.
[0222] In tablets, the active agent will typically comprise less than 50% (by weight) of the formulation, e.g., less than about 10%, such as 5% or 2.5% by weight. The main portion of the formulation includes fillers, excipients, disintegrants, lubricants, and optionally flavorings. The compositions of these additives are well known in the art. Frequently, the filler / excipient will comprise a mixture of two or more of the following ingredients: microcrystalline cellulose, mannitol, lactose (all types), starch, and dicalcium phosphate. The filler / excipient mixture typically comprises less than 98%, preferably less than 95%, e.g., 93.5%, of the formulation. Preferred disintegrants include Ac-di-sol™, Explotab™, starch, and sodium lauryl sulfate. When present, the disintegrant will usually comprise less than 10% or less than 5%, e.g., about 3%, of the formulation. A preferred lubricant is magnesium stearate. If present, lubricants will typically comprise less than 5% or less than 3%, for example about 1%, of the formulation.
[0223] Tablets can be manufactured by standard tabletting processes, such as direct compression or wet, dry or melt granulation, melt congealing processes and extrusion. Tablet cores can be single or multi-layered and can be coated with suitable protective films known in the art.
[0224] The liquid dosage form for oral administration comprises pharmaceutically acceptable emulsion, solution, suspension, syrup and elixir.In addition to the compound or combination of the present invention, liquid dosage form can contain the inert excipients commonly used in the art, for example, water or other solvent, solubilizer and emulsifier, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oil (for example, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, sesame seed oil etc.), Miglyol (available from CONDEA Vista Co., Cranford, NJ), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and sorbitan fatty acid ester, or the mixture of these substances.
[0225] Besides such inert diluents, compositions can also include additives, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0226] Oral liquid forms of the compounds or combinations of the present invention include solutions in which the active compound is completely dissolved. Examples of solvents include all pharmaceutically precedent solvents suitable for oral administration, especially those in which the compounds of the present invention exhibit good solubility, such as polyethylene glycol, polypropylene glycol, edible oils, and glyceryl and glyceride-based systems. Glyceryl and glyceride-based systems include, for example, the following branded products (and corresponding generic products): Captex™ 355EP (glyceryl tricaprylate / caprate, manufactured by Abitec, Columbus, Ohio), Crodamol™ GTC / C (medium-chain triglycerides, manufactured by Croda, Cowick Hall, UK) or Labrafac™ CC (medium-chain triglycerides, manufactured by Gattefosse), Captex™ 500P (glyceryl triacetate, i.e., triacetin, manufactured by Abitec), Capmul™ MCM (medium-chain mono- and diglycerides, manufactured by Abitec), Migyol™ 812 (caprylic / capric triglyceride, manufactured by Condea, Cranford, OH). NJ), Migyol™ 829 (caprylic / capric / succinic triglyceride, manufactured by Condea), Migyol™ 840 (propylene glycol dicaprylate / dicaprate, manufactured by Condea), Labrafil™ M1944CS (oleoyl macrogol-6 glyceride, manufactured by Gattefosse), Peceol™ (glyceryl monooleate, manufactured by Gattefosse), and Maisine™ 35-1 (glyceryl monooleate, manufactured by Gattefosse). Of particular interest are medium chain (about C8 to C9) glycerides. 10 ) triglyceride oils. These solvents frequently constitute the majority of the composition, i.e., greater than about 50%, usually greater than about 80%, e.g., greater than about 95% or 99%. Adjuvants and additives may be included along with the solvents, primarily as taste masking agents, palatability and flavoring agents, antioxidants, stabilizers, texture and viscosity modifiers, and solubilizers.
[0227] Suspensions may further comprise, in addition to a compound or combination of the present invention, a carrier such as a suspending agent, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, or mixtures of these substances.
[0228] Compositions for rectal or vaginal administration preferably include suppositories, which can be prepared by mixing a compound or combination of the present invention with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ordinary room temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity, thereby releasing the active ingredient.
[0229] Dosage forms for topical administration of the compounds or combinations of this invention include ointments, creams, lotions, powders and sprays. The drug is admixed with a pharmaceutically acceptable excipient, diluent or carrier, and any preservatives, buffers or propellants that may be required.
[0230] Some of the compounds of the present invention may have poor aqueous solubility, e.g., less than about 1 μg / mL, and therefore liquid compositions in solubilizing non-aqueous solvents such as the medium chain triglyceride oils discussed above are preferred dosage forms for these compounds.
[0231] Solid amorphous dispersions, including dispersions formed by spray drying processes, are also preferred dosage forms for the poorly soluble compounds of the present invention. "Solid amorphous dispersion" refers to a solid material in which at least a portion of the poorly soluble compound is in amorphous form and dispersed in a water-soluble polymer. "Amorphous" refers to the poorly soluble compound being non-crystalline. "Crystalline" refers to the compound exhibiting three-dimensional long-range order of at least 100 repeat units in each dimension. Thus, the term "amorphous" is intended to include not only materials that are essentially disordered, but also materials that may have a small degree of order, but that order is less than three-dimensional and / or short-range. Amorphous materials can be characterized by techniques known in the art, such as powder X-ray diffraction (PXRD) crystallography, solid-state NMR, or thermal techniques such as differential scanning calorimetry (DSC).
[0232] Preferably, at least a majority (i.e., at least about 60 wt%) of the poorly soluble compound in the solid amorphous dispersion is amorphous. The compound can exist within the solid amorphous dispersion in relatively pure amorphous domains or regions, as a solid solution of the compound homogeneously distributed throughout the polymer, or any combination of these states or intermediate states. Preferably, the solid amorphous dispersion is substantially homogeneous, so that the amorphous compound is dispersed as homogeneously as possible throughout the polymer. As used herein, "substantially homogeneous" means that the proportion of the compound present in the relatively pure amorphous domains or regions within the solid amorphous dispersion is relatively small, approximately less than 20 wt%, preferably less than 10 wt% of the total amount of drug.
[0233] Water-soluble polymers suitable for use in solid amorphous dispersions should be inert, in the sense that they do not chemically react in a deleterious manner with the poorly soluble compound, are pharmaceutically acceptable, and have at least some solubility in aqueous solution at physiologically relevant pH (e.g., 1 to 8). The polymer can be neutral or ionizable and should have an aqueous solubility of at least 0.1 mg / mL over at least a portion of the pH range from 1 to 8.
[0234] Water-soluble polymers suitable for use in the present invention may be cellulosic or non-cellulosic. The polymers may be neutral or ionizable in aqueous solution. Of these, ionizable and cellulosic polymers are preferred, with ionizable cellulosic polymers being more preferred.
[0235] Exemplary water-soluble polymers include hydroxypropylmethylcellulose acetate succinate (HPMCAS), hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate (HPMCP), carboxymethylethylcellulose (CMEC), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), polyvinylpyrrolidone (PVP), hydroxypropylcellulose (HPC), methylcellulose (MC), block copolymers of ethylene oxide and propylene oxide (PEO / PPO, also known as poloxamer), and mixtures thereof. Particularly preferred polymers include HPMCAS, HPMC, HPMCP, CMEC, CAP, CAT, PVP, poloxamer, and mixtures thereof. Most preferred is HPMCAS. See European Patent Application Publication No. 0901786A2, the disclosure of which is incorporated herein by reference.
[0236] The solid amorphous dispersion can be prepared according to any process for forming a solid amorphous dispersion that results in at least a majority (at least 60%) of the poorly soluble compound being in an amorphous state. Such processes include mechanical, thermal, and solvent processes. Exemplary mechanical processes include milling and extrusion; melt processes, including high-temperature melting, solvent-modified fusion, and melt-congealing processes; and solvent processes, including non-solvent precipitation, spray coating, and spray drying. See, for example, the following U.S. patents, the relevant disclosures of which are incorporated herein by reference: U.S. Patents Nos. 5,456,923 and 5,939,099, which describe forming dispersions by extrusion processes; Nos. 5,340,591 and 4,673,564, which describe forming dispersions by milling processes; and Nos. 5,707,646 and 4,894,235, which describe forming dispersions by melt-congealing processes. In a preferred process, the solid amorphous dispersion is formed by spray drying, as disclosed in European Patent Application Publication No. 0901786A2. In this process, the compound and polymer are dissolved in a solvent such as acetone or methanol, and then the solvent is rapidly removed from the solution by spray drying to form the solid amorphous dispersion. The solid amorphous dispersion can be prepared to contain up to about 99 wt% of the compound, for example, 1 wt%, 5 wt%, 10 wt%, 25 wt%, 50 wt%, 75 wt%, 95 wt%, or 98 wt%, as desired.
[0237] The solid dispersion may be used as a dosage form itself or may serve as a manufacturing use product (MUP) in the preparation of other dosage forms, such as capsules, tablets, solutions, or suspensions. An example of an aqueous suspension is an aqueous suspension of a 1:1 (w / w) compound / HPMCAS-HF spray-dried dispersion containing 2.5 mg / mL of compound in 2% polysorbate-80. Solid dispersions for use in tablets or capsules will generally be mixed with other additives or adjuvants typically found in such dosage forms. For example, an exemplary filler for a capsule contains a 2:1 (w / w) compound / HPMCAS-MF spray-dried dispersion (60%), lactose (fast flow) (15%), microcrystalline cellulose (e.g., Avicel (RO-102) (15.8%), sodium starch (7%), sodium lauryl sulfate (2%), and magnesium stearate (1%).
[0238] HPMCAS polymers are available in low, medium, and high grades as Aqoat®-LF, Aqoat®-MF, and Aqoat®-HF from Shin-Etsu Chemical Co., Ltd. of Tokyo, Japan. The higher MF and HF grades are generally preferred.
[0239] Advantageously, the compounds (or combinations) of the present invention can be carried in drinking water so that a therapeutic dosage of the compound is ingested with the daily water supply. The compound, preferably in the form of a liquid, water-soluble concentrate (such as an aqueous solution of a water-soluble salt), can be metered directly into the drinking water.
[0240] These compounds may be administered to non-human animals, for example, for the indications detailed above. The exact dosage of each active ingredient administered will vary depending on any number of factors, including, but not limited to, the type of animal and type of condition being treated, the age of the animal, and the route of administration.
[0241] The dosage of the combined pharmaceutical agent used in conjunction with Formula I compound or its salt is that which is effective for the indication being treated.This dosage can be determined by standard assay such as the one referred to above and provided herein.The combined agent can be administered simultaneously or sequentially in any order.
[0242] These dosages are based on an average human subject weighing approximately 60 kg to 70 kg. A physician will readily be able to determine dosages for subjects whose weight falls outside this range, such as infants and the elderly.
[0243] Dosage regimens can be adjusted to provide the optimum desired response. For example, a single bolus can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is particularly advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suitable as a unit dosage for the mammalian subject to be treated, each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic effect together with the required pharmaceutical carrier. The specifications for the dosage unit form of the present invention are determined by and directly depend on (a) the unique characteristics of the chemotherapeutic agent and the specific therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the technical field of compounding such active compounds for the treatment of susceptibility in individuals.
[0244] Thus, based on the disclosure provided herein, one skilled in the art will understand that doses and administration regimens will be adjusted according to methods well known in the therapeutic arts. That is, the maximum tolerated dose can be readily established, and the effective amount that provides a detectable therapeutic benefit to a patient can be determined, as can the primary requirement for administering each agent to provide a detectable therapeutic benefit to a patient. Thus, although certain doses and administration regimens are exemplified herein, these examples in no way limit the doses and administration regimens that can be provided to a patient when practicing the present invention.
[0245] It should be noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses.It should be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual needs and the professional judgment of the person administering or supervising the administration of the composition, and that the dosage ranges specified herein are merely exemplary and are not intended to limit the scope or practice of the claimed compositions.For example, dosages may be adjusted based on pharmacokinetic or pharmacodynamic parameters, which may include toxic effects and / or clinical effects such as laboratory values.Therefore, the present invention encompasses intra-patient dose escalation as determined by those skilled in the art.Determining the appropriate dosage and regimen for administering chemotherapeutic agents is well known in the relevant technical field, and will be understood to be encompassed by those skilled in the art given the teachings disclosed herein.
[0246] The present invention further includes the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament (such as a unit dose tablet or unit dose capsule). In another embodiment, the present invention includes the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament (such as a unit dose tablet or unit dose capsule) for treating one or more of the conditions previously identified in the section above discussing methods of treatment.
[0247] The pharmaceutical composition of the present invention can be prepared, packaged or sold in bulk as a single unit dose or as a plurality of single unit doses.As used herein, " unit dose " is the discrete amount of pharmaceutical composition that contains a predetermined amount of active ingredient.The amount of active ingredient is generally equal to the dosage of active ingredient that will be administered to subject, or the convenient proportion of such dosage, for example, half or one-third of such dosage.
[0248] These agents and compounds of the invention can be combined with a pharmaceutically acceptable vehicle, such as saline, Ringer's solution, dextrose solution, etc. The particular dosing regimen, i.e., dosage, timing and repetition, will depend on the particular individual and that individual's medical history.
[0249] Acceptable carriers, additives, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include buffers such as phosphate, citrate, and other organic acids; salts such as sodium chloride; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); and low molecular weight (less than about 10 residues) polypeptides. ; proteins such as serum albumin, gelatin, or Ig; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG).
[0250] Liposomes containing these agents and / or compounds of the present invention are prepared by methods known in the art, such as those described in U.S. Patent Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be produced by the reverse-phase evaporation method using a lipid composition containing phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
[0251] These agents and / or compounds of the present invention may be encapsulated in microcapsules prepared, for example, by coacervation techniques, or by interfacial polymerization, e.g., hydroxymethylcellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or macroemulsions, respectively. Such techniques are disclosed in Remington, The Science and Practice of Pharmacy, 20th Edition, Mack Publishing (2000).
[0252] Sustained-release preparations can be used.Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the compound of the present invention, and this matrix is in the form of shaped articles, for example, films or microcapsules.Examples of sustained-release matrices include polyester, hydrogels [for example, poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)], polylactide (US Pat. No. 3,773,919), copolymers of L-glutamic acid and 7L-ethyl glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers, for example, those used in LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymers and leuprolide acetate), sucrose acetate isobutyrate, and poly-D-(-)-3-hydroxybutyric acid.
[0253] Preparations used for intravenous administration must be sterile. This is readily accomplished, for example, by filtration through sterile filtration membranes. The compounds of the present invention are generally placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper that can be pierced by a hypodermic injection needle.
[0254] Suitable emulsions can be prepared using commercially available fat emulsions, such as Intralipid™, Liposyn™, Infonutrol™, Lipofundin™, and Lipiphysan™. The active ingredient can be dissolved in a premixed emulsion composition, or alternatively, in an emulsion formed upon mixing of oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil, or almond oil) and phospholipids (e.g., egg phospholipids, soybean phospholipids, or soybean lecithin) with water. It will be appreciated that other ingredients, such as glycerol or glucose, may be added to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, e.g., between 5 and 20%. The fat emulsion can contain fat droplets between 0.1 and 1.0 μm, particularly between 0.1 and 0.5 μm, and have a pH within the range of 5.5 to 8.0.
[0255] The emulsion composition can be one prepared by mixing a compound of the present invention with Intralipid™ or its components (soybean oil, egg phospholipids, glycerol, and water).
[0256] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents or mixtures thereof, as well as powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable additives as specified above. In some embodiments, the compositions are administered by oral or nasal respiratory route for local or systemic effect. Compositions, preferably in sterile, pharmaceutically acceptable solvents, can be nebulized by the use of gases. Nebulized solutions can be inhaled directly from the nebulizing device, or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered, preferably orally or intranasally, from a device that delivers the formulation in an appropriate manner.
[0257] The compound granules herein may be formulated in a form suitable for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular, or subcutaneous) or rectal administration, or for administration by inhalation. The compounds of the invention may also be formulated for sustained delivery.
[0258] Methods for preparing various pharmaceutical compositions with a particular amount of active ingredient are known or will be apparent to those skilled in the art in light of this disclosure. For examples of methods for preparing pharmaceutical compositions, see Remington, The Science and Practice of Pharmacy, 20th Edition (Lippincott Williams & Wilkins, 2000).
[0259] Pharmaceutical compositions according to the invention may contain 0.1% to 95%, preferably 1% to 70%, of a compound of the invention, In any event, the composition administered will contain a quantity of a compound according to the invention in an amount effective to treat the disease / condition of the subject being treated.
[0260] Because the present invention has an aspect relating to the treatment of the diseases / conditions described herein using a combination of active ingredients that can be administered separately, the present invention also relates to combining separate pharmaceutical compositions in kit form. The kit comprises two separate pharmaceutical compositions: a compound of Formula I or a pharmaceutically acceptable salt or prodrug thereof, or a salt of such a compound or prodrug, and a second compound as described above. The kit includes a means for containing the separate compositions, such as a container, a divided bottle, or a divided foil packet. Typically, the kit includes instructions for administering the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
[0261] An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are widely used for packaging pharmaceutical unit dosage forms (tablets, capsules, etc.). Blister packs generally consist of a sheet of relatively rigid material covered with a foil, preferably a transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape in which the tablets or capsules are packed. The tablets or capsules are then placed in the recesses, and the sheet of relatively rigid material is sealed to the plastic foil on the side of the foil opposite to the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably, the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure to the recesses, thereby forming an opening in the sheet at the location of the recess. The tablets or capsules can then be removed through the opening.
[0262] It may be desirable to provide a memory aid in the kit, for example, in the form of numbers next to the tablets or capsules that correspond to the number of days in the regimen when the so-designated tablets or capsules should be taken. Another example of such a memory aid is, for example, a calendar printed on a card, for example, as follows: "Week 1, Monday, Tuesday, etc.... Week 2, Monday, Tuesday..." etc. Other variations of memory aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several pills or capsules to be taken on a given day. Also, a daily dose of a compound of the present invention may consist of one tablet or capsule, while a daily dose of a second compound may consist of several tablets or capsules, or vice versa. The memory aid should reflect this.
[0263] In another specific embodiment of the present invention, a dispenser is provided that is designed to dispense daily doses one at a time in the order of their intended use.Preferably, the dispenser is equipped with a memory aid, so as to further facilitate compliance with the regimen.An example of such a memory aid is a mechanical counter that indicates the number of daily doses that have been dispensed.Another example of such a memory aid is a battery-powered microchip memory that is coupled with a liquid crystal display or an audible reminder signal, for example, that reads out the date that the last daily dose was taken and / or reminds the date that the next dose should be taken.
[0264] Also, since the present invention has aspects relating to the treatment of diseases / conditions described herein with combinations of active ingredients that can be administered together, the present invention also relates to combining separate pharmaceutical compositions in a single dosage form such as (but not limited to) a single tablet or capsule, a bi-layer or multi-layer tablet or capsule, or by the use of segregated components or compartments within a tablet or capsule.
[0265] The active ingredient may be delivered as a solution in an aqueous or non-aqueous vehicle with or without additional solvents, co-solvents, additives or complexing agents selected from pharmaceutically acceptable excipients, additives, vehicles or carriers.
[0266] The active ingredient may be formulated with pharmaceutically acceptable excipients as a solid dispersion or as a self-emulsifying drug delivery system (SEDDS).
[0267] The active ingredient may be formulated as an immediate-release or controlled (e.g., suspended, delayed, or sustained) release tablet or capsule. Alternatively, the active ingredient may be delivered alone as the active ingredient within a capsule shell without additional additives. [Example]
[0268] The following illustrates the synthesis of various compounds of the present invention. Additional compounds within the scope of the present invention can be prepared using the methods illustrated in these examples, either alone or in combination with techniques generally known in the art. All starting materials in these preparations and examples are either commercially available or can be prepared by methods known in the art or as described herein.
[0269] Reactions were carried out in air or, when oxygen- or moisture-sensitive reagents or intermediates were used, under an inert atmosphere (nitrogen or argon). Where appropriate, reaction apparatus was dried under dynamic vacuum using a heat gun, and anhydrous solvents (Sure-Seal™ products from Aldrich Chemical Company, Milwaukee, Wisconsin, or DriSolv™ products from EMD Chemicals, Gibbstown, NJ) were used. In some cases, commercially available solvents were passed through columns packed with 4 Å molecular sieves until the following water QC criteria were reached: a) less than 100 ppm for dichloromethane, toluene, N,N-dimethylformamide, and tetrahydrofuran; b) less than 180 ppm for methanol, ethanol, 1,4-dioxane, and diisopropylamine. For highly sensitive reactions, solvents were further treated with sodium metal, calcium hydride, or molecular sieves and distilled immediately before use. Other commercially available solvents and reagents were used without further purification. In syntheses that refer to procedures in other examples or methods, reaction conditions (reaction time and temperature) may vary. Products were generally dried under vacuum before being carried on to further reactions or sent for biological testing.
[0270] Where indicated, reactions were heated by microwave irradiation using a Biotage Initiator or a Personal Chemistry Emries Optimizer microwave instrument. Reaction progress was monitored using thin-layer chromatography (TLC), liquid chromatography-mass spectrometry (LCMS), high-performance liquid chromatography (HPLC), and / or gas chromatography-mass spectrometry (GCMS) analysis. TLC was performed on precoated silica gel plates with a fluorescent indicator (254 nm excitation wavelength) and visualized under UV light and / or with I, KMnO, CoCl, phosphomolybdic acid, and / or ceric ammonium molybdate stains. LCMS data were acquired on an Agilent 1100 series instrument using a Leap Technologies autosampler, a Gemini C18 column, an acetonitrile / water gradient, and either trifluoroacetic acid, formic acid, or ammonium hydroxide modifiers. Column eluents were analyzed using a Waters ZQ mass spectrometer scanning from 100 to 1200 Da in both positive and negative ion modes. Other similar instruments were also used. HPLC data were acquired on an Agilent 1100 series instrument using a Gemini or XBridge C18 column, an acetonitrile / water gradient, and either trifluoroacetic acid or ammonium hydroxide modifier. GCMS data were acquired using a Hewlett-Packard 6890 oven with an HP6890 injector, an HP-1 column (12 m × 0.2 mm × 0.33 μm), and helium carrier gas. Samples were analyzed on an HP5973 mass-selective detector, scanning from 50 to 550 Da using electron ionization. Purification was performed by medium-pressure liquid chromatography (MPLC) using an Isco Combiflash Companion, an AnaLogix IntelliFlash 280, a Biotage SP1, or a Biotage Isolera One instrument and prepacked Isco ReadySep or Biotage Snap Silica cartridges.Chiral purification was performed by chiral supercritical fluid chromatography (SFC) using a Berger or Thar instrument; ChiralPak-AD, -AS, -IC, Chiralcel-OD, or -OJ columns; and CO mixtures with methanol, ethanol, 2-propanol, or acetonitrile, either alone or modified with trifluoroacetic acid or propan-2-amine. UV detection was used to induce fraction collection. For syntheses referencing procedures in other examples or methods, purification may vary: generally, the solvents and solvent ratios used in the eluents / gradients were determined using the appropriate R. fS or retention time was selected to provide.
[0271] Mass spectrometry data are reported by LCMS analysis. Mass spectrometry (MS) was performed via atmospheric pressure chemical ionization (APCI), electrospray ionization (ESI), electron impact ionization (EI) or electron scattering (ES) ionization sources. Proton magnetic resonance spectroscopy ( 1H NMR chemical shifts are reported in parts per million downfield from tetramethylsilane and were recorded on Varian, Bruker, or Jeol analyzers at 300, 400, 500, or 600 MHz. Chemical shifts are expressed in parts per million (ppm, δ) referenced to deuterated solvent residual peaks (chloroform, 7.26 ppm; CD2HOD, 3.31 ppm; acetonitrile-d2, 1.94 ppm; dimethyl sulfoxide-d5, 2.50 ppm; DHO, 4.79 ppm). Peak shapes are described as follows: s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; m, multiplet; brs, broad singlet; app, apparent. Analytical SFC data were acquired on a Berger analytical instrument as described above. Optical rotation data were acquired on a PerkinElmer Model 343 polarimeter using a 1 dm cell. Silica gel chromatography was primarily performed using a medium-pressure Biotage or ISCO system using prepackaged columns from various commercial suppliers, including Biotage and ISCO. Microanalysis was performed by Quantitative Technologies Inc. and was within 0.4% of calculated values.
[0272] Unless otherwise noted, chemical reactions were carried out at room temperature (approximately 23 degrees Celsius).
[0273] Unless otherwise noted, all reactants were either commercially obtained without further purification or prepared using methods known in the literature.
[0274] The terms "concentrated," "evaporated," and "concentrated in vacuo" refer to removal of solvent at reduced pressure in a rotary evaporator with a bath temperature below 60° C. The abbreviations "min" and "h" stand for "minutes" and "hours," respectively. The term "TLC" refers to thin layer chromatography, "room or ambient temperature" means a temperature between 18° C. and 25° C., "GCMS" refers to gas chromatography-mass spectrometry, "LCMS" refers to liquid chromatography-mass spectrometry, "UPLC" refers to ultra-performance liquid chromatography, "HPLC" refers to high-performance liquid chromatography, and "SFC" refers to supercritical fluid chromatography.
[0275] Hydrogenation can be carried out under pressurized hydrogen gas in a Parr shaker or in a Thales-nano H cube flow hydrogenator at the specified temperature with full hydrogen and a flow rate between 1 and 2 mL / min.
[0276] HPLC, UPLC, LCMS, GCMS, and SFC retention times were determined using the methods noted in the procedures.
[0277] In some examples, chiral separations were performed to separate enantiomers, diastereomers, or atropisomers (or atropenantiomers) of certain compounds of the invention (in some examples, the separated enantiomers are designated ENANT-1 and ENANT-2 according to their order of elution; similarly, the separated diastereomers are designated DIAST-1 and DIAST-2 according to their order of elution, and the separated atropisomers (or atropenantiomers) are designated ATROP-1 and ATROP-2 according to their order of elution). In some examples, the optical rotations of the enantiomers or atropisomers (or atropenantiomers) were measured using a polarimeter. The observed According to the rotational data (or specific rotational data) given, the enantiomer or atropisomer (or atropenantiomer) with clockwise rotation is designated as the (+)-enantiomer or (+)-atropisomer [or (+) atropenantiomer], and the enantiomer or atropisomer (or atropenantiomer) with counterclockwise rotation is designated as the (-)-enantiomer or (-)-atropisomer [or (-) atropenantiomer]. Racemates are indicated either by the absence of drawn or written stereochemistry or by the presence of (+ / -) adjacent to the structure; in the latter case, the indicated stereochemistry represents only one of the two enantiomers that make up the racemic mixture.
[0278] The compounds and intermediates described below were named using the naming conventions provided by ACD / ChemSketch 2019.1.1, file version C05H41, build 110712 (Advanced Chemistry Development, Inc., Toronto, Ontario, Canada). The naming conventions provided by ACD / ChemSketch 2019.1.1 are well known to those skilled in the art, and are generally believed to conform to the IUPAC (International Union of Pure and Applied Chemistry) recommendations and CAS index rules for the nomenclature of organic compounds.
[0279] Preparation example Preparations P1 to P25 describe the preparation of some of the starting materials or intermediates used in the preparation of certain compounds of the invention.
[0280] Preparation example P1 (6-{[(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]amino}-2-methylpyridin-3-yl)boronic acid (P1)
[0281] [ka] Step 1. Synthesis of tert-butyl (3S)-3-[(6-methylpyridin-2-yl)amino]pyrrolidine-1-carboxylate (C3). BrettPhos{dicyclohexyl[3,6-dimethoxy-2',4',6'-tri(propan-2-yl)[1,1'-biphenyl]-2-yl]phosphane; 7.83 g, 14.5 mmol}, palladium(II) acetate (1.57 g, 6.90 mmol), and sodium tert-butoxide (216 g, 2.25 mol) were added to tetrahydrofuran (2.0 L) at 20°C. After stirring the reaction mixture for 20 minutes, 2-chloro-6-methylpyridine (C2) (191 g, 1.50 mol) and tert-butyl (3S)-3-aminopyrrolidine-1-carboxylate (C1) (293 g, 1.58 mol) were added, and the reaction mixture was stirred at 70°C for 2 hours. The mixture was concentrated under reduced pressure, and ice water (2.0 L) was added to the residue. The resulting mixture was extracted with dichloromethane (2 x 3.0 L); the combined organic layers were washed with water (3 x 3.0 L) and saturated aqueous sodium chloride solution (3.0 L), dried over sodium sulfate, filtered, and concentrated in vacuo. Trituration from ethyl acetate / petroleum ether (0.8 L / 1.6 L) provided C3 as a gray solid. Yield: 396 g, 1.43 mol, 95%. LCMS m / z 278.3 [M+H] + . 1H NMR (400 MHz, chloroform-d) δ 7.34 (dd, J = 7.8, 7.8 Hz, 1H), 6.47 (d, J = 7.3 Hz, 1H), 6.20 (d, J = 8.2 Hz, 1H), 4.77 - 4.55 (m, 1H), 4.33 - 4.12 (m, 1H), 3.78 - 3.62 (m, 1H), 3.57 - 3.35 (m, 2H), 3.33 - 3.11 (m, 1H), 2.36 (s, 3H), 2.26 - 2.12 (m, 1H), 1.96 - 1.79 (m, 1H), 1.45 (s, 9H).
[0282] Step 2. Synthesis of tert-butyl (3S)-3-[(5-bromo-6-methylpyridin-2-yl)amino]pyrrolidine-1-carboxylate (C4). To a mixture of C3 (650 g, 2.34 mol) in dichloromethane (19.5 L), 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (341 g, 1.19 mol) was slowly added in five portions over 2 h at 5 to 10 °C. The reaction mixture was stirred at 10 °C for 1 h, whereupon it was diluted with dichloromethane (8.0 L); the resulting mixture was washed with aqueous sodium sulfite (5%, 10 L) and saturated aqueous sodium chloride (10 L), dried over sodium sulfate, filtered, and concentrated in vacuo. Trituration with tetrahydrofuran / tert-butyl methyl ether (150 mL / 1 L) provided C4 as an off-white solid. 1 H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 760 g, 2.13 mol, 91%. LCMS m / z 356.1 (bromine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 7.48 (d, J = 8.7 Hz, 1H), 6.93 - 6.84 (m, 1H), 6.29 (d, J = 8.7 Hz, 1H), 4.36 - 4.17 (m, 1H), 3.60 - 3.47 (m, 1H), 3.44 - 3.22 (m, 2H, estimated; Partially obscured by water peaks), 3.13 - 3.00 (m, 1H), 2.36 (s, 3H), 2.16 - 2.01 (m, 1H), 1.87 - 1.70 (m, 1H), [1.39 (s) and 1.38 (s), total 9H].
[0283] Step 3. Synthesis of (6-{[(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]amino}-2-methylpyridin-3-yl)boronic acid (P1). To a solution of C4 (930 g, 2.61 mol) in tetrahydrofuran (6.5 L) was added bis(triphenylphosphine)nickel(II) dichloride (51.2 g, 78.3 mmol). Then, a solution of tetrahydroxydiboron (702 g, 7.83 mol) in methanol (6.5 L) was added dropwise via cannula over 1.5 h at 25 °C. N,N-Diisopropylethylamine (1.01 kg, 7.83 mol) was added dropwise to the resulting mixture over 1 h at 20 to 25 °C, and the reaction mixture was stirred at 20 °C for 2 h, whereupon it was filtered through a pad of diatomaceous earth, and the filtrate was concentrated in vacuo. The residue was dissolved in a mixture of aqueous sodium hydroxide (2 M; 12 L) and tert-butyl methyl ether (6 L) at 0 °C, and the layers were separated. The organic layer was further extracted with aqueous sodium hydroxide (1 M; 4 L), and the combined aqueous layers were stirred while the pH was adjusted to 9-10 by adding 6 M hydrochloric acid. After stirring the mixture for an additional 20 min, the solid was collected by filtration. The solid was combined with material (75 g) obtained from a similar, smaller-scale experiment and dissolved in ethyl acetate (8 L). The organic layer was washed with water (3 L) and saturated aqueous sodium chloride (3 L), dried over sodium sulfate, filtered, and concentrated in vacuo. The crude product was triturated with tert-butyl methyl ether / n-hexane (1 L / 2 L), then dissolved in tetrahydrofuran (3 L) and concentrated under reduced pressure to give P1 as an off-white solid. Combined yield: 635 g, 1.98 mol, 67%. LCMS m / z 322.1 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.71 (br s, 1H), 6.52 (br s, 1H), 4.43 - 4.29 (m, 1H), 3.73 - 3.62 (m, 1H), 3.57 - 3.37 (m, 2H), 3.28 - 3.22 (m, 1H), 2.47 (s, 3H), 2.31 - 2.16 (m, 1H), 2.00 - 1.86 (m, 1H), 1.46 (br s, 9H).
[0284] Preparation example P2 6-Methyl-5-(1-methyl-1H-imidazol-4-yl)-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride (P2)
[0285] [ka] Step 1. Synthesis of 6-chloro-2-methyl-3-(1-methyl-1H-imidazol-4-yl)pyridine (C7). To a mixture of 4-iodo-1-methyl-1H-imidazole (C5; 20.8 g, 100 mmol) in 1,4-dioxane (300 mL) and water (50 mL) was added (6-chloro-2-methylpyridin-3-yl)boronic acid (C6) (17.1 g, 100 mmol), potassium carbonate (27.6 g, 200 mmol), and Pd(amphos)Cl {bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II); 3.54 g, 5.00 mmol}. The reaction mixture was stirred at 100 °C for 18 hours, whereupon it was filtered, and the filtrate was concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 3% methanol in dichloromethane) provided C7 as a yellow solid. Yield: 14.7 g, 70.8 mmol, 71%. LCMS m / z 208.1 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 8.13 (d, J = 8.2 Hz, 1H), 7.55 - 7.52 (m, 1H), 7.21 (br d, J = 8.2 Hz, 1H), 7.09 (br d, J = 1 Hz, 1H), 3.77 (s, 3H), 2.68 (s, 3H).
[0286] Step 2. Synthesis of tert-butyl (3S)-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidine-1-carboxylate (C8). A mixture of C1 (10.1 g, 54.2 mmol), C7 (13.7 g, 66.0 mmol), BrettPhos PdG3 {[(2-dicyclohexylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate; 2.99 g, 3.30 mmol}, BrettPhos (3.54 g, 6.59 mmol), and cesium carbonate (43.0 g, 132 mmol) in 2-methylbutan-2-ol (150 mL) was stirred at 105 °C for 18 h. The reaction mixture was filtered, and the filtrate was concentrated in vacuo; purification by silica gel chromatography (gradient: 0% to 5% methanol in dichloromethane) provided C8 as a yellow solid. Yield: 12.7g, 35.5mmol, 65%. LCMS m / z 358.3 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.91 (d, J = 8.5 Hz, 1H), 7.48 - 7.45 (m, 1H), 6.92 (d, J = 1.1 Hz, 1H), 6.33 (d, J = 8.5 Hz, 1H), 4.76 - 4.52 (m, 1H), 4.37 - 4.18 (m, 1H), 3.82 - 3.64 (m, 1H), 3.73 (s, 3H), 3.59 - 3.36 (m, 2H), 3.35 - 3.15 (m, 1H), 2.53 (s, 3H), 2.28 - 2.15 (m, 1H), 1.99 - 1.81 (m, 1H), 1.46 (s, 9H).
[0287] Step 3. Synthesis of 6-methyl-5-(1-methyl-1H-imidazol-4-yl)-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride salt (P2). To a 25° C. solution of C8 (12.7 g, 35.5 mmol) in a mixture of dichloromethane (120 mL) and methanol (30 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4 M; 44.3 mL, 177 mmol), and the reaction mixture was stirred at room temperature for 2 hours. The mixture was filtered, and the filter cake was washed with ethyl acetate (20 mL) to give P2 as a white solid. Yield: 11.5 g, 34.8 mmol, 98%. LCMS m / z 258.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 9.08 (br s, 1H), 8.01 (d, J = 9.2 Hz, 1H) 7.83 (d, J = 1.3 Hz, 1H), 7.18 (d, J = 9.3 Hz, 1H), 4.86 - 4.77 (m, 1H, estimated; partially obscured by water peak), 4.02 (s, 3H), 3.73 (dd, J = 12.5, 6.6 Hz, 1H), 3.65 - 3.56 (m, 1H), 3.54 - 3.42 (m, 2H), 2.67 (s, 3H), 2.61 - 2.49 (m, 1H), 2.29 - 2.17 (m, 1H).
[0288] Preparation Examples P3 and P3-OH 2-(4-Fluorophenyl)-1-[(3S)-3-{[6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]ethan-1-one (P3) and [6-({(3S)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}amino)-2-methylpyridin-3-yl]boronic acid (P3-OH)
[0289] [ka] Step 1. Synthesis of tert-butyl {(3S)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}carbamate (C11). To a 25° C. solution of (4-fluorophenyl)acetic acid (C10) (20.7 g, 134 mmol) and tert-butyl (3S)-pyrrolidin-3-ylcarbamate (C9) (25 g, 130 mmol) in dichloromethane (300 mL) was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (T3P, 50 wt % solution in ethyl acetate; 94.0 g, 148 mmol) and N,N-diisopropylethylamine (34.7 g, 268 mmol). The reaction mixture was stirred for 24 hours, after which it was concentrated in vacuo. The residue was triturated with ethyl acetate to give C11 as a white solid. Yield: 32.5 g, 101 mmol, 78%. LCMS m / z 323.2 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.23 (dd, J = 8.5, 5.4 Hz, 2H), 7.00 (dd, J = 8.6, 8.6 Hz, 2H), 4.57 (br s, 1H), 4.30 - 4.11 (m, 1H), 3.71 (dd, J = 11.5, 6.1 Hz, 1H), 3.63 - 3.46 (m, 2H), 3.61 (s, 2H), 3.42 - 3.27 (m, 1H), 2.28 - 2.06 (m, 1H), 2.02 - 1.68 (m, 1H, estimated; partially obscured by water peak), 1.44 (s, 9H).
[0290] Step 2. Synthesis of 1-[(3S)-3-aminopyrrolidin-1-yl]-2-(4-fluorophenyl)ethan-1-one, hydrochloride salt (C12). To a 0° C. mixture of C11 (32.5 g, 101 mmol) in dichloromethane (100 mL) was added dropwise a solution of hydrogen chloride in 1,4-dioxane (4.0 M; 101 mL, 404 mmol). After the reaction mixture was stirred at room temperature for 2 hours, it was concentrated in vacuo and triturated with ethyl acetate to give C12 as a white solid. Yield: 25.2 g, 97.4 mmol, 96%. LCMS m / z 223.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.62 - 8.42 (m, 3H), 7.30 - 7.21 (m, 2H), 7.16 - 7.07 (m, 2H), 3.88 - 3.69 (m, 2H), 3.67 - 3.32 (m, 3H), 3.62 (s, 2H), 2.30 - 1.90 (m, 2H).
[0291] Step 3. Synthesis of 1-{(3S)-3-[(5-bromo-6-methylpyridin-2-yl)amino]pyrrolidin-1-yl}-2-(4-fluorophenyl)ethan-1-one (C14). To a solution of C12 (12.5 g, 48.3 mmol) and 3-bromo-6-fluoro-2-methylpyridine (C13) (9.18 g, 48.3 mmol) in dimethyl sulfoxide (150 mL) was added N,N-diisopropylethylamine (18.7 g, 145 mmol). After the reaction mixture was stirred at 140 °C for 12 hours, it was poured into water and extracted with ethyl acetate (2 × 200 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 100% ethyl acetate in petroleum ether) provided C14 as a yellow solid. Yield: 7.10 g, 18.1 mmol, 37%. 1 H NMR analysis indicated that this material contained a mixture of rotamers. LCMS m / z 394.1 (bromine isotope pattern observed) [M+H] + . 1H NMR (400 MHz, chloroform-d) δ [7.50 (d, J = 8.6 Hz) and 7.48 (d, J = 8.6 Hz), total 1H], 7.26 - 7.17 (m, 2H, estimated; partially obscured by solvent peaks), 7.05 - 6.93 (m, 2H), [6.14 (d, J = 8.7 Hz) and 6.09 (d, J = 8.6 Hz), total 1H], [4.82 - 4.65 (m) and 4.54 - 4.42 (m), total 1H], [4.41 - 4.31 (m) and 4.30 - 4.20 (m), total 1H], 3.87 - 3.79 (m, 1H), 3.74 - 3.52 (m, 4H), [3.45 (dd, J = 12.5, 4.3 Hz) and 3.34 (dd, J = 10.5, 4.8 Hz), total 1H], 2.47 (br s, 3H), 2.35 - 2.17 (m, 1H), [2.07 - 1.97 (m) and 1.91 - 1.80 (m), total 1H].
[0292] Step 4. Synthesis of 2-(4-fluorophenyl)-1-[(3S)-3-{[6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]ethan-1-one (P3). A mixture of C14 (6.7 g, 17.1 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (8.67 g, 34.2 mmol), potassium acetate (4.18 g, 42.7 mmol), and Pd(dppf)Cl2 {[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II); 1.25 g, 1.71 mmol} in 1,4-dioxane (300 mL) was stirred at 100 °C for 16 h. The reaction mixture was concentrated in vacuo and then purified by silica gel chromatography (eluent: 30% ethyl acetate in petroleum ether) to provide P3 as a gray solid. 1H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 3.20 g, 7.28 mmol, 43%. LCMS m / z 440.2 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ [7.81 (d, J = 8.4 Hz) and 7.79 (d, J = 8.4 Hz), total 1H], 7.26 - 7.16 (m, 2H, estimated; partially obscured by solvent peaks), 7.05 - 6.92 (m, 2H), [6.19 (d, J = 8.3 Hz) and 6.15 (d, J = 8.3 Hz), total 1H], [4.92 - 4.75 (m) and 4.63 (br d, J = 6.5 Hz), total 1H], [4.45 - 4.35 (m) and 4.33 - 4.23 (m), total 1H], [3.86 (d, J = 5.9 Hz) and 3.83 (dd, J = 6.0, 3.2 Hz), total 1H], 3.74 - 3.52 (m, 2H), [3.62 (s) and 3.57 (s), total 2H], [3.46 (dd, J = 12.5, 4.2 Hz) and 3.33 (dd, J = 10.4, 4.9 Hz), total 1H], 2.57 (s, 3H), 2.34 - 2.18 (m, 1H), [2.08 - 1.97 (m) and 1.92 - 1.80 (m), total 1H], [1.32 (s) and 1.31 (s), total 12H].
[0293] Step 5. Synthesis of [6-({(3S)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}amino)-2-methylpyridin-3-yl]boronic acid (P3-OH). To a 25°C mixture of C14 (5.5 g, 14.0 mmol) in tetrahydrofuran (50 mL) was added bis(triphenylphosphine)nickel(II) dichloride (275 mg, 0.42 mmol), and the mixture was degassed by evacuation and then backfilling with nitrogen; this degassing procedure was repeated five times. A separate reactor was charged with methanol (50 mL) and tetrahydroxydiboron (3.77 g, 42.1 mmol), and the mixture was stirred until completely homogeneous. This solution was degassed in the same manner. The tetrahydroxydiboron solution was then added to the first reactor via syringe over 5 minutes, immediately followed by the dropwise addition of N,N-diisopropylethylamine (7.0 mL, 42 mmol). After stirring the reaction mixture at 25°C for 2 hours, the reaction was filtered through a pad of diatomaceous earth. The methanol and tetrahydrofuran were removed in vacuo, and the residue was dissolved in a 0°C mixture of aqueous sodium hydroxide (1 M; 50 mL) and tert-butyl methyl ether (50 mL), and any residue was removed using ethyl acetate. The organic layer was extracted with aqueous sodium hydroxide (1 M; 2 × 30 mL), and the combined aqueous layers were stirred with the dropwise addition of 6 M aqueous hydrochloric acid (pH approximately 9 to 10) until a solid precipitated. The resulting mixture was stirred at room temperature for 20 minutes, whereupon ethyl acetate (20 mL) was added to provide a solution. This was transferred to a separatory funnel and vigorously shaken; the aqueous layer was extracted with ethyl acetate (2 × 60 mL), and the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered through a pad of diatomaceous earth, and concentrated in vacuo to provide P3-OH as a white powder. 1 H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 3.46 g, 9.69 mmol, 69%. LCMS m / z 358.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.71 - 7.46 (m, 1H), [7.28 (dd, J = 8.3, 5.5 Hz) and 7.23 (dd, J = 8.4, 5.5 Hz), total 2H], [7.04 (br dd, J = 8.8, 8.7 Hz) and 6.98 (br dd, J = 8.8, 8.7 Hz), total 2H], 6.59 - 6.24 (m, 1H), 4.49 - 4.35 (m, 1H), [3.89 (dd, J = 10.8, 5.7 Hz) and 3.79 (dd, J = 12.4, 6.2 Hz), total 1H], [3.76 - 3.60 (m) and 3.60 - 3.37 (m), total 5H], 2.42 (br s, 3H), 2.39 - 2.18 (m, 1H), 2.09 - 1.88 (m, 1H).
[0294] Preparation example P4 5-[2-(difluoromethyl)-1-methyl-1H-imidazol-4-yl]-6-methyl-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride (P4)
[0295] [ka] Step 1: Synthesis of 4-bromo-2-(difluoromethyl)-1-methyl-1H-imidazole (C16) To a 0°C solution of 4-bromo-1-methyl-1H-imidazole-2-carbaldehyde (C15) (1.86 g, 9.84 mmol) in dichloromethane was added [bis(2-methoxyethyl)amino]sulfur trifluoride (BAST; 7.3 mL, 39 mol). After stirring the reaction mixture at 25°C for 7 hours, the mixture was treated with saturated aqueous sodium bicarbonate until basic (pH 7 to 8). The aqueous layer was extracted with dichloromethane (3 x 30 mL), and the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 15% ethyl acetate in petroleum ether) provided C16 as a pale yellow oil, which gradually solidified. Yield: 1.79 g, 8.48 mmol, 86%. LCMS m / z 211.1 (bromine isotope pattern observed) [M+H] + . 1H NMR (400 MHz, methanol-d4) δ 7.29 (s, 1H), 6.81 (t, J HF = 52.3 Hz, 1H), 3.82 (s, 3H).
[0296] Step 2: Synthesis of tert-butyl (3S)-3-({5-[2-(difluoromethyl)-1-methyl-1H-imidazol-4-yl]-6-methylpyridin-2-yl}amino)pyrrolidine-1-carboxylate (C17). A mixture of C16 (100 mg, 0.47 mmol), P1 (167 mg, 0.52 mmol), Pd(amphos)Cl (17 mg, 24 μmol), and potassium bicarbonate (142 mg, 1.42 mmol) in a mixture of 1,4-dioxane (3.0 mL) and water (0.5 mL) was heated at 80° C. for 17 hours. The reaction mixture was concentrated in vacuo; the residue was purified by silica gel chromatography (gradient: 0% to 5% methanol in dichloromethane) to provide C17 as a white solid. LCMS m / z 408.2 [M+H] + . 1 H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 133 mg, 0.326 mmol, 69%. 1 H NMR (400 MHz, methanol-d4) δ 7.62 (d, J = 8.6 Hz, 1H), 7.28 (s, 1H), 6.87 (t, J HF = 52.6 Hz, 1H), 6.44 (d, J = 8.6 Hz, 1H), 4.46 - 4.38 (m, 1H), 3.88 (s, 3H), [3.70 (d, J = 6.1 Hz), 3.68 (d, J = 6.1 Hz), 3.59 - 3.37 (m), 3.24 (br d, J = 3.9 Hz), and 3.21 (br d, J = 3.4 Hz), total 4H], 2.46 (s, 3H), 2.31 - 2.16 (m, 1H), 2.01 - 1.85 (m, 1H), [1.47 (s) and 1.46 (s), total 9H].
[0297] Step 3: Synthesis of 5-[2-(difluoromethyl)-1-methyl-1H-imidazol-4-yl]-6-methyl-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride salt (P4). Acetyl chloride (3.90 mL, 55.2 mmol) was added slowly to propan-2-ol (15 mL, 200 mmol) to control the expected exotherm. The resulting solution was added in one portion to a solution of C17 (2.25 g, 5.52 mmol) in propan-2-yl acetate (15 mL). After the mixture was stirred at 25° C. for 4 h, the solvent was removed in vacuo to give P4 (2.4 g, estimated quantitative) as a white solid. LCMS m / z 308.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.16 (d, J = 9.3 Hz, 1H), 7.85 (s, 1H), 7.27 (t, J = 52.1 Hz, 1H), 7.21 (d, J = 9.3 Hz, 1H), 4.85 - 4.77 (m, 1H), 4.02 (s, 3H), [3.76 (d, J = 6.6 Hz), 3.73 (d, J = 6.6 Hz), 3.67 - 3.56 (m), 3.56 - 3.42 (m) total 4H], 2.72 (s, 3H), 2.62 - 2.50 (m, 1H), 2.30 - 2.19 (m, 1H).
[0298] Preparation example P5 6-Methyl-5-(2-methyl-2H-tetrazol-5-yl)-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride (P5)
[0299] [ka] Step 1: Synthesis of 6-chloro-2-methyl-3-[(E)-(2-methylhydrazinylidene)methyl]pyridine (C19). A mixture of methylhydrazine sulfate (8.65 g, 60.0 mmol) in methanol (60 mL) and triethylamine (18.2 g, 180 mmol) was added to a solution of 6-chloro-2-methylpyridine-3-carbaldehyde (C18) (9.33 g, 60.0 mmol) in methanol (140 mL). The mixture was stirred at 25° C. for 30 minutes; then it was concentrated in vacuo and purified by silica gel chromatography (gradient: 0% to 40% ethyl acetate in petroleum ether) to provide C19 as a yellow solid. Yield: 9.24 g, 50.3 mmol, 84%. LCMS m / z 184.1 (chlorine isotope pattern observed) [M+H] + ; 1 H NMR (400 MHz, DMSO-d6) δ 7.97 (d, J = 8.3 Hz, 1H), 7.85 - 7.79 (m, 1H), 7.38 (s, 1H), 7.24 (d, J = 8.1 Hz, 1H), 2.85 (d, J = 4.2 Hz, 3H), 2.50 (s, 3H).
[0300] Step 2: Synthesis of 6-chloro-2-methyl-3-(2-methyl-2H-tetrazol-5-yl)pyridine (C20). To a solution of C19 (9.18 g, 50.0 mmol) in a mixture of dichloromethane (50 mL) and 2,2,2-trifluoroethanol (50 mL) were added di-tert-butyl azodicarboxylate (13.8 g, 60.0 mmol) and [bis(trifluoroacetoxy)iodo]benzene (43.0 g, 100 mmol). The reaction mixture was stirred at 25° C. for 30 minutes, whereupon it was concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 40% ethyl acetate in petroleum ether) provided C20 as a white solid. Yield: 4.63 g, 22.1 mmol, 44%. LCMS m / z 210.1 (chlorine isotope pattern observed) [M+H] + ; 1 H NMR (400 MHz, DMSO-d6) δ 8.32 (d, J = 8.3 Hz, 1H), 7.58 - 7.48 (m, 1H), 4.47 (s, 3H), 2.75 (s, 3H).
[0301] Step 3: Synthesis of tert-butyl (3S)-3-{[6-methyl-5-(2-methyl-2H-tetrazol-5-yl)pyridin-2-yl]amino}pyrrolidine-1-carboxylate (C21). A solution of C20 (210 mg, 1.00 mmol), C1 (196 mg, 1.05 mmol), sodium tert-butoxide (193 mg, 2.00 mmol), Pd2(dba)3 [tris(dibenzylideneacetone)dipalladium(0); 91.7 mg, 0.100 mmol], and 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (RuPhos; 93.5 mg, 0.200 mmol) in toluene (15 mL) was stirred at 100 °C for 16 h, whereupon the reaction mixture was concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 10% methanol in dichloromethane) provided C21 as a yellow solid. 1H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 270 mg, 0.751 mmol, 75%. LCMS m / z 360.1 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.95 (d, J = 8.8 Hz, 1H), 6.47 (d, J = 8.8 Hz, 1H), 4.57 - 4.46 (m, 1H), 4.39 (s, 3H), [3.72 (d, J = 6.4 Hz) and 3.69 (d, J = 6.1 Hz), total 1H], 3.58 - 3.37 (m, 2H), [3.26 (d, J = 4.6 Hz) and 3.23 (d, J = 4.6 Hz), total 1H], 2.65 (s, 3H), 2.31 - 2.38 (m, 1H), 2.00 - 1.87 (m, 1H), [1.47 (s) and 1.46 (s), total 9H].
[0302] Step 4: Synthesis of 6-methyl-5-(2-methyl-2H-tetrazol-5-yl)-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride salt (P5). To a 20° C. solution of C21 (270 mg, 0.751 mmol) in dichloromethane (5 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4 M; 5 mL, 20 mmol). After the reaction mixture was stirred for 3 h, it was concentrated in vacuo to give P5 as a yellow solid. Yield: 205 mg, 0.617 mmol, 82%. LCMS m / z 260.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 9.38 (br s, 2H), 8.27 - 8.06 (m, 1H), 6.99 - 6.73 (m, 1H), 4.98 - 4.46 (m, 3H), 4.42 (s, 3H), 3.57 - 3.46 (m, 1H), 3.45 - 3.32 (m, 1H), 3.32 - 3.21 (m, 1H), 3.21 - 3.11 (m, 1H), 2.75 (br s, 3H), 2.37 - 2.24 (m, 1H), 2.04 - 1.92 (m, 1H).
[0303] Preparation example P6 5-[5-(1,1-difluoroethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methyl-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride (P6)
[0304] [ka] Step 1: Synthesis of 3,5-dibromo-1-methyl-1H-1,2,4-triazole (C23). A solution of 3,5-dibromo-1H-1,2,4-triazole (C22) (16.5 g, 72.7 mmol), potassium carbonate (20.1 g, 145 mmol), and iodomethane (15.5 g, 109 mmol) in N,N-dimethylformamide (30 mL) was stirred at 25° C. for 2 hours. The reaction mixture was then treated with water (30 mL) and extracted with dichloromethane (2×35 mL); the combined organic layers were concentrated in vacuo and purified by silica gel chromatography (eluent: 20% ethyl acetate in petroleum ether) to provide C23 as a white solid. Yield: 13.6 g, 56.5 mmol, 78%. LCMS m / z 242.0 (dibromo isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 3.87 (br s, 3H).
[0305] Step 2: Synthesis of 1-(3-bromo-1-methyl-1H-1,2,4-triazol-5-yl)ethan-1-ol (C24). To a −78° C. solution of C23 (10.3 g, 42.8 mmol) in tetrahydrofuran (40 mL) was added dropwise a solution of n-butyllithium in hexane (2.4 M; 19.6 mL, 47.0 mmol). The mixture was stirred at −40° C. for 2.5 hours, and then a solution of acetaldehyde in tetrahydrofuran (5 M; 17.1 mL, 85.5 mmol) was added at −78° C. Stirring was continued at −78° C. for 16 hours, whereupon the mixture was diluted with water (20 mL) and concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 10% methanol in dichloromethane) afforded C24 as a yellow oil. Yield: 5.10 g, 24.8 mmol, 58%. LCMS m / z 206.1 (bromine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 4.98 (br q, J = 6.8 Hz, 1H), 3.91 (s, 3H), 3.56 (br s, 1H), 1.60 (d, J = 6.7 Hz, 3H).
[0306] Step 3: Synthesis of 1-(3-bromo-1-methyl-1H-1,2,4-triazol-5-yl)ethan-1-one (C25). A solution of C24 (5.1 g, 24.7 mmol) and 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (Dess-Martin periodinane; 11.5 g, 27.2 mmol) in dichloromethane (40 mL) was stirred at 25 °C for 3.5 h. After concentration of the reaction mixture in vacuo, silica gel chromatography (gradient: 0% to 20% ethyl acetate in petroleum ether) provided C25 as a white solid. Yield: 4.47 g, 21.9 mmol, 89%. LCMS m / z 204.0 (bromine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 4.16 (br s, 3H), 2.68 (br s, 3H).
[0307] Step 4: Synthesis of tert-butyl (3S)-3-{[5-(5-acetyl-1-methyl-1H-1,2,4-triazol-3-yl)-6-methylpyridin-2-yl]amino}pyrrolidine-1-carboxylate (C26). A solution of C25 (4.57 g, 22.4 mmol), P1 (7.91 g, 24.6 mmol), potassium carbonate (6.19 g, 44.8 mmol), and Pd(amphos)Cl (1.59 g, 2.24 mmol) in a mixture of 1,4-dioxane and water (40:1, 41 mL) was stirred at 90° C. for 16 h. The reaction mixture was concentrated in vacuo and then immediately purified by silica gel chromatography (gradient: 0% to 40% ethyl acetate in petroleum ether) to provide C26 as a yellow solid. 1 H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 3.49 g, 8.71 mmol, 39%. LCMS m / z 401.3 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.94 (d, J = 8.6 Hz, 1H), 6.45 (d, J = 8.6 Hz, 1H), 4.54 - 4.43 (m, 1H), 4.19 (s, 3H), 3.71 (dd, J = 11.1, 6.1 Hz, 1H), 3.58 - 3.38 (m, 2H), 3.25 (dd, J = 11.1, 4.8 Hz, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.31 - 2.17 (m, 1H), 2.01 - 1.87 (m, 1H), [1.47 (s) and 1.46 (s), total 9H].
[0308] Step 5: Synthesis of tert-butyl (3S)-3-({5-[5-(1,1-difluoroethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidine-1-carboxylate (C27). A solution of C26 (3.49 g, 8.71 mmol) in [bis(2-methoxyethyl)amino]sulfur trifluoride (BAST; 20 mL) at 25° C. was stirred for 16 hours. The reaction mixture was diluted with dichloromethane (300 mL), quenched with saturated aqueous sodium bicarbonate (300 mL), and extracted with dichloromethane (2×30 mL); the combined organic layers were concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 40% ethyl acetate in petroleum ether) provided C27 as a yellow solid. 1 H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 2.50 g, 5.92 mmol, 68%. LCMS m / z 423.3 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.89 (d, J = 8.7 Hz, 1H), 6.44 (d, J = 8.7 Hz, 1H), 4.53 - 4.42 (m, 1H), 4.07 (t, J = 1.4 Hz, 3H), 3.70 (dd, J = 11.1, 6.1 Hz, 1H), 3.56 - 3.38 (m, 2H), 3.28 - 3.20 (m, 1H), 2.63 (s, 3H), 2.29 - 2.16 (m, 1H), 2.17 (t, J HF = 19.2 Hz, 3H), 2.00 - 1.87 (m, 1H), [1.47 (s) and 1.46 (s), total 9H].
[0309] Step 6: Synthesis of 5-[5-(1,1-difluoroethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methyl-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride salt (P6). To a 25° C. solution of C27 (2.5 g, 5.92 mmol) in dichloromethane (20 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4.0 M; 5.92 mL, 23.7 mmol). After the reaction was stirred for 4 h, it was concentrated in vacuo. The residue was washed with ethyl acetate to give P6 as a yellow solid. Yield: 1.72 g, 4.35 mmol, 73%. LCMS m / z 323.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.59 (d, J = 9.4 Hz, 1H), 7.18 (br d, J = 9.4 Hz, 1H), 4.83 - 4.73 (m, 1H), 4.12 (t, J = 1.3 Hz, 3H), 3.73 (dd, component of ABX system, J = 12.6, 6.7 Hz, 1H), 3.66 - 3.56 (m, 1H), 3.55 - 3.41 (m, 2H), 2.96 (s, 3H), 2.61 - 2.49 (m, 1H), 2.29 - 2.17 (m, 1H), 2.19 (t, J HF = 19.2 Hz, 3H).
[0310] Preparation example P7 6-Methyl-5-(pyrimidin-2-yl)-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride (P7)
[0311] [ka] Step 1. Synthesis of tert-butyl (3S)-3-{[6-methyl-5-(pyrimidin-2-yl)pyridin-2-yl]amino}pyrrolidine-1-carboxylate (C28). Aqueous tripotassium phosphate (2.0 M; 311 mL, 622 mmol) was added to a solution of P1 (80 g, 250 mmol) and 2-bromopyrimidine (43.6 g, 274 mmol) in tetrahydrofuran (1.0 L), followed by sparging with nitrogen for 10 minutes. Dichlorobis(triphenylphosphine)palladium(II) (3.5 g, 5.0 mmol) was added, and the reaction mixture was again sparged with nitrogen for 10 minutes, whereupon it was heated to 65° C. for 18 hours. The reaction mixture was cooled to room temperature and partitioned between ethyl acetate and water. After extracting the aqueous layer three times with ethyl acetate, the combined organic layers were dried over sodium sulfate, filtered through a pad of diatomaceous earth, and concentrated in vacuo to give C28 as a solid. Yield: 85.0 g, 239 mmol, 96%. LCMS m / z 356.3 [M+H] + . 1 H NMR (400 MHz, methanol-d4), characteristic peaks: δ 8.80 (d, J = 4.9 Hz, 2H), 7.93 (d, J = 8.7 Hz, 1H), 7.28 (t, J = 4.9 Hz, 1H), 6.47 (d, J = 8.7 Hz, 1H), 4.56 - 4.45 (m, 1H), 3.25 (dd, J = 11.0, 4.5 Hz, 1H), 2.62 (s, 3H), 2.00 - 1.89 (m, 1H), 1.46 (s, 9H).
[0312] Step 2. Synthesis of 6-methyl-5-(pyrimidin-2-yl)-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride (P7). Acetyl chloride (71.6 g, 912 mmol, 64.8 mL) was added dropwise to propan-2-ol (174 mL) at 0° C. In a separate flask, C28 (81 g, 228 mmol) was dissolved in a 4:1 mixture of propan-2-yl acetate / propan-2-ol (760 mL), which required heating to 50° C. The hydrogen chloride solution was added dropwise to the solution of C28 at 50° C., and the reaction mixture was stirred at 50° C. for 6 h. The heat was turned off and the reaction was allowed to cool slowly to room temperature with stirring, whereupon the mixture was filtered to provide P7 as a solid. Yield: 72 g, 220 mmol, 96%. LCMS m / z 256.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.94 (d, J = 5.0 Hz, 2H), 8.73 (d, J = 9.3 Hz, 1H), 7.49 - 7.44 (m, 1H), 7.23 (d, J = 9.4 Hz, 1H), 4.86 - 4.77 (m, 1H), 3.76 (dd, J = 12.5, 6.6 Hz, 1H), 3.67 - 3.57 (m, 1H), 3.57 - 3.42 (m, 2H), 2.97 (s, 3H), 2.63 - 2.51 (m, 1H), 2.32 - 2.19 (m, 1H).
[0313] Preparation example P8 5-[5-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methyl-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride (P8)
[0314] [ka] Step 1. Synthesis of 3-bromo-5-(difluoromethyl)-1-methyl-1H-1,2,4-triazole (C29). [Bis(2-methoxyethyl)amino]sulfur trifluoride (BAST; 47.0 mL, 255 mmol) was added dropwise to a 0° C. mixture of 3-bromo-1-methyl-1H-1,2,4-triazole-5-carbaldehyde (24.2 g, 127 mmol) in dichloromethane (400 mL). The reaction mixture was allowed to warm to 20° C. and stirred at 20° C. for 16 hours, whereupon it was treated dropwise with aqueous sodium bicarbonate and extracted with dichloromethane (3×300 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, and filtered. After the filtrate was concentrated to dryness in vacuo below 38° C., the residue was purified by chromatography on silica gel (gradient: 50% to 70% dichloromethane in petroleum ether) to provide C29 as a pale yellow oil. Yield: 17.7 g, 83.5 mmol, 66%. LCMS m / z 212.0 (bromine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.06 (t, J HF = 52.2 Hz, 1H), 4.02 (s, 3H).
[0315] Step 2. Synthesis of tert-butyl (3S)-3-({5-[5-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidine-1-carboxylate (C30). To a nitrogen-sparged 25°C mixture of P1 (110 g, 342 mmol) and C29 (68.0 g, 321 mmol) in tetrahydrofuran (800 mL) was added aqueous tripotassium phosphate (2.5 M; 311 mL, 778 mmol), followed by dichlorobis(triphenylphosphine)palladium(II) (1.09 g, 1.56 mmol). The reaction mixture was sparged with nitrogen for 10 minutes, heated to 70°C for 18 hours, and cooled to room temperature. After partitioning the reaction mixture between ethyl acetate (250 mL) and water (250 mL), the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed sequentially with saturated aqueous sodium bicarbonate and saturated aqueous sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo; the resulting material was dissolved in warm ethyl acetate, treated with heptane, and allowed to cool. The precipitate was collected by filtration to provide C30 as a white solid. Yield: 105 g, 257 mmol, 80%. LCMS m / z 409.3 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 8.00 (d, J = 8.6 Hz, 1H), 6.86 (t, J HF = 52.6 Hz, 1H), 6.31 (d, J = 8.6 Hz, 1H), 4.80 - 4.67 (m, 1H), 4.41 - 4.23 (m, 1H), 4.08 (s, 3H), 3.80 - 3.65 (m, 1H), 3.57 - 3.38 (m, 2H), 3.36 - 3.15 (m, 1H), 2.70 (s, 3H), 2.29 - 2.16 (m, 1H), 1.99 - 1.81 (m, 1H), 1.46 (s, 9H).
[0316] Step 3. Synthesis of 5-[5-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methyl-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride salt (P8). Acetyl chloride (2.99 mL, 42.1 mmol) was added dropwise to propan-2-ol (8.0 mL) at 0° C. In a separate flask, C30 (4.30 g, 10.5 mmol) was dissolved in propan-2-ol (30 mL) by heating to 60° C. Once the material was dissolved, the temperature was reduced to 50° C. and hydrogen chloride solution was added dropwise at 50° C. After the reaction mixture was stirred at 50° C. for 3 hours, it was slowly cooled to room temperature with stirring; the precipitate was collected by filtration to give P8 as a white solid. Yield: 2.85 g, 7.48 mmol, 71%. LCMS m / z 309.3 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.58 (d, J = 9.4 Hz, 1H), 7.19 (d, J = 9.4 Hz, 1H), 7.17 (t, J HF = 52.2 Hz, 1H), 4.83 - 4.74 (m, 1H), 4.11 (br s, 3H), 3.74 (dd, J = 12.6, 6.7 Hz, 1H), 3.66 - 3.56 (m, 1H), 3.55 - 3.42 (m, 2H), 2.96 (s, 3H), 2.62 - 2.49 (m, 1H), 2.29 - 2.18 (m, 1H).
[0317] Preparation Example P9 6-Methyl-N-[(3S)-pyrrolidin-3-yl]-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridin-2-amine, dihydrochloride (P9)
[0318] [ka] Step 1. Synthesis of tert-butyl (3S)-3-[(5-cyano-6-methylpyridin-2-yl)amino]pyrrolidine-1-carboxylate (C83). A solution of 6-chloro-2-methylpyridine-3-carbonitrile (5.00 g, 32.8 mmol), C1 (6.10 g, 32.8 mmol), and N,N-diisopropylethylamine (8.47 g, 65.5 mmol) in dimethyl sulfoxide (25 mL) was stirred at 120° C. for 16 hours. The reaction mixture was then diluted with water (30 mL) and extracted with ethyl acetate (2×35 mL); the combined organic layers were concentrated in vacuo to give C83 as a yellow solid. Yield: 8.50 g, 28.1 mmol, 86%. LCMS m / z 303.0 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.53 (d, J = 8.7 Hz, 1H), 6.24 (d, J = 8.6 Hz, 1H), 5.04 (br s, 1H), 4.50 - 4.31 (m, 1H), 3.78 - 3.64 (m, 1H), 3.57 - 3.38 (m, 2H), 3.36 - 3.14 (m, 1H), 2.56 (s, 3H), 2.31 - 2.15 (m, 1H), 1.98 - 1.82 (m, 1H), 1.46 (s, 9H).
[0319] Step 2. Synthesis of tert-butyl (3S)-3-{[5-(N'-hydroxycarbamimidoyl)-6-methylpyridin-2-yl]amino}pyrrolidine-1-carboxylate (C31). A mixture of C83 (8.50 g, 28.1 mmol), hydroxylamine hydrochloride (7.81 g, 112 mmol), and sodium carbonate (11.9 g, 112 mmol) in ethanol (150 mL) was stirred at 90° C. for 16 hours. After the reaction mixture was concentrated in vacuo, it was diluted with saturated aqueous sodium bicarbonate (40 mL) and extracted with ethyl acetate (2×50 mL). The combined organic layers were concentrated under reduced pressure to give C31 as a yellow solid. Yield: 8.68 g, 25.9 mmol, 92%. LCMS m / z 336.2 [M+H] + . 1H NMR (400 MHz, chloroform-d) δ 7.46 (br d, J = 8.4 Hz, 1H), 6.22 (d, J = 8.5 Hz, 1H), 5.52 (br s, 1H), 4.78 (br s, 2H), 4.26 - 4.09 (m, 1H), 3.74 - 3.61 (m, 1H), 3.49 - 3.29 (m, 2H), 3.28 - 3.09 (m, 1H), 2.48 (s, 3H), 2.22 - 2.08 (m, 1H), 1.87 - 1.69 (m, 1H), 1.45 (s, 9H).
[0320] Step 3. Synthesis of tert-butyl (3S)-3-({6-methyl-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridin-2-yl}amino)pyrrolidine-1-carboxylate (C32). To a 25° C. solution of C31 (100 mg, 0.298 mmol) in 1,4-dioxane (2.0 mL) was added potassium carbonate (124 mg, 0.894 mmol), followed by trifluoroacetic anhydride (150 mg, 0.1 mL, 0.714 mmol). After stirring the reaction mixture for 20 hours, it was filtered and concentrated in vacuo; silica gel chromatography (gradient: 0% to 5% methanol in dichloromethane) provided C32 as a yellow solid. Yield: 64.0 mg, 0.155 mmol, 52%. LCMS m / z 414.3 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.47 (d, J = 9.5 Hz, 1H), 7.16 (d, J = 9.5 Hz, 1H), 4.58 - 4.44 (m, 1H), 3.82 - 3.67 (m, 1H), 3.63 - 3.47 (m, 2H), 3.43 (dd, J = 11.6, 3.8 Hz, 1H), 2.91 (s, 3H), 2.42 - 2.28 (m, 1H), 2.19 - 2.04 (m, 1H), 1.47 (s, 9H).
[0321] Step 4. Synthesis of 6-methyl-N-[(3S)-pyrrolidin-3-yl]-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridin-2-amine, dihydrochloride (P9). To a 25° C. solution of C32 (64.0 mg, 0.155 mmol) in methanol (5 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4.0 M; 2 mL, 8 mmol). The reaction mixture was stirred for 3 h, whereupon it was concentrated in vacuo to give P9 as a yellow solid. Yield: 41.0 mg, 0.106 mmol, 68%. LCMS m / z 314.1 [M+H] + . 1 H NMR (400 MHz, methanol-d4), characteristic peaks: δ 8.54 (d, J = 9.1 Hz, 1H), 7.32 (d, J = 9.2 Hz, 1H), 3.79 (dd, J = 12.5, 6.2 Hz, 1H), 3.69 - 3.59 (m, 1H), 3.59 - 3.47 (m, 2H), 2.98 (s, 3H), 2.66 - 2.53 (m, 1H), 2.35 - 2.22 (m, 1H).
[0322] Preparation example P10 5-[2-(1,1-difluoroethyl)-1-methyl-1H-imidazol-4-yl]-6-methyl-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride (P10)
[0323] [ka]
[0324] [ka] Step 1. Synthesis of 2,2-difluoropropanamide (C34). To a 0° C. solution of 2,2-difluoropropanoic acid (C33) (10.0 g, 90.9 mmol) in tetrahydrofuran (150 mL) was added oxalyl chloride (8.46 mL, 99.9 mmol) dropwise, followed by three drops of N,N-dimethylformamide. The reaction mixture was stirred at 25° C. for 2 hours, and then aqueous ammonia (25%, 100 mL) was added dropwise over 20 minutes at 0° C. After stirring the reaction mixture at 25° C. for 16 hours, it was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo to give C34 as a white solid. Yield: 5.88 g, 53.9 mmol, 59%. LCMS m / z 110.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 1.75 (t, J HF = 19.1 Hz, 3H).
[0325] Step 2. Synthesis of 2,2-difluoropropanenitrile (C35). To a solution of C34 (10.2 g, 93.5 mmol) in pyridine (60 mL) at 25° C., a solution of trifluoroacetic acid (14.3 mL, 103 mmol) in pyridine (30 mL) was added dropwise. The reaction mixture was heated to 110° C., and the product was distilled directly at this temperature into a receiving flask cooled in an ice bath to give C35 as a colorless oil. Yield: 5.90 g, 64.8 mmol, 69%. 1 H NMR (400 MHz, methanol-d4) δ 1.83 (t, J HF = 19.0 Hz, 3H).
[0326] Step 3. Synthesis of 2,2-difluoropropanimidamide (C36). Starting material C35 (5.90 g, 64.8 mmol) was condensed into a flask immersed in a dry ice-ethanol bath and equipped with a dry ice-ethanol condenser. Liquid ammonia (approximately 30 mL) was added to the flask, the cooling bath was removed, and the reaction mixture was refluxed for 1 h. The ammonia was then vented off to provide C36 as a colorless oil. Yield: 5.4 g, 50 mmol, 77%. LCMS m / z 109.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 1.83 (t, J HF = 19.0 Hz, 3H).
[0327] Step 4. Synthesis of 6-chloro-N-methoxy-N,2-dimethylpyridine-3-carboxamide (C38). To a 25° C. solution of 6-chloro-2-methylpyridine-3-carboxylic acid (C37) (5.0 g, 29 mmol), 1H-benzotriazol-1-ol (HOBt; 5.91 g, 43.7 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI; 8.38 g, 43.7 mmol), and N,O-dimethylhydroxylamine hydrochloride (3.41 g, 35.0 mmol) in dichloromethane (100 mL) was added triethylamine (12.6 mL, 87.4 mmol). After stirring the reaction mixture for 2 hours, it was washed sequentially with saturated aqueous ammonium chloride solution (50 mL), water (100 mL), and saturated aqueous sodium chloride solution (50 mL), and then concentrated in vacuo to provide C38 as a colorless oil (6.45 g). The majority of this material was carried on to the next step. LCMS m / z 215.1 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.76 (d, J = 8.1 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 3.50 (br s, 3H), 3.37 (br s, 3H), 2.47 (s, 3H).
[0328] Step 5. Synthesis of 1-(6-chloro-2-methylpyridin-3-yl)ethan-1-one (C39). To a 10° C. solution of C38 (from the previous step; ∼6.10 g, 27.4 mmol) in tetrahydrofuran (60 mL) was added dropwise a solution of methylmagnesium bromide in tetrahydrofuran (3.0 M; 23.7 mL, 71.1 mmol), whereupon the reaction mixture was stirred at 25° C. for 1 h. It was then cooled to below 10° C., quenched by the addition of saturated aqueous ammonium chloride solution, and poured into water (200 mL). The resulting mixture was extracted with ethyl acetate (2×100 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 30% ethyl acetate in petroleum ether) provided C39 as a colorless oil. Yield: 3.49 g, 20.6 mmol, 75% over two steps. LCMS m / z 170.1 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.20 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 2.66 (s, 3H), 2.59 (s, 3H).
[0329] Step 6. Synthesis of 2-bromo-1-(6-chloro-2-methylpyridin-3-yl)ethan-1-one (C40) To a 25° C. solution of C39 (3.50 g, 20.6 mmol) in acetonitrile (60 mL) was added N-bromosuccinimide (4.41 g, 24.8 mmol) and p-toluenesulfonic acid (355 mg, 2.06 mmol), whereupon the reaction mixture was stirred at 80° C. for 5 hours and then concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) provided C40 as a brown oil. Yield: 3.23 g, 13.0 mmol, 63%. LCMS m / z 247.9 (bromochloro isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.21 (d, J = 8.3 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 4.61 (s, 2H), 2.65 (s, 3H).
[0330] Step 7. Synthesis of 6-chloro-3-[2-(1,1-difluoroethyl)-1H-imidazol-4-yl]-2-methylpyridine (C41). A mixture of C40 (3.23 g, 13.0 mmol), triethylamine (1.82 mL, 13.1 mmol), and C36 (2.11 g, 19.5 mmol) in tetrahydrofuran (40 mL) was stirred at reflux for 4 hours. The reaction mixture was poured into water (60 mL) and extracted with ethyl acetate (80 mL); the organic layer was concentrated in vacuo and subjected to silica gel chromatography (gradient: 0% to 30% ethyl acetate in petroleum ether) to provide C41 as a colorless gum. Yield: 1.18 g, 4.58 mmol, 35%. LCMS m / z 258.1 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.05 (d, J = 8.2 Hz, 1H), 7.46 (s, 1H), 7.33 (d, J = 8.2 Hz, 1H), 2.64 (s, 3H), 2.09 (t, J HF = 18.6 Hz, 3H).
[0331] Step 8. Synthesis of 6-chloro-3-[2-(1,1-difluoroethyl)-1-methyl-1H-imidazol-4-yl]-2-methylpyridine (C42). A mixture of C41 (1.47 g, 5.70 mmol), iodomethane (0.426 mL, 6.84 mmol), and potassium carbonate (1.57 g, 11.4 mmol) in N,N-dimethylformamide (20 mL) was stirred at 50° C. for 5 hours. After the reaction mixture was cooled, it was poured into water and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, concentrated in vacuo, and purified by silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) to give C42 as a white solid. Yield: 900 mg, 3.31 mmol, 58%. LCMS m / z 272.1 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.08 (d, J = 8.2 Hz, 1H), 7.50 (s, 1H), 7.32 (d, J = 8.2 Hz, 1H), 3.91 (s, 3H), 2.64 (s, 3H), 2.15 (t, J HF = 19.0 Hz, 3H).
[0332] Step 9. Synthesis of tert-butyl (3S)-3-({5-[2-(1,1-difluoroethyl)-1-methyl-1H-imidazol-4-yl]-6-methylpyridin-2-yl}amino)pyrrolidine-1-carboxylate (C43). A mixture of C1 (617 mg, 3.31 mmol), C42 (900 mg, 3.31 mmol), Pd2(dba)3 (303 mg, 0.331 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (RuPhos; 309 mg, 0.663 mmol), and sodium tert-butoxide (637 mg, 6.63 mmol) in toluene (20 mL) was stirred at 100° C. for 10 h. The reaction mixture was concentrated in vacuo and subjected to silica gel chromatography (gradient: 0% to 60% ethyl acetate in petroleum ether) to provide C43 as a white solid. 1 H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 850 mg, 2.02 mmol, 61%. LCMS m / z 422.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.62 (d, J = 8.5 Hz, 1H), 7.22 (s, 1H), 6.43 (d, J = 8.5 Hz, 1H), 4.48 - 4.38 (m, 1H), 3.88 (br t, J = 1 Hz, 3H), 3.69 (dd, J = 11.1, 6.1 Hz, 1H), 3.57 - 3.37 (m, 2H), 3.23 (br dd, J = 11.1, 4.5 Hz, 1H), 2.45 (s, 3H), 2.29 - 2.17 (m, 1H), 2.12 (t, J HF = 18.9 Hz, 3H), 1.99 - 1.85 (m, 1H), [1.47 (s) and 1.46 (s), total 9H].
[0333] Step 10. Synthesis of 5-[2-(1,1-difluoroethyl)-1-methyl-1H-imidazol-4-yl]-6-methyl-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride salt (P10). To a 25° C. solution of C43 (850 mg, 2.02 mmol) in methanol (5 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4 M; 5 mL, 20 mmol). The reaction mixture was stirred for 2 h, whereupon it was concentrated in vacuo to give P10 as a gray solid. Yield: 746 mg, 1.89 mmol, 94%. LCMS m / z 322.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.30 (d, J = 9.3 Hz, 1H), 7.61 (s, 1H), 7.13 (d, J = 9.3 Hz, 1H), 4.78 - 4.70 (m, 1H), 3.94 (br t, J = 1 Hz, 3H), 3.72 (dd, J = 12.6, 6.6 Hz, 1H), 3.64 - 3.55 (m, 1H), 3.53 - 3.46 (m, 1H), 3.43 (dd, J = 12.6, 4.2 Hz, 1H), 2.75 (s, 3H), 2.60 - 2.48 (m, 1H), 2.27 - 2.16 (m, 1H), 2.17 (t, J HF = 19.0 Hz, 3H).
[0334] Preparation example P12 6-Methyl-5-[1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride (P12)
[0335] [ka] Step 1. Synthesis of tert-butyl (3S)-3-({6-methyl-5-[1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyridin-2-yl}amino)pyrrolidine-1-carboxylate (C50). A mixture of 3-bromo-1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazole (C49) (8.95 g, 37.4 mmol), P1 (12.0 g, 37.4 mmol), Pd(amphos)Cl (2.65 g, 3.74 mmol), and potassium bicarbonate (11.2 g, 112 mmol) in 1,4-dioxane (150 mL) and water (35 mL) was heated at 100° C. for 4 hours. The reaction mixture was concentrated in vacuo and purified using silica gel chromatography (gradient: 0% to 50% ethyl acetate in petroleum ether) to afford C50 as a white solid. 1 H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 9.82 g, 23.0 mmol, 61%. LCMS m / z 427.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.92 (d, J = 8.7 Hz, 1H), 6.45 (d, J = 8.6 Hz, 1H), 4.55 - 4.43 (m, 1H), 4.10 (q, J = 1.0 Hz, 3H), 3.70 (dd, J = 11.1, 6.1 Hz, 1H), 3.57 - 3.38 (m, 2H), 3.24 (dd, J = 11.1, 4.7 Hz, 1H), 2.65 (s, 3H), 2.30 - 2.17 (m, 1H), 2.00 - 1.86 (m, 1H), [1.47 (s) and 1.46 (s), total 9H].
[0336] Step 2. Synthesis of 6-methyl-5-[1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-N-[(3S)-pyrrolidin-3-yl]pyridin-2-amine, dihydrochloride salt (P12). To a 25° C. solution of C50 (9.8 g, 23 mmol) in methanol (40 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4.0 M; 57.5 mL, 230 mmol) and the reaction mixture was stirred for 2 h. It was then concentrated in vacuo to give P12 as a white solid. Yield: 9.05 g, 22.7 mmol, 99%. LCMS m / z 327.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d6), Characteristic peaks: δ 4.78 - 4.57 (m, 1H), 4.13 - 4.07 (m, 3H), 3.58 - 3.46 (m, 1H), 3.44 - 3.32 (m, 1H), 3.32 - 3.21 (m, 1H), 3.21 - 3.11 (m, 1H), 2.77 (br s, 3H), 2.37 - 2.24 (m, 1H), 2.03 - 1.92 (m, 1H).
[0337] Preparation example P13 2-(5-chloro-2-methoxypyridin-4-yl)propanoic acid (P13)
[0338] [ka] Step 1. Synthesis of methyl (5-chloro-2-methoxypyridin-4-yl)acetate (C51). A solution of lithium diisopropylamide in tetrahydrofuran (2 M; 1.9 L, 3.8 mol) was added dropwise to a −30° C. solution of 5-chloro-2-methoxy-4-methylpyridine (197 g, 1.25 mol) in tetrahydrofuran (1.4 L). The reaction mixture was stirred at −30° C. for 1 hour, followed by the dropwise addition of dimethyl carbonate (338 g, 3.75 mol); upon completion of the addition, the reaction mixture was warmed to 25° C. and stirred for 1 hour. It was then poured into hydrochloric acid (0.5 M, 7 L, 3.5 mol) and extracted with ethyl acetate (2×1.5 L); the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 20% ethyl acetate in petroleum ether) provided C51 as a yellow oil. Yield: 203 g, 0.941 mol, 75%. LCMS m / z 216.1 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.10 (s, 1H), 6.82 (s, 1H), 3.90 (s, 3H), 3.79 (s, 2H), 3.71 (s, 3H).
[0339] Step 2. Synthesis of methyl 2-(5-chloro-2-methoxypyridin-4-yl)propanoate (C52). To a −78° C. solution of C51 (175 g, 0.812 mol) in tetrahydrofuran (1.2 L) was added dropwise a solution of sodium bis(trimethylsilyl)amide in tetrahydrofuran (2 M; 455 mL, 0.910 mol). The reaction mixture was stirred at −78° C. for 1 hour, whereupon a solution of iodomethane (172.6 g, 1.216 mol) in tetrahydrofuran (100 mL) was added dropwise at −78° C., and stirring was continued at this temperature for 2 hours. The reaction mixture was then poured into saturated aqueous ammonium chloride solution (500 mL) and extracted with ethyl acetate (2×100 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated in vacuo to provide C52 as a brown oil. 1 H NMR and LCMS analysis showed that this material was contaminated with some of the dimethylated by-product methyl 2-(5-chloro-2-methoxypyridin-4-yl)-2-methylpropanoate. Yield: 136 g, ∼0.592 mol, ∼73%. LCMS m / z 230.1 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4), product peaks only: δ 8.10 (s, 1H), 6.76 (s, 1H), 4.10 (q, J = 7.2 Hz, 1H), 3.89 (s, 3H), 3.69 (s, 3H), 1.48 (d, J = 7.2 Hz, 3H).
[0340] Step 3. Synthesis of 2-(5-chloro-2-methoxypyridin-4-yl)propanoic acid (P13). To a 25° C. solution of C52 (168 g, 0.732 mol) in tetrahydrofuran (1 L) was added a solution of lithium hydroxide monohydrate (61.4 g, 0.146 mol) in water (300 mL) in a dropwise manner. The reaction mixture was stirred for 2 hours, whereupon it was concentrated in vacuo. The aqueous residue was poured into water (500 mL) and washed with tert-butyl methyl ether (2×500 mL). The aqueous layer was then adjusted to pH 4 by adding 3 M hydrochloric acid and extracted with ethyl acetate (2×500 mL); the combined ethyl acetate layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under reduced pressure to provide P13 as a white solid. Yield: 122 g, 0.566 mol, 77%. LCMS m / z 216.1 (chlorine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 8.10 (s, 1H), 6.79 (s, 1H), 4.06 (q, J = 7.1 Hz, 1H), 3.89 (s, 3H), 1.48 (d, J = 7.2 Hz, 3H).
[0341] Preparation Examples P14 and P15 (2R)-2-(5-chloro-2-methoxypyridin-4-yl)propanoic acid (P14) and (2S)-2-(5-chloro-2-methoxypyridin-4-yl)propanoic acid (P15)
[0342] [ka] Separation of P13 (5.00 g, 23.2 mmol) into its constituent enantiomers was carried out by supercritical fluid chromatography (column: Chiral Technologies Chiralpak IG, 30 × 250 mm, 5 μm; mobile phase: 95:5 carbon dioxide / methanol; flow rate: 80 mL / min; back pressure: 120 bar). The first-eluting enantiomer, an oil that solidified upon standing, was designated P14, and the second-eluting enantiomer was designated P15. The indicated absolute stereochemistry was assigned by X-ray crystal structure determination of Example 6, which was synthesized using P14 (see below). P14-Yield: 2.4 g, 11.1 mmol, 48%. 1 H NMR (400 MHz, chloroform-d) δ 8.13 (s, 1H), 6.75 (s, 1H), 4.12 (q, J = 7.2 Hz, 1H), 3.91 (s, 3H), 1.53 (d, J = 7.2 Hz, 3H). Retention time: 3.98 min (Analytical conditions: Column: Chiral Technologies Chiralpak IG, 4.6 × 250 mm, 5 μm; Mobile phase A: carbon dioxide; Mobile phase B: methanol; Gradient: 5% B over 1.00 min, then 5% to 60% B over 8 min; Flow rate: 3.0 mL / min; Back pressure: 120 bar). P15 - Yield: 2.4 g, 11.1 mmol, 48%. Retention time: 4.22 min (same analytical conditions as used for P14).
[0343] Preparation example P16 2-(5-Fluoro-2-methoxypyridin-4-yl)propanoic acid (P16)
[0344] [ka] Step 1. Synthesis of dibenzyl (5-fluoro-2-methoxypyridin-4-yl)propanedioate (C53). This reaction was carried out in three parallel batches. To a 25°C solution of dibenzylpropanedioate (607 g, 2.13 mol) in tetrahydrofuran (1.5 L) was added pyridine-2-carboxylic acid (35.0 g, 284 mmol), followed by copper(I) iodide (27.1 g, 142 mmol), and then freshly ground cesium carbonate (1.39 kg, 4.27 mol). After heating the reaction mixture to 70°C, it was treated dropwise with a solution of 5-fluoro-4-iodo-2-methoxypyridine (360 g, 1.42 mol) in tetrahydrofuran (800 mL), whereupon stirring was continued at 70°C for 16 hours. The three reaction mixtures were combined at this point and filtered through diatomaceous earth. The filter pad was rinsed with ethyl acetate (3 x 500 mL), and the combined filtrate was concentrated in vacuo while maintaining the internal temperature below 40°C. The residue was dissolved in ethyl acetate (2 L), washed sequentially with saturated aqueous ammonium chloride (500 mL) and saturated aqueous sodium chloride (500 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure at 40° C. Chromatography on silica gel (gradient: 1% to 8% ethyl acetate in petroleum ether) afforded C53 (1.87 kg) as a yellow oil. 1 H NMR analysis showed that this material was contaminated with dibenzylpropanedioate; a portion of this was used in the next step. LCMS m / z 410.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d), product peak only: δ 8.01 (d, J = 1.3 Hz, 1H), 7.40 - 7.25 (m, 10H, estimated; partially obscured by residual dibenzylpropanedioate), 6.83 (d, J = 4.8 Hz, 1H), 5.20 (AB quartet, J AB = 12.2 Hz, Δν AB = 11.9 Hz, 4H), 5.00 (s, 1H), 3.89 (s, 3H).
[0345] Step 2. Synthesis of dibenzyl (5-fluoro-2-methoxypyridin-4-yl)(methyl)propanedioate (C54). This reaction was carried out in two parallel batches. A solution of C53 (from the previous step; 575 g, 1.31 mol) in acetonitrile (1.5 L) was stirred in an ice-water bath for 20 minutes, immediately followed by the addition of potassium carbonate (582 g, 4.21 mol). Stirring was continued for an additional 10 minutes. Iodomethane (302 g, 2.13 mol) was then added to the reaction mixture at 0 °C, and the reaction was allowed to proceed until LCMS analysis indicated conversion to C54. After combining the two reaction mixtures, they were filtered through diatomaceous earth, and the filter cake was washed with acetonitrile (2 × 1 L). The combined filtrate was concentrated at 40 °C, and the residue was partitioned between ethyl acetate (2 L) and water (500 mL). The aqueous layer was extracted with ethyl acetate (2 × 1 L), and the combined organic layers were washed with saturated aqueous sodium chloride solution (1 L), dried over sodium sulfate, filtered, and concentrated under reduced pressure at 40 °C. The resulting crude product was dissolved in petroleum ether (1.5 L) and stirred at 0° C. for 2 hours; the solid was collected by filtration. The filtrate was concentrated in vacuo, and the residue was dissolved in petroleum ether (500 mL) and then cooled to 0° C. to provide an additional solid, which was isolated by filtration. The two solids were combined, suspended in petroleum ether (800 mL), and stirred at 20° C. for 16 hours. It was then collected by filtration to give C54 as a yellow solid. Yield: 670 g, 1.58 mol, 60% for two steps. LCMS m / z 423.8 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.94 (d, J = 2.6 Hz, 1H), 7.36–7.20 (m, 10H), 6.54 (d, J = 5.1 Hz, 1H), 5.18 (s, 4H), 3.87 (s, 3H), 1.85 (s, 3H).
[0346] Step 3. Synthesis of 2-(5-fluoro-2-methoxypyridin-4-yl)propanoic acid (P16). The reaction was carried out in four parallel batches. To a 25°C solution of C54 (200 g, 472 mmol) in ethyl acetate (1 L) was added 10% palladium on carbon (wet; 40 g). The mixture was degassed under vacuum and then purged with nitrogen; this evacuation-purge cycle was repeated a total of three times. The mixture was again degassed under vacuum and then purged with hydrogen; this evacuation-purge cycle was also repeated a total of three times. The mixture was hydrogenated (30 psi) at 50°C for 16 hours, whereupon the four reaction mixtures were combined and filtered through a pad of diatomaceous earth, and the filtrate was concentrated in vacuo at 45°C. Chromatography on silica gel (gradient: 10% to 20% ethyl acetate in petroleum ether) provided P16 as a white solid. Combined yield: 270 g, 1.36 mmol, 72%. LCMS m / z 199.7 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.98 (d, J = 1.7 Hz, 1H), 6.70 (d, J = 4.9 Hz, 1H), 3.97 (q, J = 7.3 Hz, 1H), 3.89 (s, 3H), 1.53 (d, J = 7.3 Hz, 3H).
[0347] Preparation Examples P17 and P18 (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)propanoic acid (P17) and (2S)-2-(5-fluoro-2-methoxypyridin-4-yl)propanoic acid (P18)
[0348] [ka] Separation of P16 (700 g, 3.51 mol) into its constituent enantiomers was carried out by supercritical fluid chromatography (column: Chiral Technologies Chiralpak AD-H, 50 × 250 mm, 5 μm; mobile phase: 9:1 carbon dioxide / propan-2-ol; flow rate: 250 mL / min; back pressure: 120 bar). The first-eluting enantiomer was designated P17, and the second-eluting enantiomer was designated P18; both were isolated as solids. The indicated absolute stereochemistry for P17 and P18 was assigned based on the X-ray crystal structure determination performed for Example 7 (see below); 7 was synthesized using a sample of P17 separated from P18 using the same chromatographic conditions described above. P17 - Yield: 260 g, 1.30 mol, 37%. Retention time: 3.17 min (analytical conditions: Column: Chiral Technologies Chiralpak AD-H, 4.6 x 250 mm, 5 μm; Mobile phase A: carbon dioxide; Mobile phase B: propan-2-ol; Gradient: 5% B over 1.00 min, then 5% to 60% B over 8 min; Flow rate: 3.0 mL / min; Back pressure: 120 bar). P18 - Yield: 400 g, 2.01 mol, 57%. Retention time: 3.36 min (same analytical conditions as used for P17).
[0349] First alternative preparation of P17 (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)propanoic acid (P17)
[0350] [ka] Step 1. Synthesis of disodium (5-fluoro-2-methoxypyridin-4-yl)(methyl)propanedioate (C55). A 1.0 M, pH 8.0 buffer solution was prepared in the following manner: a solution of 2-amino-2-(hydroxymethyl)propane-1,3-diol (Tris; 121 g, 1.00 mol) in water (900 mL) was adjusted to pH 8.0 by adding hydrochloric acid (37.5 wt%, approximately 40 mL) and then brought to a volume of 1 L by adding water.
[0351] A hydrogenation reactor was charged with palladium hydroxide on carbon (10%; 5.00 g). To this was added a solution of C54 (50.0 g, 118 mmol) in toluene (50 mL, 1 volume); additional toluene (50 mL) was used to rinse the flask, which was also added to the reaction mixture. A mixture of aqueous sodium hydroxide (2.0 M; 118 mL, 236 mmol), the above pH 8.0 buffer (1.0 M; 250 mL, 250 mmol), and water (132 mL) was added, and the resulting mixture was purged with nitrogen (3.5 bar) followed by hydrogen (3.5 bar); this purging process was repeated three times. The mixture was brought to 20°C while stirring at 100 rpm, and then pressurized with hydrogen to 3.45 bar, after which the stirring speed was increased to 750 rpm. After hydrogenation was allowed to proceed for 4 hours at 20°C, the stirring speed was reduced to 250 rpm and the reaction was purged with nitrogen (3.5 bar) three times. The catalyst was removed by filtration and the reactor was rinsed with water (100 mL), which was then used to wash the filter cake. The aqueous phase of the combined filtrate (590 mL, pH 8.2), containing C55, was carried on directly to the next step. LCMS m / z 244.2 [M+H] + .
[0352] Step 2. Synthesis of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)propanoic acid (P17). A 2 L jacketed vessel equipped with an overhead stirrer (set at 20°C jacket temperature) was charged with C55 (aqueous solution from the previous step; ∼118 mmol) and the stirring speed was set at 200 rpm. Bordetella bronchiseptica AMDase lyophilized cell-free extract powder (1.75 gm) in water (17.5 mL) was then added. [This arylmalonate decarboxylase (AMDase) from Bordetella bronchiseptica is the wild-type enzyme described in the literature under accession number Q05115, and was recombinantly expressed in E. coli and charged as a lyophilized cell-free extract powder.] A solution of [References: S.K. Gassmeyer et al., ChemCatChem, 2016, 8, 916-921; K. Okrasa et al., Angew. Chem. Int. Ed. 2009, 48, 7691-7694] was charged to the reactor along with a water rinse (5 mL) from the enzyme vessel. After 15 h, the stirring speed was reduced to 100 rpm, and the pH of the reaction mixture was adjusted to pH 6.0 by sequential addition of hydrochloric acid (4.0 M; 5 mL increments, 38 mL). At this point, the mixture was stirred for 1.5 h until gas evolution subsided, after which it was acidified to a pH of 2.0 or less by further addition of hydrochloric acid (4.0 M; total 85 mL). tert-Butyl methyl ether (300 mL) was added, and stirring was continued at 200 rpm for 15 min. The mixture was then filtered through diatomaceous earth (25 g) using a Buchner funnel and filter paper; the reactor was rinsed with tert-butyl methyl ether (100 mL), which was then used to wash the filter cake. The aqueous layer of the combined filtrate was extracted with tert-butyl methyl ether (300 mL) in the same manner. The combined organic layer was dried over sodium sulfate (50 g) and filtered; the filter cake was washed with tert-butyl methyl ether (25 mL). The combined filtrate was concentrated in vacuo at 30° C. to provide an oil, which solidified under vacuum drying overnight to give P17 as an off-white solid. Yield: 18.88 g, 94.8 mmol, 80% over two steps. 1H NMR (400 MHz, chloroform-d) δ 11.4 - 10.3 (br s, 1H), 7.98 (d, J = 1.6 Hz, 1H), 6.70 (d, J = 4.9 Hz, 1H), 3.97 (q, J = 7.2 Hz, 1H), 3.89 (s, 3H), 1.53 (d, J = 7.2 Hz, 3H).
[0353] P17 (18.6 g, 93.4 mmol) from this step and P17 (24.9 g, 125 mmol) from a similar reaction of C55 with AMDase were combined to give a slightly pink solid with an enantiomeric excess of 98.5%. 1 H NMR (400 MHz, methanol-d4) δ 7.94 (d, J = 1.9 Hz, 1H), 6.74 (d, J = 5.0 Hz, 1H), 3.93 (q, J = 7.3 Hz, 1H), 3.87 (s, 3H), 1.48 (d, J = 7.3 Hz, 3H). Retention time: 2.86 min [Column: Chiral Technologies Chiralpak IG, 4.6 x 250 mm, 5 μm; Mobile phase A: carbon dioxide; Mobile phase B: methanol; Gradient: 5% B over 1 min, then 5% to 60% B over 7 min; Flow rate: 3 mL / min; Back pressure: 120 bar].
[0354] The absolute configuration of this sample of P17 was confirmed by comparison with samples of P17 isolated from Preparations P17 and P18: Retention time of P17 from preparations P17 and P18: 2.86 min. Retention time of P17 from the first alternative preparation of P17: 2.86 min. Retention times of the racemic mixture of P17 and P18: 2.87 and 3.16 min.
[0355] These three analyses were performed using the same analytical method: [Column: Chiral Technologies Chiralpak IG, 4.6 × 250 mm, 5 μm; Mobile phase A: carbon dioxide; Mobile phase B: methanol; Gradient: 5% B over 1 min, then 5% to 60% B over 7 min; Flow rate: 3 mL / min; Back pressure: 120 bar].
[0356] Second Alternative Preparation of P17 (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)propanoic acid (P17)
[0357] [ka] Step 1. Synthesis of dibenzyl (5-fluoro-2-methoxypyridin-4-yl)propanedioate (C53). A mixture of pyridine-2-carboxylic acid (24.6 g, 0.200 mol), copper(I) iodide (19.1 g, 0.100 mol), and cesium carbonate (977 g, 3.00 mol) in tetrahydrofuran (1.26 L; 5 volumes) was heated to an internal temperature of 60 to 70 °C, whereupon a solution of 5-fluoro-4-iodo-2-methoxypyridine (253 g, 1.00 mol) and dibenzylpropanedioate (426 g, 1.50 mol) in tetrahydrofuran (250 mL, 1 volume) was added. The reaction mixture was heated at 60 to 70 °C for approximately 3 to 6 hours, after which it was cooled to 15 to 30 °C and filtered through diatomaceous earth (250 g). The filter cake was washed with tetrahydrofuran (500 mL, 2 volumes), and the combined filtrate containing C53 was used directly in the next step. A representative 1 H NMR (500 MHz, chloroform-d) δ 8.00 (d, J = 1.3 Hz, 1H), 7.40 - 7.24 (m, 10H, estimated; partially obscured by residual dibenzylpropanedioate), 6.82 (d, J = 4.8 Hz, 1H), 5.20 (AB quartet, J AB = 12.3 Hz, ΔνAB = 14.9 Hz, 4H), 4.99 (s, 1H), 3.88 (s, 3H).
[0358] Step 2. Synthesis of dibenzyl (5-fluoro-2-methoxypyridin-4-yl)(methyl)propanedioate (C54). Iodomethane (284 g, 2.00 mol) was slowly added to a 10° C. to 20° C. mixture of cesium carbonate (977 g, 3.00 mol) and a solution of C53 (from the previous step in tetrahydrofuran; 1.00 mol or less). The reaction mixture was stirred at 10° C. to 20° C. for approximately 10 to 12 hours, after which it was filtered through diatomaceous earth (250 g). The filter cake was washed with tetrahydrofuran (500 mL, 1.2 volumes), and the combined filtrate was concentrated to 1 to 2 volumes. The resulting mixture was diluted with propan-2-yl acetate (1.25 L, 3.1 volumes), washed sequentially with water (750 mL, 1.8 volumes), aqueous ammonium chloride (20%; 750 mL), and aqueous sodium chloride (20%; 750 mL), and concentrated in vacuo. The remaining solvent was exchanged with heptane, and precipitation proceeded from heptane (2 to 3 volumes) at 15 to 25°C. The resulting solid was collected by filtration and triturated with a mixture of heptane (450 mL) and propan-2-yl acetate (50 mL) to give C54 as a solid. Three batches of chemistry in steps 1 and 2 were performed, and the final lots of C54 were combined. Combined yield: 675 g, 1.59 mol, approximately 53% for the two steps. Typical 1 H NMR (500 MHz, DMSO-d6) δ 8.15 (d, J = 2.0 Hz, 1H), 7.39 - 7.21 (m, 10H), 6.75 (d, J = 5.0 Hz, 1H), 5.21 (s, 4H), 3.81 (s, 3H), 1.81 (s, 3H).
[0359] Step 3. Synthesis of disodium (5-fluoro-2-methoxypyridin-4-yl)(methyl)propanedioate (C55). A buffer solution [pH 8.0; 2-amino-2-(hydroxymethyl)propane-1,3-diol (Tris; 121 g, 1.00 mol) in water (1 L, 5 vol.) and concentrated hydrochloric acid (46 mL, 0.23 vol.)] and palladium hydroxide on carbon (10%, 20 g) were added to a 15° C. to 25° C. mixture of C54 (200 g, 0.472 mol) in toluene (400 mL, 2 vol.). A solution of sodium hydroxide (38.8 g, 0.970 mol) in water (1 L, 5 vol.) was added, whereupon the mixture was stirred for approximately 10 to 20 minutes. The reactor was purged with nitrogen and then with hydrogen, and the reaction mixture was stirred under a bag of hydrogen (approximately 10 L) at 15° C. to 30° C. until HPLC analysis indicated that no more than 0.5% C54 was present (approximately 22 hours). (Retention time: 11.44 min. HPLC conditions: Column: Agilent Technologies ZORBAX Eclipse Plus C18, 4.6 x 100 mm, 3.5 μm; Mobile phase A: 0.1% phosphoric acid in water; Mobile phase B: acetonitrile; Gradient: 5% B over 3 min, then 5% to 100% B over 9 min, then 100% B over 3 min; Flow rate: 1.5 mL / min). The reaction mixture was filtered and the filter cake was washed with water (2.6 volumes); the aqueous layer of the filtrate, containing C55, was carried directly to the next step.
[0360] Step 4. Synthesis of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)propanoic acid (P17). A mixture of AMDase (7 g) in water (70 mL, 0.35 vol) and C55 (from the previous step, ∼0.472 mol as a solution in water) was stirred at 15 to 30 °C until HPLC analysis indicated ∼0.5% C55 was present (approximately 16 h). [Retention time: 5.80 min. HPLC conditions identical to those described in Step 3, Synthesis of Disodium (5-fluoro-2-methoxypyridin-4-yl)(methyl)propanedioate (C55)]. Hydrochloric acid (4.0 M) was then slowly added until the pH of the reaction mixture reached 6.0, whereupon stirring was continued for 1.5 h. The pH was then adjusted to ∼2.0 (range, 1.5 to 2.0) by further addition of hydrochloric acid (4.0 M). After the addition of tert-butyl methyl ether (1.2 L, 6 volumes), the mixture was filtered through diatomaceous earth (100 g), and the aqueous phase of the filtrate was extracted with tert-butyl methyl ether (800 mL, 4 volumes). The combined organic layers were washed with aqueous sodium chloride (15%; 600 mL, 3 volumes) and concentrated to 2 to 2.5 volumes at a temperature of 45°C or less and a pressure of -0.08 MPa or less. n-Heptane (600 mL, 3 volumes) was added, and the mixture was concentrated to 3 to 5 volumes at a temperature of 45°C or less and a pressure of -0.08 MPa or less; this heptane dilution / concentration was performed a total of three times. The resulting mixture was stirred at 0°C to 10°C for approximately 1 to 2 hours, after which the precipitate was collected by filtration to provide P17 as an off-white solid with an enantiomeric excess of 99.8%. Yield: 80.0 g, 0.402 mol, 85% over two steps. Typical yields: 1 H NMR (500 MHz, chloroform-d) δ 11.68 (v br s, 1H), 7.99 (br s, 1H), 6.70 (d, J = 4.9 Hz, 1H), 3.97 (q, J = 7.2 Hz, 1H), 3.88 (s, 3H), 1.52 (d, J = 7.3 Hz, 3H).
[0361] Preparation example P19 2-[3-(difluoromethoxy)-5-methoxyphenyl]propanoic acid (P19)
[0362] [ka] Step 1. Synthesis of 1-(difluoromethoxy)-3-methoxy-5-methylbenzene (C56). Aqueous potassium hydroxide (20%; 60.9 g, 217 mmol) and [bromo(difluoro)methyl](trimethyl)silane (11.3 mL, 72.7 mmol) were added sequentially to a 0° C. solution of 3-methoxy-5-methylphenol (5.00 g, 36.2 mmol) in dichloromethane (50 mL). After the reaction mixture was stirred at 0° C. for 4.5 hours, it was diluted with water (50 mL) and extracted with dichloromethane (3×100 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, concentrated in vacuo, and purified by chromatography on silica gel (gradient: 0% to 5% ethyl acetate in petroleum ether) to afford C56 as a colorless oil. Yield: 6.27 g, 33.3 mmol, 92%. 1 H NMR (400 MHz, methanol-d4) δ 6.76 (t, J HF = 74.4 Hz, 1H), 6.60 (br s, 1H), 6.53 (br s, 1H), 6.49 - 6.46 (m, 1H), 3.76 (s, 3H), 2.30 (s, 3H).
[0363] Step 2. Synthesis of 1-(bromomethyl)-3-(difluoromethoxy)-5-methoxybenzene (C57). A mixture of C56 (3.00 g, 15.9 mmol), 2,2′-azobisisobutyronitrile (262 mg, 1.60 mmol), and N-bromosuccinimide (2.84 g, 15.9 mmol) in tetrachloromethane (90 mL) was stirred at 80° C. for 8 hours. Concentration in vacuo provided C57 as a yellow oil (4.0 g), which was used in the next step. 1H NMR (400 MHz, methanol-d4), characteristic product peaks: δ 6.84 (s, 1H), 6.77 (s, 1H), 6.63 - 6.60 (m, 1H), 4.50 (s, 2H), 3.81 (s, 3H).
[0364] Step 3. Synthesis of [3-(difluoromethoxy)-5-methoxyphenyl]acetonitrile (C58). To a solution of C57 (from the previous step; 4.0 g, ∼15 mmol) in acetonitrile (150 mL) were added potassium carbonate (3.11 g, 22.5 mmol) and trimethylsilyl cyanide (2.2 g, 22 mmol) sequentially. The resulting mixture was stirred at 80 °C for 16 h, at which time LCMS analysis indicated the presence of C58: LCMS m / z 214.1 [M+H] + The reaction mixture was concentrated under reduced pressure, diluted with water (50 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, concentrated in vacuo, and purified using silica gel chromatography (gradient: 0% to 30% ethyl acetate in petroleum ether) to afford C58 as a yellow oil. Yield: 1.20 g, 5.63 mmol, 35% over two steps. 1 H NMR (400 MHz, methanol-d4) δ 6.84 (t, J HF = 73.9 Hz, 1H), 6.81 (br s, 1H), 6.73 (br s, 1H), 6.68 - 6.66 (m, 1H), 3.89 (s, 2H), 3.82 (s, 3H).
[0365] Step 4. Synthesis of 2-[3-(difluoromethoxy)-5-methoxyphenyl]propanenitrile (C59). To a −78° C. solution of C58 (3.00 g, 14.1 mmol) in tetrahydrofuran (150 mL) was added a solution of sodium bis(trimethylsilyl)amide (2 M; 8.4 mL, 17 mmol). After stirring the reaction mixture at −78° C. for 1 h, iodomethane (0.876 mL, 14.1 mmol) was added and stirring was continued at −78° C. for 2 h, whereupon LCMS analysis indicated conversion to C59: LCMS m / z 228.1 [M+H] + The reaction was quenched by adding saturated aqueous ammonium chloride (10 mL), and the resulting mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, concentrated in vacuo, and purified by silica gel chromatography (gradient: 0% to 5% ethyl acetate in petroleum ether) to provide C59 as a yellow oil. Yield: 1.00 g, 4.40 mmol, 31%. LCMS m / z 228.1 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 6.85 (t, J HF = 73.9 Hz, 1H), 6.84 - 6.82 (m, 1H), 6.77 - 6.74 (m, 1H), 6.69 - 6.66 (m, 1H), 4.11 (q, J = 7.2 Hz, 1H), 3.82 (s, 3H), 1.60 (d, J = 7.3 Hz, 3H).
[0366] Step 5. Synthesis of ethyl 2-[3-(difluoromethoxy)-5-methoxyphenyl]propanoate (C60). Thionyl chloride (5.3 mL, 73 mmol) was added dropwise to a 0° C. solution of C59 (900 mg, 3.96 mmol) in ethanol (40 mL). The reaction mixture was stirred at 85° C. for 16 hours, whereupon it was diluted with water (50 mL) and extracted with ethyl acetate (3×30 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo. Silica gel chromatography (gradient: 0% to 6% ethyl acetate in petroleum ether) provided C60 as a yellow oil. Yield: 700 mg, 2.55 mmol, 64%. LCMS m / z 275.1 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 6.80 (t, J HF = 74.2 Hz, 1H), 6.74 - 6.71 (m, 1H), 6.65 (br s, 1H), 6.59 (dd, J = 2.2, 2.2 Hz, 1H), 4.19 - 4.05 (m, 2H), 3.79 (s, 3H), 3.72 (q, J = 7.2 Hz, 1H), 1.44 (d, J = 7.2 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H).
[0367] Step 6. Synthesis of 2-[3-(difluoromethoxy)-5-methoxyphenyl]propanoic acid (P19). To a solution of C60 (700 mg, 2.55 mmol) in tetrahydrofuran (30 mL) was added a solution of lithium hydroxide monohydrate (535 mg, 12.8 mmol) in water (10 mL). After the reaction mixture was stirred at 25° C. for 16 hours, it was concentrated in vacuo, diluted with water (20 mL), and washed with dichloromethane (3×25 mL). The organic layers were discarded. The aqueous layer was adjusted to a pH of approximately 2 using 2 M hydrochloric acid; it was then extracted with dichloromethane (3×25 mL). The combined organic layers were washed with saturated aqueous sodium chloride (10 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give P19 as a yellow oil. Yield: 628 mg, 2.55 mmol, quantitative. LCMS m / z 247.1 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 6.79 (t, J HF = 74.2 Hz, 1H), 6.77 - 6.73 (m, 1H), 6.69 - 6.66 (m, 1H), 6.59 (dd, J = 2.2, 2.2 Hz, 1H), 3.79 (s, 3H), 3.69 (q, J = 7.2 Hz, 1H), 1.44 (d, J = 7.2 Hz, 3H).
[0368] Preparation example P20 Lithium 2-(6-methoxy-2-methylpyrimidin-4-yl)propanoate (P20)
[0369] [ka] Step 1. Synthesis of dimethyl (6-methoxy-2-methylpyrimidin-4-yl)(methyl)propanedioate (C61) and methyl 2-(6-methoxy-2-methylpyrimidin-4-yl)propanoate (C62). Sodium hydride (60% in mineral oil; 1.14 g, 28.5 mmol) was added to a solution of dimethylmethylpropanedioate (5.53 g, 37.8 mmol) in N,N-dimethylformamide (25 mL). After 30 minutes, 4-chloro-6-methoxy-2-methylpyrimidine (3.00 g, 18.9 mmol) was added, whereupon the reaction mixture was heated at 100° C. for 16 hours. It was then diluted with water (150 mL) and extracted with ethyl acetate (3×50 mL); the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, concentrated in vacuo, and purified by silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) to give the product (2.60 g) as a yellow oil. Based on NMR and LCMS analysis, this was determined to be an impure mixture of C61 and C62, which was carried on directly to the next step. LCMS m / z 211.1 [M+H] + and 269.2 [M+H] + . 1 H NMR (400 MHz, methanol-d4), characteristic peaks: δ 6.68 (s), 6.60 (s), 3.96 (s), 3.94 (s), 3.81 (q, J = 7.2 Hz), 3.75 (s), 3.68 (s), 2.54 (s), 2.52 (s), 1.79 (s), 1.47 (d, J = 7.3 Hz).
[0370] Step 2. Synthesis of lithium 2-(6-methoxy-2-methylpyrimidin-4-yl)propanoate (P20). A solution of C61 and C62 (from the previous step; 2.60 g, 18.9 mmol) and lithium hydroxide monohydrate (1.22 g, 29.1 mmol) in a mixture of tetrahydrofuran (45 mL) and water (15 mL) was stirred at 45° C. for 3 h. After the reaction mixture was concentrated in vacuo, the residue was lyophilized to provide P20 as a white solid. Yield: 2.3 g, 11 mmol, 58% for two steps. LCMS m / z 197.1 [M+H] + . 1H NMR (400 MHz, methanol-d4) δ 6.66 (s, 1H), 3.94 (s, 3H), 3.61 (q, J = 7.3 Hz, 1H), 2.53 (s, 3H), 1.44 (d, J = 7.2 Hz, 3H).
[0371] Preparation example P21 2-[2-(difluoromethoxy)-6-methoxypyridin-4-yl]propanoic acid (P21)
[0372] [ka] Step 1. Synthesis of methyl 2-(difluoromethoxy)-6-methoxypyridine-4-carboxylate (C63). To a 25°C solution of methyl 2-hydroxy-6-methoxypyridine-4-carboxylate (900 mg, 4.91 mmol) in N,N-dimethylformamide (15 mL) was added sodium chloro(difluoro)acetate (1.12 g, 7.35 mmol) and potassium carbonate (1.36 g, 9.84 mmol), whereupon the reaction mixture was heated at 50°C for 16 hours. After addition of water (100 mL), the mixture was extracted with ethyl acetate (3 x 50 mL); the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo. Chromatography on silica gel (gradient: 0% to 8% ethyl acetate in petroleum ether) provided C63 as a colorless oil. Yield: 720 mg, 3.09 mmol, 63%. LCMS m / z 234.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.39 (t, J HF = 73.0 Hz, 1H), 7.10 (br s, 1H), 7.00 (br s, 1H), 3.94 (s, 3H), 3.93 (s, 3H).
[0373] Step 2. Synthesis of 2-(difluoromethoxy)-6-methoxypyridine-4-carboxylic acid (C64). To a solution of C63 (1.10 g, 4.72 mmol) in tetrahydrofuran (30 mL) was added a solution of lithium hydroxide monohydrate (990 mg, 23.6 mmol) in water (10 mL). After the reaction mixture was stirred at 25° C. for 5 hours, it was concentrated in vacuo. The residue was diluted with water (20 mL) and extracted with dichloromethane (3×20 mL). The organic extract was discarded, and the aqueous layer was adjusted to a pH of approximately 2 by adding 2 M hydrochloric acid. The resulting mixture was extracted with dichloromethane (3×20 mL); the combined organic layers were washed with saturated aqueous sodium chloride (20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to give C64 as a white solid. Yield: 980 mg, 4.47 mmol, 95%. LCMS m / z 220.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.41 (t, J HF = 72.8 Hz, 1H), 7.15 (d, J = 1.1 Hz, 1H), 7.05 (d, J = 1.0 Hz, 1H), 3.95 (s, 3H).
[0374] Step 3. Synthesis of methyl [2-(difluoromethoxy)-6-methoxypyridin-4-yl]acetate (C65). A solution of C64 (980 mg, 4.47 mmol) in thionyl chloride (6.49 mL, 89.0 mmol) was stirred at 70° C. for 2.5 hours, whereupon it was concentrated under reduced pressure. The resulting acyl chloride was dissolved in a mixture of tetrahydrofuran (8 mL) and acetonitrile (8 mL), which was then cooled to 0° C. and treated with freshly distilled triethylamine (0.87 mL, 6.2 mmol) followed by (diazomethyl)(trimethyl)silane (2 M solution in diethyl ether; 3.35 mL, 6.70 mmol). The reaction mixture was stirred at 0° C. for 8 hours, whereupon it was diluted with diethyl ether (25 mL) and washed sequentially with 10% aqueous citric acid (5 mL), saturated aqueous sodium bicarbonate (15 mL), and saturated aqueous sodium chloride (25 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to provide the crude diazoketone. This material was suspended in methanol (10 mL) in an ultrasonic bath; a solution of silver benzoate (512 mg, 2.24 mmol) in triethylamine (1.86 mL, 13.3 mmol) was slowly added at room temperature while the reaction mixture was sonicated. After 30 min, the volatiles were removed in vacuo, and the residue was purified using chromatography on silica gel (gradient: 0% to 10% ethyl acetate in petroleum ether) to provide C65 as a colorless oil. Yield: 340 mg, 1.38 mmol, 31%. LCMS m / z 248.0 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 7.40 (t, J HF = 73.4 Hz, 1H), 6.45 (br s, 1H), 6.40 (br s, 1H), 3.88 (s, 3H), 3.71 (s, 3H), 3.57 (s, 2H).
[0375] Step 4. Synthesis of methyl 2-[2-(difluoromethoxy)-6-methoxypyridin-4-yl]propanoate (C66). To a −78° C. solution of C65 (230 mg, 0.930 mmol) in tetrahydrofuran (20 mL) was added sodium bis(trimethylsilyl)amide (2 M solution in tetrahydrofuran; 0.56 mL, 1.1 mmol), and the reaction mixture was stirred at −78° C. for 1 h. Iodomethane (57.9 μL, 0.93 mmol) was then added, and stirring was continued at −78° C. for 2 h. After the addition of saturated aqueous ammonium chloride (10 mL), the mixture was combined with a similar reaction carried out using C65 (100 mg, 0.405 mmol) and extracted with ethyl acetate (3×20 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo; silica gel chromatography (gradient: 0% to 4% ethyl acetate in petroleum ether) afforded C66 as a colorless oil. Combined yield: 150 mg, 0.574 mmol, 43%. LCMS m / z 262.1 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.51 (t, J HF = 73.3 Hz, 1H), 6.50 (br d, J = 1 Hz, 1H), 6.43 (br d, J = 1 Hz, 1H), 3.88 (s, 3H), 3.78 (q, J = 7.2 Hz, 1H), 3.68 (s, 3H), 1.44 (d, J = 7.2 Hz, 3H).
[0376] Step 5. Synthesis of 2-[2-(difluoromethoxy)-6-methoxypyridin-4-yl]propanoic acid (P21). A solution of lithium hydroxide monohydrate (125 mg, 2.98 mmol) in water (3.0 mL) was added to a solution of C66 (130 mg, 0.498 mmol) in tetrahydrofuran (9.0 mL), and the reaction mixture was stirred at 25° C. for 2 hours. After the reaction mixture was concentrated in vacuo, the residue was diluted with water (10 mL) and washed with dichloromethane (3×15 mL). The aqueous layer was then adjusted to a pH of approximately 5 by adding 2 M hydrochloric acid and extracted with dichloromethane (3×15 mL); these three organic layers were combined and concentrated in vacuo to provide P21 as a colorless oil. Yield: 101 mg, 0.409 mmol, 82%. LCMS m / z 248.0 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.51 (t, J HF = 73.3 Hz, 1H), 6.53 (br d, J = 1.1 Hz, 1H), 6.46 (br d, J = 1.1 Hz, 1H), 3.88 (s, 3H), 3.72 (q, J = 7.1 Hz, 1H), 1.44 (d, J = 7.2 Hz, 3H).
[0377] Preparation example P22 2-Fluoro-2-(2-methoxypyridin-4-yl)propanoic acid (P22)
[0378] [ka] Step 1. Synthesis of dimethyl(2-methoxypyridin-4-yl)propanedioate (C67). To a −10° C. solution of 2-methoxy-4-methylpyridine (5.00 g, 40.6 mmol) in tetrahydrofuran (30 mL) was added lithium diisopropylamide (2 M solution in tetrahydrofuran; 81.2 mL, 162 mmol). After stirring the reaction mixture at −10° C. for 1.5 hours, dimethyl carbonate (14.6 g, 162 mmol) was added and stirring was continued at −10° C. for 1.5 hours. The reaction mixture was then warmed to 25° C. and stirred for 16 hours, whereupon it was quenched by adding aqueous ammonium chloride solution. The resulting mixture was extracted with ethyl acetate (3×30 mL), and the combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by chromatography on silica gel (gradient: 0% to 20% ethyl acetate in petroleum ether) provided C67 as a yellow oil. Yield: 4.92 g, 20.6 mmol, 51%. LCMS m / z 240.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 8.17 (d, J = 5.0 Hz, 1H), 6.95 (d, J = 4.8 Hz, 1H), 6.80 (s, 1H), 4.59 (s, 1H), 3.96 (s, 3H), 3.77 (s, 6H).
[0379] Chromatographic purification also afforded the mono-acylated product, methyl (2-methoxypyridin-4-yl)acetate. Yield: 1.29 g, 7.12 mmol, 18%. LCMS m / z 182.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 8.11 (br d, J = 5.3 Hz, 1H), 6.81 (dd, J = 5.4, 1.5 Hz, 1H), 6.68 - 6.66 (m, 1H), 3.93 (s, 3H), 3.71 (s, 3H), 3.57 (s, 2H).
[0380] Step 2. Synthesis of dimethyl(2-methoxypyridin-4-yl)(methyl)propanedioate (C68). Sodium bis(trimethylsilyl)amide (2 M solution in tetrahydrofuran; 14.0 mL, 28.0 mmol) was added to a −78° C. solution of C67 (4.47 g, 18.7 mmol) in tetrahydrofuran (30 mL). The reaction mixture was stirred at −78° C. for 1 hour, after which iodomethane (1.40 mL, 22.5 mmol) was added. The reaction mixture was then warmed to −40° C., stirred for 2 hours, warmed to 25° C., and stirred for an additional 16 hours, whereupon it was quenched with aqueous ammonium chloride. The resulting mixture was extracted with ethyl acetate (2×30 mL), and the combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. Silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) afforded C68 as a yellow oil. Yield: 3.29 g, 13.0 mmol, 70%. LCMS m / z 254.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 8.15 (d, J = 5.5 Hz, 1H), 6.88 (br d, J = 5.5 Hz, 1H), 6.74 (br s, 1H), 3.95 (s, 3H), 3.78 (s, 6H), 1.83 (s, 3H).
[0381] Step 3. Synthesis of 2-(2-methoxypyridin-4-yl)propanoic acid (C69). A solution of C68 (3.28 g, 13.0 mmol) and lithium hydroxide (1.24 g, 51.8 mmol) in a mixture of tetrahydrofuran (20 mL) and water (10 mL) was stirred at 45° C. for 5 h. LCMS analysis indicated conversion to C69: LCMS m / z 182.1 [M+H] + The reaction mixture was concentrated in vacuo to provide C69 as a white solid (2.40 g), which was used as is in the next step.
[0382] Step 4. Synthesis of methyl 2-(2-methoxypyridin-4-yl)propanoate (C70). A mixture of C69 (from the previous step; 2.40 g, ∼13.0 mmol) and sulfuric acid (2.5 mL) in methanol (25 mL) was stirred at 60 °C for 16 h. The reaction mixture was then concentrated in vacuo, washed with aqueous sodium bicarbonate, and extracted with ethyl acetate (2 × 20 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give C70 as a colorless oil. Yield: 1.56 g, 7.99 mmol, 61% for two steps. LCMS m / z 196.2 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 8.10 (d, J = 5.4 Hz, 1H), 6.81 (dd, J = 5.4, 1.5 Hz, 1H), 6.67 (br s, 1H), 3.93 (s, 3H), 3.67 (s, 3H), 3.66 (q, J = 7.1 Hz, 1H), 1.47 (d, J = 7.2 Hz, 3H).
[0383] Step 5. Synthesis of methyl 2-fluoro-2-(2-methoxypyridin-4-yl)propanoate (C71). To a −78° C. solution of C70 (500 mg, 2.56 mmol) in tetrahydrofuran (13 mL) was added a solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (1 M; 3.33 mL, 3.33 mmol). After the reaction mixture was stirred at −78° C. for 30 minutes, a solution of N-(benzenesulfonyl)-N-fluorobenzenesulfonamide (969 mg, 3.07 mmol) in tetrahydrofuran (2 mL) was added. The reaction mixture was stirred at −10° C. for 3 hours, whereupon it was quenched with aqueous ammonium chloride and extracted with ethyl acetate (3×20 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo; silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) afforded 71 as a yellow oil. Yield: 400 mg, 1.88 mmol, 73%. LCMS m / z 214.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 8.18 (d, J = 5.4 Hz, 1H), 7.00 (dd, J = 5.5, 1.6 Hz, 1H), 6.88 (br d, J = 1.5 Hz, 1H), 3.96 (s, 3H), 3.78 (s, 3H), 1.89 (d, J HF = 22.3 Hz, 3H).
[0384] Step 6. Synthesis of 2-fluoro-2-(2-methoxypyridin-4-yl)propanoic acid (P22). A solution of C71 (400 mg, 1.88 mmol) and lithium hydroxide (89.9 mg, 3.75 mmol) in a mixture of tetrahydrofuran (10 mL) and water (2 mL) was stirred at 45° C. for 4 hours. The reaction mixture was then concentrated in vacuo, diluted with water (12 mL), and adjusted to pH 6 by adding 3 M hydrochloric acid. The resulting mixture was extracted with ethyl acetate (2×20 mL), and the combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to provide P22 as a yellow oil. Yield: 300 mg, 1.51 mmol, 80%. LCMS m / z 200.1 [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 9.9–9.4 (br s, 1H), 8.21 (d, J = 5.6 Hz, 1H), 7.08 (dd, J = 5.6, 1.6 Hz, 1H), 6.95 (br s, 1H), 3.95 (s, 3H), 1.92 (d, J HF = 22.2 Hz, 3H).
[0385] Preparation example P23 2-Bromo-6,6-difluoro-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b][1,3]oxazine (P23)
[0386] [ka] Step 1. Synthesis of 1-{[tert-butyl(dimethyl)silyl]oxy}-3-(3,5-dibromo-1H-1,2,4-triazol-1-yl)propan-2-ol (C72). To a solution of C22 (4.00 g, 17.6 mmol) in toluene (100 mL) was added N,N-diisopropylethylamine (3.5 mL, 21.2 mmol) and tert-butyl(dimethyl)[(oxiran-2-yl)methoxy]silane (3.65 g, 19.4 mmol). The reaction mixture was stirred at 80 °C for 16 h, whereupon it was concentrated in vacuo and purified by silica gel chromatography (gradient: 0% to 20% ethyl acetate in petroleum ether) to afford C72 as a colorless oil. Yield: 4.06 g, 9.78 mmol, 56%. LCMS m / z 413.9 (dibromo isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 4.32 (dd, ABX component, J = 14.0, 4.0 Hz, 1H), 4.22 (dd, ABX component, J = 14.1, 8.1 Hz, 1H), 4.05 (dddd, J = 8.3, 6.4, 4.2, 4.2 Hz, 1H), 3.72 (dd, ABX system components, J = 10.5, 4.5 Hz, 1H), 3.65 (dd, ABX system components, J = 10.5, 6.4 Hz, 1H), 0.93 (s, 9H), 0.11 (s, 3H), 0.11 (s, 3H).
[0387] Step 2. Synthesis of 1-{[tert-butyl(dimethyl)silyl]oxy}-3-(3,5-dibromo-1H-1,2,4-triazol-1-yl)propan-2-one (C73). To a 25° C. solution of C72 (4.06 g, 9.78 mmol) in dichloromethane (120 mL) was added 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (8.30 g, 19.6 mmol) in small portions. After the reaction mixture was stirred for 16 hours, it was diluted with saturated aqueous sodium sulfate (100 mL) and extracted with dichloromethane (100 mL). The organic layer was concentrated in vacuo and purified by silica gel chromatography (gradient: 0% to 10% ethyl acetate in petroleum ether) to provide C73 as a colorless oil. 1 H NMR analysis estimated this to exist as a mixture of keto and enol forms. Yield: 3.82 g, 9.24 mmol, 94%. LCMS m / z 412.0 (dibromo isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 5.36 - 5.30 (m, enol, 1H), 4.46 (s, keto, ca. 2H), 4.34 - 4.29 (m, enol, 2H), 3.63 (AB quartet, keto, J AB = 11.0 Hz, Δν AB = 50.6 Hz, 2H), [0.97 (s) and 0.94 (s), 9H total for the keto and enol], [0.16 (s), 0.13 (s), and 0.12 (s), 6H total for the keto and enol].
[0388] Step 3. Synthesis of 3,5-dibromo-1-(3-{[tert-butyl(dimethyl)silyl]oxy}-2,2-difluoropropyl)-1H-1,2,4-triazole (C74). A solution of C73 (2.00 g, 4.84 mmol) in dichloromethane (100 mL) was added to 4-(trifluoro-λ 4-sulfanyl)morpholine (Morpho-DAST; 0.592 mg, 4.84 mmol) was added, whereupon the reaction mixture was stirred at 30° C. for 16 hours. It was then poured into saturated aqueous sodium bicarbonate (100 mL) and extracted with dichloromethane (2×100 mL). The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo; purification by silica gel chromatography (gradient: 0% to 5% ethyl acetate in petroleum ether) provided C74 as a colorless oil. Yield: 910 mg, 2.09 mmol, 43%. LCMS m / z 436.0 (dibromo isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 4.75 (t, J HF = 13.3 Hz, 2H), 3.92 (t, J HF = 12.2 Hz, 2H), 0.94 (s, 9H), 0.14 (s, 6H).
[0389] Step 4. Synthesis of 2-bromo-6,6-difluoro-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b][1,3]oxazine (P23). To a 25°C solution of C74 (910 mg, 2.09 mmol) in tetrahydrofuran (15 mL) was added tetrabutylammonium fluoride (1.64 g, 6.27 mmol), whereupon the reaction mixture was stirred for 2 hours. The solvent was then evaporated in vacuo, and the residue was diluted with ethyl acetate (100 mL), washed sequentially with saturated aqueous ammonium chloride and saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo. Silica gel chromatography (gradient: 0% to 10% methanol in dichloromethane) provided P23 as a white solid. Yield: 310 mg, 1.29 mmol, 62%. LCMS m / z 239.9 (bromine isotope pattern observed) [M+H] + . 1H NMR (400 MHz, methanol-d4) δ 4.73 (tt, J = 10.8, 1 Hz, 2H), 4.64 (tt, J =12.0, 1 Hz, 2H).
[0390] Preparation example P24 3-Bromo-1-( 2 H3) Methyl-5-(trifluoromethyl)-1H-1,2,4-triazole (P24)
[0391] [ka] Step 1. 3,5-Dibromo-1-( 2 H3) Synthesis of methyl-1H-1,2,4-triazole (C75). C22 (25 g, 110 mmol), potassium carbonate (30.5 g, 220 mmol) and iodine ( 2 H3) A 25° C. mixture of methane (25.6 g, 176 mmol) was stirred for 20 hours. The reaction mixture was diluted with ethyl acetate, filtered through a pad of diatomaceous earth, and concentrated in vacuo. Purification by silica gel chromatography (gradient: 0% to 30% ethyl acetate in heptane) provided C75 as a white solid. Yield: 24.3 g, 99.6 mmol, 90%. GCMS m / z 244.0 (dibromo isotope pattern observed) [M] + .
[0392] Step 2. 3-Bromo-1-( 2 H3) Synthesis of methyl-5-(trifluoromethyl)-1H-1,2,4-triazole (P24). To a mixture of C75 (2.0 g, 8.20 mmol) and copper(I) iodide (2.34 g, 12.3 mmol) in N,N-dimethylformamide (20 mL), methyl difluoro(fluorosulfonyl)acetate (4.73 g, 3.1 mL, 24.6 mmol) was added in one portion, and the reaction mixture was heated at 110 °C for 22 h. The cooled reaction mixture was partitioned between diethyl ether (200 mL) and a mixture of water and concentrated ammonium hydroxide solution (1:1, approximately 100 mL), whereupon the aqueous layer was extracted with tert-butyl methyl ether. The combined organic layers were washed with water, dried over magnesium sulfate, filtered, and concentrated in vacuo to afford P24 as a pale yellow syrup; this material was used directly in further chemistry. Yield: 1.67 g, 7.17 mmol, 87%. GCMS m / z 232.1 (bromine isotope pattern observed) [M] + .
[0393] Preparation example P25 3-Bromo-5-(difluoromethyl)-1-( 2 H3) Methyl-1H-1,2,4-triazole (P25)
[0394] [ka] Step 1. 3-Bromo-1-( 2 H3) Synthesis of methyl-1H-1,2,4-triazole-5-carbaldehyde (C76). To a −45° C. solution of C75 (7.60 g, 31.2 mmol) in tetrahydrofuran (60 mL) was added dropwise a solution of n-butyllithium in hexane (2.5 M; 15.0 mL, 37.5 mmol). After stirring the reaction mixture at −45° C. for 30 minutes, additional n-butyllithium solution (2.5 M; 1.0 mL, 2.5 mmol) was added, and stirring was continued at −40° C. for 30 minutes. The reaction mixture was then cooled to −78° C. and treated with N,N-dimethylformamide (3.12 mL, 40.3 mmol), whereupon stirring was continued at −78° C. for another 30 minutes. The reaction mixture was then slowly warmed to room temperature; hydrochloric acid (1 M; 60 mL, 60 mmol) was added, and stirring was continued for 10 minutes. The resulting precipitate was slowly dissolved, and sodium carbonate was added until gas evolution ceased. The mixture was then separated; the aqueous layer was extracted twice with ethyl acetate, and the combined organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo. Purification by silica gel chromatography (gradient: 20% to 70% ethyl acetate in heptane) afforded C76 as a white solid. Yield: 3.06 g, 15.8 mmol, 51%. 1 H NMR (400 MHz, chloroform-d) δ 9.91 (s, 1H).
[0395] Step 2. 3-Bromo-5-(difluoromethyl)-1-( 2 H3) Synthesis of methyl-1H-1,2,4-triazole (P25). To a 0° C. solution of C76 (3.06 g, 15.8 mmol) in dichloromethane (60 mL) was added difluoro(morpholin-4-yl)sulfanium tetrafluoroborate (XtalFluor-M®; 7.7 g, 31.7 mmol) and triethylamine trihydrofluoride (TREAT-HF; 5.11 g, 31.7 mmol). The reaction mixture was stirred at room temperature for 18 hours before being treated with saturated aqueous sodium bicarbonate and extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered, concentrated in vacuo, and purified using silica gel chromatography (gradient: 0% to 20% ethyl acetate in heptane) to afford P25 as a yellow oil that solidified at low temperature under vacuum. Yield: 1.88 g, 8.74 mmol, 55%. GCMS m / z 214.0 (bromine isotope pattern observed) [M+H] + . 1 H NMR (400 MHz, chloroform-d) δ 6.77 (t, J HF = 52.3 Hz, 1H).
[0396] General Procedure 1
[0397] [ka] To a solution of carboxylic acid (1 equivalent), N,N-diisopropylethylamine (2 equivalents), and amine dihydrochloride (1 equivalent) in N,N-dimethylformamide (0.1 M) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (1.5 equivalents) and 1H-benzotriazol-1-ol (1.1 equivalents). The reaction mixture was stirred at 25° C. for 16 hours, whereupon it was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by either silica gel chromatography or reverse-phase HPLC to afford the product.
[0398] Example 1 (2R)-2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-(2-methyl-2H-tetrazol-5-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one (1)
[0399] [ka] To a 25°C solution of P14 (50 mg, 0.23 mmol) in acetonitrile (10.0 mL) was added pyridinium trifluoromethanesulfonate (133 mg, 0.58 mmol), followed by 1,1'-carbonyldiimidazole (40 mg, 0.24 mmol). After stirring the resulting mixture for 1 hour, P5 (69 mg, 0.21 mmol) was added, and the reaction mixture was stirred for 4 hours, whereupon it was added to water (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed sequentially with saturated aqueous ammonium chloride (30 mL), saturated aqueous sodium bicarbonate (30 mL), and saturated aqueous sodium chloride (30 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative thin-layer chromatography on silica gel (eluent: 5% dichloromethane in methanol) to provide (2R)-2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-(2-methyl-2H-tetrazol-5-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one (1) as a white solid. 1 H NMR analysis indicated that this material contained a mixture of rotamers. Yield: 25 mg, 55 μmol, 26%. LCMS m / z 457.0 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ [8.15 (s) and 8.13 (s), total 1H], 7.94 (d, J = 8.6 Hz, 1H), [6.77 (s) and 6.75 (s), total 1H], [6.46 (d, J = 8.8 Hz) and 6.43 (d, J = 8.6 Hz), total 1H], [4.56 - 4.42 (m), 4.40 (s), and 4.39 (s), Total 4H], [4.29 (q, J = 6.8 Hz) and 4.21 (q, J = 6.8 Hz), Total 1H], [3.90 (s) and 3.88 (s), Total 3H], [3.88 - 3.82 (m), 3.80 - 3.64 (m), and 3.58 - 3.39 (m), total 4H], [2.64 (s) and 2.61 (s), total 3H], [2.40 - 2.29 (m), 2.28 - 2.15 (m), and 2.04 - 1.91 (m), total 2H], [1.42 (d, J = 7.1 Hz) and 1.38 (d, J = 7.1 Hz), total 3H].
[0400] Example 2 (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(3S)-3-({6-methyl-5-[1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyridin-2-yl}amino)pyrrolidin-1-yl]propan-1-one (2)
[0401] [ka] Pyridinium trifluoromethanesulfonate (39.1 g, 171 mmol) was added to a mixture of P17 (90%, 18.0 g, 81.3 mmol) in acetonitrile (300 mL), and the mixture was stirred until a solution was obtained. 1,1'-carbonyldiimidazole (13.8 g, 85.4 mmol) was then added; the reaction mixture was stirred for 45 minutes, after which P12 (32.5 g, 81.4 mmol) was added, and stirring was continued for 3 hours. The reaction mixture was then partitioned between ethyl acetate and water. The organic layer was washed successively with water (twice), saturated aqueous ammonium chloride, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting foam was dissolved in ethyl acetate (50 mL) with heating (80 °C), and heptane (180 mL) was added until the mixture became cloudy; heating was discontinued, and the mixture was allowed to cool to room temperature. An oil appeared, so the mixture was reheated to 80° C., whereupon additional ethyl acetate (10 mL) was added and the mixture was allowed to cool to room temperature again. The resulting precipitate was collected by filtration to provide (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(3S)-3-({6-methyl-5-[1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyridin-2-yl}amino)pyrrolidin-1-yl]propan-1-one (2) as an off-white solid. Yield: 31.8 g, 62.7 mmol, 77%. LCMS m / z 508.3 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ [7.98 (d, J = 1.0 Hz) and 7.97 (d, J = 1.0 Hz), total 1H], 7.91 (d, J = 8.6 Hz, 1H), [6.74 (d, J = 4.4 Hz) and 6.73 (d, J = 4.6 Hz), total 1H], [6.43 (d, J = 9.0 Hz) and 6.41 (d, J = 9.0 Hz), total 1H], 4.53 - 4.42 (m, 1H), [4.25 (q, J = 7.1 Hz) and 4.16 (q, J = 6.8 Hz), total 1H], 4.10 (br s, 3H), [3.90 - 3.84 (m), 3.88 (s), 3.86 (s), 3.82 - 3.63 (m), 3.58 - 3.46 (m), 3.41 (d, J = 4.6 Hz), and 3.38 (d, J = 4.9 Hz), total 7H], [2.64 (s) and 2.61 (s), total 3H], [2.39 - 2.28 (m) and 2.25 - 2.15 (m), total 1H], 2.05 - 1.90 (m, 1H), [1.44 (d, J = 6.8 Hz) and 1.40 (d, J = 6.8 Hz), total 3H].
[0402] Examples 3A and 3B 1-[(3R)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]-2-(4-fluorophenyl)ethan-1-one (3A) and 1-[(3S)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]-2-(4-fluorophenyl)ethan-1-one (3B).
[0403] [ka]
[0404] [ka] Step 1: Synthesis of tert-butyl (3R)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidine-1-carboxylate (C78a) and tert-butyl (3S)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidine-1-carboxylate (C78b). To a solution of 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (RuPhos; 2.52 g, 5.39 mmol) and palladium(II) acetate (605 mg, 2.70 mmol) in 2-methylbutan-2-ol (450 mL), sodium tert-butoxide (25.9 g, 270 mmol) was added, and the reaction mixture was heated to 80 °C. tert-Butyl 3-amino-2,2-dimethylpyrrolidine-1-carboxylate (C77) (28.9 g, 135 mmol) and C7 (28 g, 130 mmol) were then added, and the reaction mixture was heated at 80 °C for 3 h. It was then filtered through a pad of diatomaceous earth, which was rinsed twice with ethyl acetate. The filtrate was washed with water, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated in vacuo to provide crude material (40 g). This was separated into its component enantiomers by supercritical fluid chromatography (column: Chiral Technologies ChiralCel OD-H, 30 × 250 mm, 5 μm; mobile phase: 77.5 / 22.5 carbon dioxide / methanol containing 0.2% (7 M ammonia in methanol)); flow rate: 80 mL / min; back pressure: 150 bar). The first-eluting enantiomer was designated C78a, and the second-eluting enantiomer was designated C78b; both were obtained as oils. The indicated absolute stereochemistry was assigned by X-ray crystallographic structure determination of 3A, which was synthesized using C78a (see below). C78a - Yield: 17.7 g, 45.9 mmol, 35%. Retention time: 5.18 min (same analytical conditions as used for C78b). C78b - Yield: 18.1 g, 47.0 mmol, 36%. LCMS m / z 386.4 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.63 (s, 1H), 7.61 (d, J = 8.3 Hz, 1H), 7.11 (d, J = 1.2 Hz, 1H), 6.50 (d, J = 8.6 Hz, 1H), 4.50 - 4.34 (m, 1H), 3.77 (s, 3H), 3.51 (ddd, J = 2.9, 8.5, 11.2 Hz, 1H), 3.39 - 3.31 (m, 1H), 2.44 (s, 3H), 2.18 - 2.08 (m, 1H), 1.81 - 1.68 (m 1H), 1.49 (br s, 3H), 1.46 (br s, 9H), 1.26 (br s, 3H). Retention time: 6.03 min (Analytical conditions: Column: Chiral Technologies ChiralCel OD-H, 4.6 × 250 mm, 5 μm; Mobile phase A: carbon dioxide; Mobile phase B: methanol containing 0.2% (7 M ammonia in methanol); Gradient: 5% B over 1.00 min, then 5% to 60% B over 8.0 min; Flow rate: 3.0 mL / min; Back pressure: 120 bar).
[0405] Step 2. Synthesis of N-[(3R)-2,2-dimethylpyrrolidin-3-yl]-6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-amine, dihydrochloride (C79a). A mixture of C78a (40 mg, 0.10 mmol) and a solution of hydrogen chloride in 1,4-dioxane (4 M; 0.26 mL, 1.0 mmol) was heated to 50° C. for 1 h, whereupon LCMS analysis indicated the presence of C79a: LCMS m / z 286.3 [M+H] + The reaction mixture was combined with a similar reaction carried out using C78a (46 mg, 0.12 mmol) and concentrated in vacuo to provide C79a as a solid; this material was used as is in the next step.
[0406] Step 3. Synthesis of 1-[(3R)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]-2-(4-fluorophenyl)ethan-1-one (3A). To a solution of C79a (from the previous step; ∼0.22 mmol) in N,N-dimethylformamide (2.0 mL) was added C10 (48.4 mg, 0.314 mmol), 1H-benzotriazol-1-ol (50.9 mg, 0.377 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (92.3 mg, 0.481 mmol), and N,N-diisopropylethylamine (0.365 mL, 2.09 mmol). The reaction mixture was stirred at ambient temperature for 3 hours, after which it was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The organic layer was washed with saturated aqueous sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was chromatographed on silica gel (gradient: ethyl acetate in hexane), and the resulting material was partitioned between 1 M hydrochloric acid and ethyl acetate. The aqueous layer was adjusted to pH 10 by adding 1 M aqueous sodium hydroxide solution, whereupon it was extracted three times with dichloromethane. The combined dichloromethane layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give 1-[(3R)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]-2-(4-fluorophenyl)ethan-1-one (3A) as a solid. Yield: 63 mg, 0.15 mmol, 68% over two steps. LCMS m / z 422.4 [M+H] + . 1 H NMR (400 MHz, methanol-d4) δ 7.65 - 7.58 (m, 2H), 7.27 (dd, J = 8.6, 5.4 Hz, 2H), 7.11 (d, J = 1.3 Hz, 1H), 7.05 (dd, J = 8.8, 8.8 Hz, 2H), 6.49 (d, J = 8.5 Hz, 1H), 4.44 (dd, J = 10.1, 6.1 Hz, 1H), 3.76 (s, 3H), 3.72 - 3.64 (m, 1H), 3.65 (s, 2H), 3.53 (ddd, J = 10, 10, 7.1 Hz, 1H), 2.43 (s, 3H), 2.23 - 2.14 (m, 1H), 1.88 - 1.74 (m, 1H), 1.55 (s, 3H), 1.35 (s, 3H).
[0407] This material was dissolved in a minimum amount of propan-2-ol and slurried for 12 hours; the solid was then collected by filtration to give 1-[(3R)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]-2-(4-fluorophenyl)ethan-1-one (3A) as a crystalline solid. Melting point: 196-198 °C. Crystals from this lot were used in the following single crystal X-ray structure determination.
[0408] Single crystal X-ray structure determination of 3A Single crystal X-ray analysis Data collection was performed on a Bruker D8 Quest diffractometer at room temperature and consisted of omega and phi scans.
[0409] The structure was solved with intrinsic phases using the SHELX software suite in the orthorhombic space group P212121. The structure was then refined by full-matrix least-squares fitting. All non-hydrogen atoms were located and refined using anisotropic displacement parameters.
[0410] The hydrogen atoms located at the nitrogen were found from the Fourier difference distribution and refined at restricted distances. The remaining hydrogen atoms were placed at calculated positions and attached to their carrier atoms. The final refinement included isotropic displacement parameters for all hydrogen atoms.
[0411] Analysis of the absolute structure using likelihood methods (Hooft, 2008) was performed using PLATON (Spek). Results indicate that the absolute structure was correctly assigned. This method calculates a 100% probability that the structure was correctly assigned. The Hooft parameter is reported as 0.05 with an esd (estimated standard deviation) of 0.006, and the Parson parameter is reported as 0.02 with an esd of 0.005.
[0412] The final R-index was 4.2%. The final difference Fourier revealed no missing or misplaced electron density.
[0413] Software and References SHELXTL, Version 5.1, Bruker AXS, 1997. PLATON, AL Spek, J. Appl. Cryst. 2003, 36, 7-13. MERCURY, C.F. Macrae, P.R. Edington, P. McCabe, E. Pidcock, GP Shields, R. Taylor, M. Towler and J. van de Streek, J. Appl. Cryst. 2006, 39, 453-457. OLEX2, OV Dolomanov, LJ Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, J. Appl. Cryst. 2009, 42, 339-341. RWW Hooft, LH Straver and AL Spek, J. Appl. Cryst. 2008, 41, 96-103. HD Flack, Acta Cryst. 1983, A39, 867-881.
[0414] The absolute stereochemistry of compound Example 3A was determined by single crystal X-ray crystallography (e.g., using the relevant data / parameters / information used / collected, including relevant crystallographic data and refinement information; atomic coordinates; bond distances; bond angles; and displacement parameters). Figure 1 (FIG. 1) is the resulting single crystal X-ray structure (ORTEP drawing) of crystalline compound Example 3A: 1-[(3R)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]-2-(4-fluorophenyl)ethan-1-one.
[0415] In some embodiments, the present invention provides a crystalline form of 1-[(3R)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]-2-(4-fluorophenyl)ethan-1-one. In some further embodiments, the crystalline form of 1-[(3R)-2,2-dimethyl-3-{[6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]-2-(4-fluorophenyl)ethan-1-one is as described (and / or prepared) in Example 3A.
[0416] Step 4. Synthesis of N-[(3S)-2,2-dimethylpyrrolidin-3-yl]-6-methyl-5-(1-methyl-1H-imidazol-4-yl)pyridin-2-amine, dihydrochloride (C79b). Acetyl chloride (14.7 g, 188 mmol) was added slowly to propan-2-ol (36 mL) with stirring at 0° C. In a separate flask, C78b (18.1 g, 47.0 mmol) was dissolved in propan-2-ol (36 mL), which required heating up to 50° C. Once the material was dissolved, hydrogen chloride solution was added dropwise, whereupon the reaction mixture was heated at 50° C. for 3 hours. T...
Claims
1. Compounds of Formula I: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, R 1 is 1,2,4-triazolyl, tetrazolyl, 1,2,4-oxadiazolyl, imidazolyl, 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl, [1,2,4]triazolo[1,5-a]pyridinyl- or pyrimidinyl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 cycloalkyl; R 2 and R 3 Each of the groups is independently H, a halogen, C 1~4 Alkyl or C 1~4 Is it a haloalkyl? Or, R 2 and R 3 C, which together with the carbon atom to which they are attached, are optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halogen 3~4 Forming a cycloalkyl, Y 1 and Y 2 Each of the above is independently selected from the group consisting of CR 4 or N, Each R 4 are independently H, halogen, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy or C 1~4 is haloalkoxy; Each R F are independently halogen, —OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy, C 1~4 Haloalkoxy, C 3~4 Cycloalkyl or (C 3~4 Cycloalkyl)-C 1~4 is alkyl- or Or, two R F When groups are substituted on the same carbon atom of the pyrrolidine ring of formula I, they, together with the carbon atom to which they are attached, are halogen, —OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 3~6 Forming a cycloalkyl, R 7 is methyl or ethyl, t1 is 0, 1, 2, 3 or 4.
2. Compound of formula Ia: 【Chemistry 2】 or a pharma- ceutically acceptable salt thereof.
3. Compound of formula I-b: 【Chemistry 3】 or a pharma- ceutically acceptable salt thereof.
4. Compound of Formula II: 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof, R 5 and R 6 each is independently H, methyl or ethyl; Or, R 5 and R 6 together with the carbon atom to which they are attached, halogens, -OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 3~6 forming a cycloalkyl group.
2. The compound of claim 1,
5. Compound of formula II-a: 【Chemistry 5】 or a pharma- ceutically acceptable salt thereof.
6. Compound of formula II-b: 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof.
7. Compound of Formula III: 【Chemistry 7】 or a pharma- ceutically acceptable salt thereof.
5. The compound of claim 1 or 4, which is:
8. Compound of formula III-a: 【Chemistry 8】 or a pharma- ceutically acceptable salt thereof.
9. Compound of formula III-b: 【Chemistry 9】 or a pharma- ceutically acceptable salt thereof.
10. R 1 is 1,2,4-triazolyl, tetrazolyl, 1,2,4-oxadiazolyl or imidazolyl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 10. The compound or pharma- ceutically acceptable salt according to any one of claims 1 to 9, optionally substituted with 1, 2 or 3 substituents each independently selected from cycloalkyl.
11. R 1 is 1H-1,2,4-triazol-3-yl, 2H-tetrazol-5-yl, 1,2,4-thiadiazol-5-yl or 1H-imidazol-4-yl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 11. The compound or pharma- ceutically acceptable salt of claim 10, optionally substituted with 1, 2 or 3 substituents each independently selected from cycloalkyl.
12. R 1 is 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl or [1,2,4]triazolo[1,5-a]pyridinyl-, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 10. The compound or pharma- ceutically acceptable salt according to any one of claims 1 to 9, optionally substituted with 1, 2 or 3 substituents each independently selected from cycloalkyl.
13. R 1 is 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazin-2-yl or [1,2,4]triazolo[1,5-a]pyridin-2-yl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 13. The compound or pharma- ceutically acceptable salt of claim 12, optionally substituted with 1, 2 or 3 substituents each independently selected from cycloalkyl.
14. R 1 But halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 10. The compound or pharma- ceutically acceptable salt of any one of claims 1 to 9, which is pyrimidinyl optionally substituted with 1, 2 or 3 substituents each independently selected from cycloalkyl.
15. R 1 But halogen, C 1~4 Alkyl, C 1~4 Haloalkyl and C 3~4 15. The compound of claim 14, or a pharma- ceutically acceptable salt thereof, which is pyrimidin-2-yl optionally substituted with 1, 2 or 3 substituents each independently selected from cycloalkyl.
16. R 1 16. The compound of claim 15, or a pharma- ceutically acceptable salt thereof, wherein is pyrimidin-2-yl.
17. R 2 and R 3 each independently is H, F or C 1~4 17. The compound or a pharma- ceutically acceptable salt of any one of claims 1 to 16, wherein: R is alkyl;
18. R 2 and R 3 each independently is H, F or C 1~2 17. The compound or a pharma- ceutically acceptable salt of any one of claims 1 to 16, wherein: R is alkyl;
19. R 2 and R 3 17. The compound or pharma- ceutically acceptable salt of any one of claims 1 to 16, wherein each of is independently H or methyl.
20. R 2 But, C 1~2 alkyl, R 3 or a pharma- ceutically acceptable salt thereof, according to any one of claims 1 to 18, wherein:
21. R 2 is methyl, R 3 or a pharma- ceutically acceptable salt thereof, according to any one of claims 1 to 20, wherein:
22. R 5 and R 6 22. The compound or pharma- ceutically acceptable salt of any one of claims 4, 5, 6 and 10-21, wherein each of is independently H or methyl.
23. R 5 and R 6 together with the carbon atom to which they are attached, C 3~5 22. A compound or a pharma- ceutically acceptable salt according to any one of claims 4, 5, 6 and 10 to 21, which forms a cycloalkyl.
24. R 7 24. The compound or pharma- ceutically acceptable salt of any one of claims 1 to 23, wherein is methyl.
25. Y 1 and Y 2 Each of the above is independently 4 25. The compound of any one of claims 1 to 24, or a pharma- ceutically acceptable salt thereof, wherein:
26. Y 1 and Y 2 One of the two is N, and the other is Y 1 and Y 2 The other is CR 4 25. The compound of any one of claims 1 to 24, or a pharma- ceutically acceptable salt thereof, wherein:
27. Y 1 But, CR 4 And Y 2 25. The compound or pharma- ceutically acceptable salt of any one of claims 1 to 24, wherein:
28. Y 1 is N and Y 2 25. The compound or pharma- ceutically acceptable salt of any one of claims 1 to 24, wherein:
29. Each R 4 are independently H, halogen, C 1~2 Alkyl, C 1~2 Haloalkyl, C 1~2 Alkoxy or C 1~2 29. The compound or a pharma- ceutically acceptable salt of any one of claims 1 to 28, which is haloalkoxy.
30. Each R 4 are independently H, halogen or C 1~2 29. The compound or pharma- ceutically acceptable salt of any one of claims 1 to 28, which is alkoxy.
31. (2R)-2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-(2-methyl-2H-tetrazol-5-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one; (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(3S)-3-({6-methyl-5-[1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyridin-2-yl}amino)pyrrolidin-1-yl]propan-1-one; (2R)-1-[(3S)-3-({5-[5-(1,1-difluoroethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidin-1-yl]-2-(5-fluoro-2-methoxypyridin-4-yl)propan-1-one; (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-(2-methyl-2H-tetrazol-5-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one; (2R)-2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-(pyrimidin-2-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one; (2R)-1-[(3S)-3-({5-[5-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidin-1-yl]-2-(5-fluoro-2-methoxypyridin-4-yl)propan-1-one; (2R)-1-[(3S)-3-({5-[5-(difluoromethyl)-1-( 2 H 3 )methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidin-1-yl]-2-(5-fluoro-2-methoxypyridin-4-yl)propan-1-one; 2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-({5-[5-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-3-yl]-6-methylpyridin-2-yl}amino)pyrrolidin-1-yl]propan-1-one, DIAST-2; 2-(5-chloro-2-methoxypyridin-4-yl)-1-[(3S)-3-({6-methyl-5-[1-methyl-5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyridin-2-yl}amino)pyrrolidin-1-yl]propan-1-one, DIAST-2; and (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(3S)-3-{[6-methyl-5-([1,2,4]triazolo[1,5-a]pyridin-2-yl)pyridin-2-yl]amino}pyrrolidin-1-yl]propan-1-one, The compound according to claim 1, selected from or a pharma- ceutically acceptable salt thereof.
32. 32. A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharma- ceutically acceptable salt of any one of claims 1 to 31 and a pharma- ceutically acceptable carrier.
33. A method for treating an MC4R-associated condition, disease or disorder in a human, comprising administering to a human in need thereof a compound or a pharma- ceutically acceptable salt of any one of claims 1 to 31.
34. 34. A method for treating a condition, disease or disorder in a human, comprising administering to a human in need thereof a compound or a pharma- ceutically acceptable salt of any one of claims 1 to 31, wherein the condition, disease or disorder is cachexia (e.g. cachexia associated with a chronic disease, for example cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, for example cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with the treatment of a chronic disease, for example cachexia associated with cancer treatment or cachexia associated with heart failure (e.g. CHF) treatment). anorexia or anorexia nervosa (e.g., anorexia in the elderly, anorexia associated with chemotherapy and / or radiation therapy); nausea; vomiting; weight loss (e.g., involuntary weight loss); failure to thrive; sarcopenia; muscle wasting; muscle weakness; frailty; osteoporosis; bone disorders (e.g., bone loss); pain; neuropathic pain; anxiety (e.g., post-traumatic stress disorder or PTSD); depression; hypertension; malnutrition; obesity (e.g., sarcopenia resulting from chronic obesity); sexual dysfunction; and inflammatory disorders (e.g., anorexia or cachexia or inflammatory disorders associated with sarcopenia or muscle wasting).
35. Cachexia (e.g., cachexia associated with a chronic illness, including, for example, cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, including, for example, cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with the treatment of a chronic illness, including, for example, cachexia associated with the treatment of cancer or cachexia associated with the treatment of heart failure (e.g. CHF)); anorexia or anorexia nervosa (e.g., anorexia in the elderly, anorexia associated with chemotherapy and / or radiation therapy); nausea; vomiting; weight loss (e.g., 32. The compound or pharma- ceutically acceptable salt of any one of claims 1 to 31 for use in treating a condition, disease or disorder selected from: anorexia, malnutrition, obesity (e.g. sarcopenia resulting from chronic obesity), sexual dysfunction, and inflammatory diseases (e.g. anorexia or cachexia or inflammatory diseases associated with sarcopenia or muscle wasting).
36. Cachexia (e.g., cachexia associated with a chronic illness, including, for example, cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, including, for example, cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with the treatment of a chronic illness, including, for example, cachexia associated with the treatment of cancer or cachexia associated with the treatment of heart failure (e.g. CHF)); anorexia or anorexia nervosa (e.g., anorexia in the elderly, anorexia associated with chemotherapy and / or radiation therapy); nausea; vomiting; weight loss ( Use of a compound or pharma- ceutical acceptable salt according to any one of claims 1 to 31 for treating a condition, disease or disorder selected from: involuntary weight loss; growth retardation; sarcopenia; muscle wasting; muscle weakness; frailty; osteoporosis; bone disorders (e.g. bone loss); pain; neuropathic pain; anxiety (e.g. post-traumatic stress disorder or PTSD); depression; hypertension; malnutrition; obesity (e.g. sarcopenia resulting from chronic obesity); sexual dysfunction; and inflammatory diseases (e.g. anorexia or cachexia or inflammatory diseases associated with sarcopenia or muscle wasting).
37. Cachexia (e.g., cachexia associated with a chronic illness, including, for example, cachexia associated with cancer, cachexia associated with acquired immune deficiency syndrome (AIDS), cachexia associated with heart failure, including, for example, cachexia associated with congestive heart failure (CHF), cachexia associated with chronic kidney disease (CKD); cachexia associated with the treatment of a chronic illness, including, for example, cachexia associated with the treatment of cancer or cachexia associated with the treatment of heart failure (e.g. CHF)); anorexia or anorexia nervosa (e.g., anorexia in the elderly, anorexia associated with chemotherapy and / or radiation therapy); nausea; vomiting; weight loss (e.g., 32. Use of a compound or pharma- ceutical acceptable salt according to any one of claims 1 to 31 in the manufacture of a medicament for treating a condition, disease or disorder selected from: involuntary weight loss; growth retardation; sarcopenia; muscle wasting; muscle weakness; frailty; osteoporosis; bone disorders (e.g. bone loss); pain; neuropathic pain; anxiety (e.g. post-traumatic stress disorder or PTSD); depression; hypertension; malnutrition; obesity (e.g. sarcopenia resulting from chronic obesity); sexual dysfunction; and inflammatory diseases (e.g. anorexia or cachexia or inflammatory diseases associated with sarcopenia or muscle wasting).
38. 32. A method for antagonizing the melanocortin-4 receptor (MC4R), comprising the step of contacting the MC4R with a compound or a pharma- ceutically acceptable salt of any one of claims 1 to 31.
39. Compounds of Formula I: 【Chemistry 10】 or a pharma- ceutically acceptable salt thereof, R 1 is 1,2,4-triazolyl, tetrazolyl, 1,2,4-oxadiazolyl, imidazolyl, 6,7-dihydro-[1,2,4]triazolo[5,1-b][1,3]oxazinyl, [1,2,4]triazolo[1,5-a]pyridinyl-, pyrazolyl or pyrimidinyl, each of which is selected from the group consisting of halogen, C 1~4 Alkyl, C 1-~4 Deuterated alkyl, C 1~4 Haloalkyl and C 3~4 cycloalkyl; R 2 and R 3 Each of the groups is independently H, a halogen, C 1~4 Alkyl or C 1~4 Is it a haloalkyl? Or, R 2 and R 3 C, which together with the carbon atom to which they are attached, are optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halogen 3~4 Forming a cycloalkyl, Y 1 and Y 2 Each of the above is independently selected from the group consisting of CR 4 or N, Each R 4 are independently H, halogen, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy or C 1~4 is haloalkoxy; Each R F are independently halogen, —OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy, C 1~4 Haloalkoxy, C 3~4 Cycloalkyl or (C 3~4 Cycloalkyl)-C 1~4 is alkyl- or Or, two R F When groups are substituted on the same carbon atom of the pyrrolidine ring of formula I, they, together with the carbon atom to which they are attached, are halogen, —OH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy and C 1~4 C optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from haloalkoxy 3~6 may form a cycloalkyl, R 7 is methyl or ethyl, t1 is 0, 1, 2, 3 or 4.
